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Design, Development and Evaluation of Erlotinib-Loaded Hybrid Nanoparticles for
Targeted Drug Delivery to NonSmall Cell Lung Cancer
Abstract
The objective of this work was to design, develop and evaluate erlotinib-loaded coreshell type lipid
albumin hybrid nanoparticles (CSLAHNPs) for targeted drug delivery to nonsmall cell lung cancer
(NSCLC). Erlotinib (ETB) is a highly selective, potent and reversible inhibitor of epidermal growth factor
receptor tyrosine kinase (EGFR) which is overexpressed (50-90%) in NSCLC. ETB is marketed as film
coated tablets for oral delivery. However, poor survival rate along with life-threatening adverse effects
were reported from oral administration. Nanoparticulate delivery system of ETB might be advantageous
to target the tumor cells, thereby increasing therapeutic efficacy and reducing off-targeting toxicities of
ETB to healthy cells. In this work, a unique nanoparticulate carrier termed as CSLAHNPs was used for
targeted delivery of ETB. The CSLAHNPs system was composed of albumin core and phospholipid bilayer
shell. For active targeting to EGFR positive NSCLC, anti-EGFR half-antibodes (hAbs) were conjugate to
EGFR expressing NSCLC. Overall hypothesis was to improve the efficacy of ETB in EGFR positive NSCLC
using the targeted hAb-ETB- CSLAHNPs and untargeted ETB-CSLAHNPs. Blank CSLAHNPs were prepared
by two-step method using bovine serum albumin and lipid mixture composed of 60:30:10 molar ratio of
dipalmitoyl-phosphatidylcholine (DPPC), cholesterol, and 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000) respectively.
ETB was loaded into CSLAHNPs by incubation method. Murine anti-EGFR monoclonal antibody (mAb)
was reduced to hAb using tris(2- carboxyethyl)phosphine and conjugated to maleimide terminated ETBCSLAHNPs via maleimide-thiol conjugation reaction. CSLAHNPs were further characterized for
physicochemical properties including mean size, polydispersity index, zeta potential, drug loading
efficiency, in vitro drug release, and in vitro serum stability. The optimized ETBCSLAHNPs and hAb-ETBCSLAHNPs were evaluated for their in vitro biological properties including cellular association cellular
uptake, endolysosomal trafficking, cell viability, colony formation assay and western blots in two human
lung adenocarcinoma cells; A549 ( having wildtype EGFR) and HCC827 (having an acquired mutation in
EGFR) cells. The mean size of hAbETB-CSLAHNPs (targeted) and ETB-CSLAHNPs (untargeted) was
between 190-210 nm, suitable for intravenous delivery. The zeta potential, drug loading, and drug
entrapment efficiency were about -13 mV, 2 % w/w, and 31% w/w respectively. CSLAHNPs exhibited
sustained drug release profiles over 72-96 h in PBS pH 7.4. Fluorescent lipid tagged hAb-ETBCSLAHNPs
showed enhanced uptake and accumulated in the cells. Significant reduction in % cell viability was
observed for targeted hAb-ETB- CSLAHNPs compared to control groups in HCC827 cells after 72 h. The
analysis of IC50 demonstrated that both targeted hAb-ETBCSLAHNPs and untargeted ETB-CSLAHNPs
could be more effective than ETB alone in both EGFR- positive NSCLC cells. Short-term stability data at
refrigerator condition demonstrated that the lyophilized form of CSLAHNPs containing 16-fold sucrose
(lyoprotectant) significantly improved the physical and chemical stability compared to liquid dispersion
for 60 days of storage. Overall, the results indicated that hAb-ETB- CSLAHNPs and ETB-CSLAHNPs would
be promising ETB delivery systems for EGFR-overexpressing NSCLC.
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ABSTRACT
The objective of this work was to design, develop and evaluate erlotinib-loaded
core-shell type lipid albumin hybrid nanoparticles (CSLAHNPs) for targeted drug
delivery to non-small cell lung cancer (NSCLC). Erlotinib (ETB) is a highly selective,
potent and reversible inhibitor of epidermal growth factor receptor tyrosine kinase
(EGFR) which is overexpressed (50-90%) in NSCLC. ETB is marketed as film coated
tablets for oral delivery. However, poor survival rate along with life-threatening adverse
effects were reported from oral administration. Nanoparticulate delivery system of ETB
might be advantageous to target the tumor cells, thereby increasing therapeutic efficacy
and reducing off-targeting toxicities of ETB to healthy cells. In this work, a unique
nanoparticulate carrier termed as CSLAHNPs was used for targeted delivery of ETB. The
CSLAHNPs system was composed of albumin core and phospholipid bilayer shell. For
active targeting to EGFR positive NSCLC, anti-EGFR half-antibodes (hAbs) were
conjugate to EGFR expressing NSCLC. Overall hypothesis was to improve the efficacy
of ETB in EGFR positive NSCLC using the targeted hAb-ETB- CSLAHNPs and
untargeted ETB-CSLAHNPs. Blank CSLAHNPs were prepared by two-step method
using bovine serum albumin and lipid mixture composed of 60:30:10 molar ratio of
dipalmitoyl-phosphatidylcholine (DPPC), cholesterol, and 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000)
respectively. ETB was loaded into CSLAHNPs by incubation method. Murine anti-EGFR
monoclonal antibody (mAb) was reduced to hAb using tris(2-carboxyethyl)phosphine
and conjugated to maleimide terminated ETB- CSLAHNPs via maleimide-thiol
conjugation reaction. CSLAHNPs were further characterized for physicochemical
properties including mean size, polydispersity index, zeta potential, drug loading
efficiency, in vitro drug release, and in vitro serum stability. The optimized ETBCSLAHNPs and hAb-ETB-CSLAHNPs were evaluated for their in vitro biological
properties including cellular association cellular uptake, endolysosomal trafficking, cell
viability, colony formation assay and western blots in two human lung adenocarcinoma
cells; A549 ( having wild-type EGFR) and HCC827 (having an acquired mutation in
EGFR) cells. The mean size of hAb-ETB-CSLAHNPs (targeted) and ETB-CSLAHNPs
(untargeted) was between 190-210 nm, suitable for intravenous delivery. The zeta
potential, drug loading, and drug entrapment efficiency were about -13 mV, 2 % w/w,
and 31% w/w respectively. CSLAHNPs exhibited sustained drug release profiles over 7296 h in PBS pH 7.4. Fluorescent lipid tagged hAb-ETB- CSLAHNPs showed enhanced
uptake and accumulated in the cells. Significant reduction in % cell viability was
observed for targeted hAb-ETB- CSLAHNPs compared to control groups in HCC827
cells after 72 h. The analysis of IC50 demonstrated that both targeted hAb-ETBCSLAHNPs and untargeted ETB-CSLAHNPs could be more effective than ETB alone in
both EGFR- positive NSCLC cells. Short-term stability data at refrigerator condition
demonstrated that the lyophilized form of CSLAHNPs containing 16-fold sucrose
(lyoprotectant) significantly improved the physical and chemical stability compared to
liquid dispersion for 60 days of storage. Overall, the results indicated that hAb-ETBCSLAHNPs and ETB-CSLAHNPs would be promising ETB delivery systems for EGFRoverexpressing NSCLC.
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CHAPTER 1.

INTRODUCTION*

Non-Small Cell Lung Cancer and Treatment Options
Lung cancer is a major health problem and the leading cause of cancer related
mortality for both men and women worldwide (1). Every year about 1.59 million men
and women die of this deadly disease around the world with around 169,000 deaths in the
US alone (2, 3). Human lung cancer is divided into two major types based on the
histopathological appearance: small cell lung cancer (SCLC) and non-small cell lung
cancer (NSCLC). NSCLC represents 85 to 90 % of all lung cancer cases, the rest being
SCLC (4). The most common histological types of NSCLC include squamous cell,
bronchoalveolar, and adenocarcinoma. Only 15 % of the cases are detected with cancer in
the primary site while 22 % cases have lymph nodes metastasis and 55 % have distant
metastasis at the time of diagnosis (5). There are various stages of the NSCLC; occult
(hidden), stage 0 (carcinoma in situ), I (A and B), II (A and B), III (A and B), and IV.
There are different types of the treatments available for NSCLC; some treatments
are standard or conventional, while some are investigational treatments being used in
clinical trials. The treatment options include surgery, radiation therapy, chemotherapy,
targeted therapy, laser therapy, photodynamic therapy, cryosurgery, electrocautery,
chemoprevention, and new combinations therapy (6). NSCLC is treated with local
resection and radiation therapy followed by chemotherapy. In approximately 85% cases,
lung cancer patients are diagnosed with advanced inoperable stage of the disease (7), and
the main treatment option is the chemotherapy.
Chemotherapy and Molecularly Targeted Therapy for NSCLC
In traditional or conventional chemotherapy, cytotoxic anticancer drugs are
administered orally or intravenously. Depending on the stages of the disease, chemo
drugs are used as neoadjuvant therapy (before surgery), adjuvant therapy (after surgery)
or as main treatment (advanced stages). The traditional chemo drugs most often used in
NSCLC include cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine, vinorelbin,
irinotecan, etoposide, vinblastine, and premetrexed (8). In first line treatment of NSCLC
at advanced stages, mono or combination chemotherapy is followed with a 4-6 dosing
cycles of platinum based agent (cisplatin/carboplatin) alone or in combination with
docetaxel, paclitaxel or gemcitabine. If platinum based therapy fails, second line therapy
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is used as the standard treatment option. Molecularly targeted therapy has become a
routine option for the second line treatment for NSCLC. It includes 4-6 dosing cycles
with one of the cytotoxic agents (vinrelbine, premetrexed), or molecularly targeted agents
(gefitinib, erlotinib, or bevacizumab).
Of all the second line treatments available, erlotinib (brand name Tarceva®; OSI
Pharmaceuticals Inc., Melville, NY and Genentech, Inc. South San Francisco, CA) is the
most widely prescribed drug. Erlotinib (ETB) belongs to epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) class of drugs (5). In 2004, US FDA
approved ETB for the treatment of locally advanced or metastatic NSCLC after failure of
at least one chemotherapy regimen. Chemically, ETB is N-(3-ethynylphenyl)-6,7-bis(2methoxyethoxy)quinazolin-4-amine (Figure 1-1). The drug is available as ETB
hydrochloride film coated tablets in 25 mg, 100 mg and 150 mg strengths (9). It has oral
bioavailability of ~ 60%, median elimination half-life of ~ 36 h, apparent volume of
distribution 232 L, and plasma protein binding of ~ 95%. It is metabolized primarily by
CYP3A4 in liver. In a randomized, placebo-controlled, double-blind phase III trial
(BR.21), ETB showed higher overall survival (6.7 months vs 4.7 months), higher
response rate (8.9% vs <1%) (10), higher median duration response (7.9 months vs 3.7
months) and higher progression free survival (2.2 months vs 1.8 months) compared to
placebo (10). Comparison between ISEL phase III trial for gefitinib (Iressa®,
Astrazeneca) and BR.21 trail demonstrated the survival benefit for all enrolled subjects
with ETB compared to gefitinib which showed survival benefit for patients with
adenocarcinoma or never smokers (11). In two phase III trials (OPTIMAL and
EURTAC), significant progression free survival benefits were observed in patients with
advanced EGFR-mutation positive NSCLC compared to standard chemotherapy (12, 13).
With chemotherapy, 5-year survival at advanced stages (III and IV) of NSCLC remains
only about 15 % and 1% respectively (14). One of the main reasons for the poor survival
rates among NSCLC patients is the limited efficacy of traditional chemotherapy along
with severe adverse side effects of the high doses of toxic anticancer drugs.
Erlotinib and Its Mechanism of Action
The schematic representation of the mechanism of action of ETB is shown in
Figure 1-2. Epidermal growth factor receptor (EGFR) belongs to the bigger HER family
of receptors. There are four subtypes of HER family receptors; HER1 (EGFR or erbB1),
HER2 (EGFR2 or erbB2), HER3 (EGFR3 or erbB3), and HER4 (EGFR4 or erbB4).
EGFR is a 170 kDa transmembrane glycoprotein receptor with an amino terminal
extracellular domain (binds to ligands), a single hydrophobic transmembrane-anchoring
region, a tyrosine kinase (TK) region and a carboxyl-terminal cytoplasmic region with
tyrosine kinase activity (15). After binding with appropriate ligands (e.g. EGF), inactive
monomers form active homo or heterodimers, results in the autophosphorylation of TK
domain of EGFR. This process activates a complex network of downstream signaling
pathways including MAPK, PI3k/PKB, PKC, RAS-RAF-MAPK p44/42. EGFR signaling
involves cell maintenance, cell proliferation, survival, angiogenesis, and metastasis.
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Figure 1-1.

Chemical structure of erlotinib

Chemical name of erlotinib is N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)
quinazolin-4-amine.
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Figure 1-2.

Schematic diagram of the mechanism of action of erlotinib

EGFR (also known as HER1) have tyrosine kinase (TK) domains in the cytoplasmic
portion of the receptor. Binding of ligands (EGF) to the extracellular domain of EGFR
induces either homodimerization or heterodimerization of the receptors. Dimerization
results in phosphorylation of TK domain leading to autophosphorylation, followed by
intracellular signaling cascades, such as the RAS–RAF–MEK–ERK and PI3K–AKT
pathways, that induce cellular proliferation, angiogenesis, and metastases. The binding of
erlotinib to the ATP-binding site of TK domain results in blockage of the catalytic
activity of the kinase, thereby inhibiting downstream signaling pathways responsible for
cellular proliferation.
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EGFR-TK has been identified as the effective molecular target and overexpressed
(50-90%) in several cancer types including NSCLC (16). ETB is a highly selective
inhibitor of HER1/EGFR-TK. The drug binds with the ATP-binding site of the tyrosine
kinase domain of EGFR, which blocks the catalytic activity of the kinase, thereby
inhibiting downstream signaling of the pathways responsible for cell proliferation,
survival, metastasis, and angiogenesis (17).
Drawbacks of Erlotinib Therapy
ETB is administered as 25 mg to 150 mg oral tablet once daily. The oral route is
most preferred and easy way of administering drugs for systemic therapy of NSCLC.
However, a number of adverse effects or toxicities were reported. Severe skin rash and
diarrhea were observed to be the major dose- limiting toxicities from traditional oral
delivery of ETB (10, 18). Diarrhea occurred in 55% of the patients with severe diarrhea
in 6% of the patients (10). Rash was reported in 75% of the patients (19). Other immune
mediated life-threatening toxicities include drug-induced hepatitis, Stevens-Johnson
Syndrome(20), toxic epidermal necrolysis (21), gastrointestinal perforations (22), ocular
lesions (23), interstitial lung disease (24), liver and kidney problems, bleeding and
clotting problems.
Additionally, administration of oral ETB tablets is not convenient to cancer
patients with gastrointestinal disorders or abnormalities. Approximately 40% of the
cancer patients undergoing standard dose chemotherapy develop mucositis which causes
structural and functional changes to the gastrointestinal tract (25). The pathological
condition of gastrointestinal mucositis resulted in malabsorption of drugs and other
nutrients (26). Evidently, intravenous administration of erlotinib was investigated to
overcome the patient non-compliance of oral tablet. The phase I dose escalation study
reported that a high dose of intravenous ETB formulation was well-tolerated with minor
adverse events as compared to oral tablet (27).
Another major concern with ETB therapy is the development of drug resistance
by the NSCLC tumors. ETB has been used as the first line therapy in patients with EGFR
mutations consisting of either exon 19 deletions or L858R point mutation in exon 21(28,
29). However, most advanced NSCLC tumors develop resistance after 6 – 12 months of
drug therapy (30). The main mechanisms of resistance identified include secondary
resistance EGFR T90M mutations (31), oncogene kinase switch, and MET amplification
(32).
Barriers to Drug Delivery in Solid Tumors
In order to reach the target tumor cells, intravenously administered therapeutic
drug delivery systems must penetrate across blood vessel walls of the tumor and the
tissue matrix or interstitium. The complexity of in vivo system was evidenced by the
presence of multiple biological barriers that pose significant challenges in drug delivery
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to solid tumors (33-39). The emergence of nanoparticles (NPs) based drug delivery
systems showed potential advantages of efficient drug delivery to solid tumors in
experimental therapeutics (40-42). However, their full clinical success still remains
elusive with little to moderate improvement in clinical benefit (43). Only a small fraction
of the drug reaches the tumor site, imposing significant risk for the development of drug
resistance. After intravenous injection, NPs face the first barrier which is the
mononuclear phagocytic system (MPS) or reticuloendothelial system (RES). MPS/RES is
part of the immune system consisting of phagocytes cells such as monocytes and
macrophages located in reticular connective tissues of liver, kidney, and spleen (44). The
serum complement proteins such as C3, C4, and C5 form the corona around unprotected
NPs, triggering the process of opsonization, followed by phagocytosis by circulating as
well as residual macrophages (45). Opsonization process is influenced by
physicochemical properties of the NPs such as size, shape, surface charge, and surface
chemistry (46). One of the common ways to circumvent the MPS barrier is PEGylation
that is coating of NPs by hydrophilic polyethylene glycol (PEG) or PEG-containing
copolymers (47, 48). The bushy or mushroom structure of PEG chains repel the
absorption of opsonin proteins on NPs via steric repulsion forces, thereby blocking the
opsonization process (49). The second barrier is the vascular endothelial layer, a semipermeable layer of cells which lines the inner walls of the blood vessels. The presence of
proteoglycan layer (also known as glycocalix) which covers the endothelial layer, serves
to control the permeability of solutes and macromolecules across blood vessels. The
passage of molecules across healthy endothelial layer occurs by trans or paracellular
pathways with size limit of 5-6 nm. However, the tumor endothelial layer is
discontinuous with “gaps” in the lining which helps to extravasate NPs via the process
known as enhanced permeability and retention (EPR) effect (50). However, significant
differences were observed in tumor vascular morphology including pore cutoff size,
organization, and blood flow rate not only among various tumor types but also within
same tumor type. The heterogeneities of tumor vasculature have resulted in limited EPR
effect of NPs (34, 51, 52). The third barrier is the tumor microenvironment. The solid
tumor is characterized by an avascular necrotic core region, a hypoxic region, a
vascularized circumference, and an acidic front (53). The extracellular matrix (ECM) or
the tumor interstitium consists of collagen, elastin, proteoglycans, and hyaluronic acid
(54). ECM provides resistance to the diffusion of NPs through the interstitium. Interstitial
fluid pressure is higher in the center of the tumor and lower in periphery (52). The
extravasation of NPs occurs mainly by diffusion and convection based on the
concentration gradient or interstitial fluid pressure (54). Therefore, NPs has to overcome
the outward fluid convection to diffuse into the tumor. Finally, NPs have to cross cellular
barriers. The internalization of NPs into the tumor cells depends on interaction of NPs
with cell membrane. The physicochemical properties of NPs including size, surface
charge, hydrophobicity, presence of targeting ligands can influence their entry into the
cells. Once internalized, NPs has to reach its intracellular target through endosomal
vesicles and organellar barriers. Finally, overexpression of drug efflux transporter, Pglycoprotein (P-gp) may decrease the intracellular concentrations of drug inside the
tumor. It has been demonstrated that NPs can overcome the P-gp-mediated efflux pump
mechanism (55).
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A lot of progress has also been made in the field of nanoparticulate drug delivery
in order to overcome each of these barriers and a number of novel approaches have been
brought to the forefront (34, 52, 56). Targeting tumor microenvironment was
demonstrated to enhance drug distribution to tumors. Besides passive targeting by EPR
effect, active targeting can improve chemotherapy retention in tumors. The potential of
active targeting mediated drug therapy was demonstrated by FDA approval of
transtuzumab emtansine (T-DM1, Genentech), an antibody-drug conjugate in the
treatment of HER2 positive breast cancer (57). Normalization of the tumor
microenvironment is another strategy to improve drug delivery in solid tumors. Vascular,
stress and matrix normalization of the tumor microenvironment have demonstrated to
enhance tumor localization and intratumoral distribution of chemothapeutics. Vascular
normalization using antiangiogenic therapy was shown to alleviate hypoxia and improve
antitumor efficacy of NPs (58, 59). In stress normalization, targeting stromal cells and
matrix molecules (collagen, hyaluronen) reduces stress by decompressing vessels and
improves perfusion and drug delivery (60). Matrix normalization by degrading or
modifying ECM can improve the delivery of nanomedicines to solid tumors (61).
Hybrid Nanoparticles for Erlotinib Delivery to Solid Tumors
Drug delivery system (DDS) plays an important role by influencing the
pharmacokinetic profile of the drug, rate and duration of drug release, site of drug action,
and finally the pharmacological effects and adverse effects (62). An effective DDS
ensures that therapeutically active drug is available at the site of action at right
concentration and time (63, 64). Therefore, an optimal DDS for ETB should improve the
therapeutic efficacy of ETB by overcoming the barriers to drug delivery and also
minimize toxicity, and lower the total dose required for the therapy. Nanoscaled targeted
DDS meets most of the required attributes for the improved therapy of malignant diseases
such as cancer. Rationally designed DDS with optimal physicochemical characteristics
can reach to the tumor site passively through the leaky vasculature surrounding the tumor
by enhanced permeation and retention (EPR) effect. Targeting ligand conjugated to the
surface of nanoparticles (NPs) can achieve active targeting by binding to the specific
receptors overexpressed by tumors. Surface modified NPs with flexible hydrophilic
polymers have the ability to evade the RES system and prolong blood circulation time.
NPs can carry high payload of anticancer drug (s), proteins, genes, and targeting ligands.
NPs protect the entrapped drug from enzymatic inactivation. By reducing the free drug in
circulation, the systemic toxicities could be minimized. There are various types of
nanoscaled DDS which are approved or being investigated in clinical trials or in research
and development phases. This includes liposomes, polymeric NPs, albumin NPs,
nanocapsules, micelles, solid lipid NPs, dendrimers, PEGylated proteins, viral NPs,
polymer-drug conjugates, antibody-drug conjugates, carbon nanotubes, and inorganic
NPs (42).
The focus of nanoparticle design over the years has evolved toward more complex
nanoscopic core-shell architecture using a single delivery system to combine multiple
functionalities within nanoparticles. Core-shell-type lipid-polymer hybrid nanoparticles
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(CSLPHNPs), which combine the mechanical advantages of biodegradable polymeric
nanoparticles and biomimetic advantages of liposomes, have emerged as a robust and
promising delivery platform (65-70). In CSLPHNPs, a biodegradable polymeric core is
surrounded by a shell composed of layer(s) of phospholipids. The hybrid architecture can
provide advantages such as controllable particle size, surface functionality, high drug
loading, entrapment of multiple therapeutic agents, tunable drug release profile, and good
serum stability (65). The multifunctional ETB-loaded CSLAHNPs conjugated with antiEGFR half-antibody might be advantageous in selectively targeting EGFR overexpressed
on NSCLC tumor and delivering ETB to increase therapeutic efficacy and reduce offtargeting toxicities of ETB after intravenous administration. The following section
describes a comprehensive review on hybrid nanoparticles.
Review of Hybrid Nanoparticles Literature
Introduction
Nanoparticles (NPs) have attracted much attention because of their ability to
deliver drugs to the therapeutic targets at relevant times and doses. Of all the common
nanoparticulate systems, liposomes and biodegradable polymeric NPs (PNPs) have
emerged as the two dominant classes of drug nanocarriers. This is evidenced by
increasing numbers of clinical trials, research reports, and approved drug products (7173). Both classes have advantages and limitations in terms of their physicochemical and
biological properties. Historically, lipids have been used for several decades in various
drug delivery systems including liposomes (71), solid lipid NPs (74), nanostructured lipid
carriers (75), and lipid-drug conjugates (76). Most liposomes are biocompatible,
biodegradable, non-toxic or mildly toxic, flexible, and non-immunogenic for systemic
and non-systemic administration if their component lipids are from natural sources (77).
However, there are several limitations of liposomal drug products from the viewpoint of
physical and chemical stability, batch-to-batch reproducibility, sterilization, drug
entrapment, and manufacturing scale-up (73, 77-79). Generally, PNPs are advantageous
in terms of smaller particle size, tissue penetrating ability, a greater variety of preparation
methods, availability of various polymers, improved stability in biological fluids,
versatile drug loading and release profiles (72, 80). The limitations of PNPs include use
of toxic organic solvents in the production process (81), poor drug encapsulation for
hydrophilic drugs, drug leakage before reaching target tissues, polymer cytotoxicity,
polymer degradation, and scale-up issues (80).
Novel, integrated systems known as “lipid-polymer hybrid nanoparticles”
(LPHNPs) have been introduced in an effort to mitigate some limitations associated with
liposomes and PNPs (69, 82). Briefly, the biomimetic characteristics of lipids and
architectural advantage of polymer core are combined to yield a theoretically superior
delivery system. LPHNs are solid, sub-micron particles composed of at least two
components; one being the polymer and the other being the lipid. Various bioactive
molecules such as drugs, genes, proteins, and targeting ligands can be entrapped,
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adsorbed, or covalently attached in the hybrid system. The common choices of
biodegradable polymers include polylactic-co-glycolic acid (PLGA), polycaprolactone
(PCL), dextran, or albumin due to their biocompatibility, biodegradability, non-toxicity
and previous use in approved products (83, 84). Lipids used are often zwitterionic,
cationic, anionic and neutral phospholipids such as lecithin, 1,2-dipalmitoyl-sn-glycero3-phosphocholine (DPPC), 1,2-dipalmitoyl-3-trimethylammonium-propane (DPTAP),
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or 1,2-dioleoyl-sn-glycero-3phosphoethanolamine (DOPE) (85-91). Various classes of LPHNPs are summarized in
Table 1-1 and are classified depending on the arrangement of lipid and polymer in the
hybrid system. Due to their perceived advantages over other existing hybrid systems,
significant effort has been directed towards the understanding of CSLPHNPs (92-101).
The primary objective of this review article is to discuss CSLPHNPs which are composed
of polymeric core and lipid shell. Discussions on other types of LPHNs will be limited as
it is not within the scope of this communication.
Core-shell type lipid/polymer hybrid nanoparticles
CSLPHNPs continue to gain recognition in drug, gene, protein, and vaccine
delivery (102-105). Based upon the CSLPHNPs concept, a new nanoparticulate drug
delivery system, known as “Supra molecular bio-vectorTM” (SMBVTM), was introduced
in the early 1990s by Biovector Therapeutics (106). SMBVTM is an artificial analog of
virus composed of a modified polysaccharide hydrogel core covered with phospholipids
acting as a shell. Because of its size ( ~ 60 nm) and architecture mimicking the structure
of viruses (107), SMBVTM has been investigated for various purposes such as delivery of
anticancer agents (108), nasal vaccines (107), and antisense oligonucleotides (109).
Originally, core-shell type hybrid microparticles and NPs were synthesized with a lipid
shell and a core that was made from inorganic materials such as silica (110), magnetic
iron oxide (111), or organic materials such as polysaccharides (112), polystyrene (113),
polyelectrolyte capsule (114), or polymer microgels (115). Comprehensive reviews by
Troutier and Ladaviere (116) and Richter et al (117) are available on lipid membrane
systems supported by various organic and inorganic colloidal solid cores and are not
highlighted in this review. Instead, the main focus here is placed on polymeric cores
(preferably biodegradable) which can be utilized in drug delivery systems.
CSLPHNPs systems can be described as the polymeric core coated with single or
multiple layers of lipids that constitute the shell. Based on the concept of core-shell
architecture, “lipoparticles” were first synthesized for various biotechnological and
biomedical applications such as immunological kits and biosensors for amplifying
biomolecular recognition (87, 89). The special features of lipoparticles are imparted by
their method of preparation and use of the types of lipid materials. They are generally
prepared by mixing liposomes and PNPs to form lipid-polymer complexes where a lipid
bilayer or lipid multilayers cover the surface of the polymeric core. The space between
polymeric core and lipid layer is occupied with water or aqueous buffer (Figure 1-3).
Cationic or zwitterionic phospholipids have been used to construct the shell of the
lipoparticles to promote electrostatic interactions with oppositely charged polymers.
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Table 1-1.

Various types of lipid polymer hybrid nanoparticles

Type

Description

Synonyms

Reference

Polymer corelipid shell

Colloidal
supramolecular
assemblies consisting of
polymer particles coated
with lipid layers

Lipoparticles
Lipid polymer particle
assemblies
Lipid-coated NPs
Nanocell
Polymer-supported
lipid shells
Not applicable

(118),
(90),(119),
(89),(87,
88),(120),
(121), (122),
(123)

Mixed lipid polymer
particles

(84)

Not applicable

(124)

Biomimetic NPs

(125)

Polymer caged These systems are
liposomes
composed of polymers,
anchored or grafted at
the surfaces of
the liposomes to provide
stability
Monolithic
Lipid molecules are
HLPNPs
dispersed in a polymeric
matrix
Core-shell
Hollow inner core
type hollow
surrounded by
lipid-polymer- concentric lipid layer,
lipid NPs
followed by polymeric
layer, again followed by
lipid layer along with
lipid-PEG.
Erythrocyte
Sub 100 nm polymeric
membraneparticles are coated with
camouflaged
RBC membrane derived
polymeric NPs vesicles to mimic
complex surface
chemistry of erythrocyte
membrane
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(78, 79)

Figure 1-3.

Schematic diagrams of CSLPHNPs with its structural components

CSLPHNPs with lipid bilayer (left) and monolayer (right).
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In a recent report, Zhang et al (69) have designed a novel CSLPHNPs system that
were composed of three functional building blocks each having distinct attributes that
influences the whole hybrid delivery system. The first building block was polymeric core
that was composed of a biodegradable hydrophobic polymer (e.g., PLGA) and acted as
the carrier for poorly water soluble drugs. This core imparts controlled drug release from
the system. The second component was the shell or the outer corona of the hybrid
particles that was composed of hydrophilic substrates, most commonly lipid-PEG
conjugates. This layer allows the particles to evade uptake by the immune system and
imparts long-circulating characteristics. The shell can also be manipulated to facilitate the
attachment of targeting ligands. Finally, the third component was composed of a lipid
monolayer at the interface of core and shell. This layer helps to reduce drug diffusion
from the core and water penetration into the core thereby increasing drug encapsulation
and altering drug release rates.
Advantages of CSLPHNPs
The solid polymeric core of CSLPHNPs acts as a cytoskeleton that provides
mechanical stability, controlled morphology, biodegradability, narrow size distribution,
and high available specific surface area (126-128). The lipid shell enveloping the
polymeric core is biodegradable, biocompatible and exhibits biomimetic behavior similar
to cell membranes. The shell has the ability to interact with a wide variety of molecules,
either within the membrane or on the surface of the membranes (129). Improved
encapsulation of hydrophobic and hydrophilic drugs with therapeutically effective drug
entrapment efficiency and drug loading have been reported in CSLPHNPs for a number
of drugs compared to liposomes or PNPs (96, 99, 102). Amphiphilic character of lipids
facilitates the adsorption of hydrophilic compounds on the hydrophilic bilayer surface
and insertion of hydrophobic molecules into the hydrophobic lamellar region (129-132).
This feature allows CSLPHNPs to entrap and deliver multiple hydrophilic and
hydrophobic therapeutic agents simultaneously into the single delivery platform (99,
133).Optimization of the core and shell properties can result in tunable and sustained
drug release profiles (134). CSLPHNPs exhibit storage and serum stability over
prolonged periods (104, 134). Besides passive targeting of CSLPHNPs based on particle
size, they can be conjugated with appropriate targeting ligands such as aptamers (134),
folic acid (97, 135), transferrin (136), anticarcinoembryonic antigen half-antibody (94),
single-chain tumor necrosis factor (121) to deliver NPs at the target tissues for treating
cancers. Smaller than 100-nm particles (similar to virus-like architecture) are promising
for intracellular drug targeting and vaccine adjuvants (137).
Methods of preparation of CSLPHNPs
Methods used to prepare CSLPHNPs broadly fall into two categories; the twostep method and the single-step method.
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Two-step method. In this approach, the polymeric core and lipid shell are
prepared separately using two independent processes; then the two components are
combined by direct hydration, sonication or extrusion to obtain the desired lipid shell–
polymer core structure (Figure 1-4). Several investigators have prepared lipid polymer
particle assemblies or lipoparticles to obtain solid supported lipid bilayers which act as a
model for artificial cell membrane and also for drug delivery applications (87, 89, 104,
119, 120, 133, 135, 138). In the two-step process, cationic lipid vesicles and anionic
PNPs are drawn together by electrostatic interactions.(90).
The fusion of the PNPs and lipid vesicles can be accomplished by employing
different mixing protocols (116). In such processes, the dry lipid film can be hydrated
with the PNPs dispersion. Another alternative is to introduce the PNPs into pre-formed
lipid vesicles. Such a process is usually followed by low energy mixing processes such as
vortexing the resulting mixture. This mixture is heated at a temperature above phase
transition temperature (Tm) of the lipid (89). This facilitates reorganization of the lipid
onto the particle surface. The non-adsorbed lipids, micelles and free PNPs are separated
by centrifugation to obtain a final CSLPHNPs dispersion.
There are several factors that affect final particle size of lipoparticles. Examples
of relevant factors are methods applied to produce lipid vesicles (direct hydration,
sonication or extrusion), mixing protocol of lipid vesicles/PNPs, type of polymers/lipids,
pH and ionic strength of buffers used, surface charge of lipid vesicles, vesicle to particle
ratio and temperature of incubation (89, 116). In general, addition of water or an aqueous
buffered solution to dry lipid film forms large multilamellar vesicles. However use of
additional steps such as sonication or extrusion leads to formation of small unilamellar
vesicles with smaller particle sizes and a lower polydispersity index10. Troutier et al
reported that particle of approximately 100 nm were obtained using membrane extrusion
compared to 250 nm using hydration or 500 nm using sonication approach (89).
Simultaneous loading of two drugs, doxorubicin and combretastatin, into “nanocells”
using the two step approach has been reported (133). In this study, doxorubicin-PLGA
conjugated PNPs were prepared using an emulsion-solvent evaporation technique. Then,
combretastatin loaded lipid vesicles were prepared using phosphatidylcholine,
cholesterol, and PEG-DSPE. Finally, hybrid dual drug loaded “nanocells” were obtained
by extruding the mixture of PNPs and lipid vesicles. The size of the particles ranged from
180-200 nm. The authors reported that combretastatin released from the CSLPHNPs at a
faster rate compared to doxorubicin. The differential drug release was attributed to
localization differences inside “nanocells”. The authors postulated that combretastatin
was entrapped at/in the shell, whereas doxorubicin was located in the core.
In the two-step process, the particle size and drug loading of the core can be
precisely controlled to produce final lipid-polymer hybrid nanoparticles of appropriate
size, drug loading and release characteristics (89, 133). In addition, the theoretical
amount of the lipid required to uniformly coat the core with uniform bilayer of
phospholipids can be calculated based on the properties of the core and phospholipids
(139, 140). However, it should be cautioned that the two-step method may reduce drug
encapsulation efficiency for water soluble drugs due to the incubation step since drug
13

Figure 1-4. Schematic representation of the steps involved in lipoparticle
synthesis by two-step method
(a) Polymeric nanoparticle cores (PNPs) are prepared separately. (b) Lipid shells
(liposomes) are prepared separately. (c) Both polymeric cores and lipid shells are mixed
and incubated. (d) Finally, lipoparticles are obtained.
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molecules may leak out from the core before a lipid coat is formed on the core surfaces
(141). Some limitations of this method are the technical complexity and less efficient
processes of preparing both polymeric core and liposome vesicles separately.
Single-step method. In an approach to circumvent the problems of time
consuming preparation steps, a relatively simple approach which combines the dual steps
of the two-step method into a single step has been evaluated. Here a nanoprecipitation
process is synchronized with a simultaneous self-assembly process (Figure 1-5).One of
the critical factors influencing successful preparation of CSLPHNPs using this method, is
the amount of lipid for uniform lipid coating of polymeric core particles. Variations of
the single-step method have been reported in the literature. These include modified
solvent extraction/evaporation and nanoprecipitation methods.
Modified solvent extraction/evaporation method is a modification of the
emulsion-solvent evaporation method first reported by Gurny et al (142). The method has
been used to prepare CSLPHNPs loaded with docetaxel (86, 97) and paclitaxel (98).
Briefly, the polymer and drug are dissolved in a water-immiscible organic solvent such as
dichloromethane, chloroform, or ethyl acetate. Lipid is then dispersed in water by bath
sonication, mechanical stirring, or sometimes with heat. The organic solution is mixed
into aqueous phase and the resulting dispersion is sonicated using a probe sonicator in an
ice bath. The dispersed phase is broken into tiny nanodroplets, which are solidified into
nanospheres coated with lipid layer. The organic solvent is usually removed by
evaporation in a rotary evaporator under reduced pressure or stirred overnight. The
particle suspension is purified by centrifugation followed by washing. The washed
particles are freeze-dried to obtain a dry powder. Liu et al (97) used this method to
prepare folic acid-conjugated docetaxel-loaded CSLPHNPs having the particle size of
approximately 200-300 nm and drug encapsulation efficiency of 60-66 %. They observed
a decrease in mean particle size of CSLPHNPs with increasing concentrations of lipid.
This phenomenon was attributed to the presence of DLPC lipid that acts as an emulsifier
thereby lowering the surface tension of the lipid monolayer, resulting in lower surface
free energy and smaller CSLPHNPs. A typical approach to entrap hydrophilic small and
macromolecules in microparticles/NPs is to use a multiple emulsion/solvent evaporation
method. A similar approach used to prepare hollow core-shell type lipid-polymer-lipid
hybrid NPs. This method used a modified double emulsion/solvent evaporation for
encapsulation and delivery of nucleic acids (124). The hollow aqueous core acted as the
reservoir for hydrophilic small interfering RNA (siRNA). Briefly, in the first step,
primary water-in-oil (w/o) type emulsion was formed by dispersing the aqueous siRNA
into an organic solvent containing a polymer and a cationic phospholipid by sonication.
Here the phospholipid layer helps to stabilize the aqueous droplets and increase the
loading of siRNA by polycomplexation. A secondary oil-in-water (o/w) type emulsion
was prepared by adding the primary emulsion into aqueous dispersion of another
phospholipid (lecithin) and DSPE-PEG. Finally, the organic solvent was evaporated to
prepare multilayered CSLPHNPs. Not only macromolecules but also water soluble
hydrophilic small molecular weight drugs such as antibiotics have been encapsulated
within CSLPHNPs via the double-emulsion solvent evaporation method (141).
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Figure 1-5. Schematic representation of the single-step method involving
nanoprecipitation and self-assembly processes
(a) Drug, polymer dissolved in organic solvent forming organic phase. (b) The organic
phase is added dropwise into aqueous phase containing phospholipids. (c) The resulting
dispersion is sonicated or homogenized to obtain CSLPHNPs.
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In the modified nanoprecipitation method, polymer(s) and hydrophobic drug(s)
are dissolved in a water-miscible organic solvent (e.g., acetonitrile or acetone).The
organic solution is then added, drop by drop, to the aqueous dispersion containing lipid
The mixture is vortexed and subsequently homogenized or ultrasonicated to reduce the
particle size to nanometer range. Valencia et al reported a similar method based on rapid
mixing of lipid and polymer solutions using a continuous flow microfluidic device that
used hydrodynamic flow focusing in combination with passive mixing structures to
prepare CSLPHNPs in a single step (143). Their study indicates that in order to ensure
proper dispersion of lipid and lipid-PEG conjugate, it is necessary to heat the aqueous
dispersion (generally ~ 65°C) before adding the organic solution. To uniformly coat the
polymeric core with a lipid shell and to evaporate the organic solvent, the dispersion was
stirred for several hours with a magnetic or mechanical stirrer. CSLPHNPs formed were
purified by ultracentrifugation, centrifugal ultrafiltration or dialysis.
The critical factors to be optimized for particle size, polydispersity, and surface
charge include the type of the lipid, ratio of lipid/polymer, phase-volume ratio of organic
to aqueous phase and viscosity of the polymer (69, 93, 143). Docetaxel loaded
CSLPHNPs were prepared by this method to produce particles of mean size of 66 nm and
encapsulation efficiency of approximately 60 % (134).
Recently, a fast and simple method of producing CSLPHNPs using sonication
was reported by Fang et al (93). They prepared CSLPHNPs of uniform and controllable
size (~ 65 nm) and low polydispersity index (~ 0.08) by using bath sonication for 5 min
compared to a few hours for other fabrication approaches. The size and polydispersity of
the particles was effectively controlled by optimizing the ratios of lipid-PEG/polymer and
lipid/lipid-PEG/polymer.
Drug loading and entrapment efficiency of CSLPHNPs
Many small molecular weight chemotherapeutic drugs, proteins and nucleotides
have been encapsulated or entrapped in CSLPHNPs. One reason for poor drug loading
(DL) and entrapment efficiency (EE) in CSLPHNPs is the presence of excess lipids could
form vesicles by entrapment or adsorption of drug via hydrophobic interactions and/or
hydrogen bonding (144). Additionally during purification, these vesicles are washed
away, leading to drug loss. Therefore, the amount of the lipid required to uniformly coat
the core nanoparticles has to be optimized using empirical and/or experimental
techniques. There are various techniques for drug loading into CSLPHNPs. The drug can
be loaded into both the polymeric core as well as in the lipid shell, thereby increasing the
total drug payload. Moreover, two different drugs can also be loaded into the core and the
shell (145). The most commonly used strategy is to incorporate the drug during core
production or lipid film formation. Another option is to adsorb or absorb the drug with
the cores and lipid vesicles separately before combining to form CSLPHNPs. However,
the DL is generally expected to be better in the incorporation approach than the
adsorption approach (146). The adsorption method has been used to load DNA into
lipoparticles composed of PLA core/DPPC-DPTAP lipid shell (103). The
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macromolecules or proteins shows greatest loading efficiency near its isoelectric point
when it has minimum solubility and maximum adsorption (147). For small molecules, the
use of ionic interactions between the drug and polymer can be an effective way to
increase the drug loading (96). Examples of the factors which may influence the DL and
EE are aqueous solubility of the drug, affinity and miscibility of the drug in both polymer
and lipid phases (96), amount of lipid (144), drug-lipid charge interactions (141), aqueous
phase pH (148), and methods of preparation. Often it is required to carry out in-depth
physicochemical characterization during preformulation studies to optimize LC and EE
(149). For instance, Li et al have analyzed the combined solubility parameters and
partition coefficients for screening the best lipid and polymer for the highest LC and the
maximum binding capacity to the cationic drug verapamil (149). Based on the approach,
they have reported drug EE greater than 90% and DL between 5 to 36.1 % (96). The
amount of the lipid is also a decisive factor for EE of lipophilic drugs in CSLPHNPs. Liu
et al reported the decrease in EE from 42 % to 15 % when the lipid component was
lowered from 0.1 % to 0.01 % for paclitaxel particles (144). Drug lipid charge
interactions may be important for encapsulation of drugs. Cheow et al reported successful
encapsulation of zwitterionic levofloxacin and ofloxacin when PLGA polymer and
phosphatidyl choline (PC) lipid were used, whereas formation and loading of cationic
ciprofloxacin into the CSLPHNPs was unsuccessful (141). When PC was replaced with
non-ionic polyvinyl alcohol, ciprofloxacin loaded CSLPHNPs were successfully
produced. The results suggested the possibility of unfavorable ionic interactions between
the anionic PC and cationic ciprofloxacin for the failed formulation. The method of
preparation also affects the DL and EE. The method used during core PNPs preparation,
such as solvent displacement method leads to poor DL and EE for hydrophilic
compounds (150). Another problem of the two-step method is that encapsulated drugs
leak out before the lipid coat is formed (141).
Surface modifications of CSLPHNPs
In addition to the incorporation of drug, the outer surface of the CSLPHNPs can
be functionalized to make long circulating particles along with the capability of active
targeting. PEGs have become a standard for creating long-circulating NPs, thereby
reducing plasma protein adsorption, macrophage uptake and particle aggregation, while
increasing circulation time (151). For long circulating CSLPHNPs, outer surface is
coated with hydrophilic polymeric chains of PEGs anchored in the bilayer with DSPE.
The functional coating of PEG stabilizes the particles in storage due to steric hindrance
by its long polymer chains (93). Another surface modification relates to the acidic
environment of tumors. A pH-sensitive PEG coating shed its coating under the acidic
condition, fused with cell membrane and entered into tumor cells (92). A red blood cell
approach to particle surface functionalization was made by coating biodegradable PNPs
with natural erythrocyte membranes. The membrane included both membrane lipids and
associated proteins (125). The erythrocyte membrane which covered the polymeric core
mimicked the natural endogenous erythrocyte, thus escaping from the recognition by the
reticulo-endothelial system and producing a prolonged circulation time. Erythrocytes
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have different surface antigens (blood groups) and patients should be cross-matched
before injecting these “erythrocyte membrane camouflaged NPs”.
Surfaces of CSLPHNPs can also be modified with folic acid, monoclonal
antibodies or therapeutic cytokines for targeting to tumors located in the various parts of
the body. In general, antibodies or other targeting ligands are attached to the surface of
liposomes and NPs using various covalent and non-covalent coupling techniques, as
reviewed by Nobs et al (152). For example, anti-carcinoembryonic antigen (CEA) halfantibody was conjugated to the LPHNPs surface by a maleimide-thiol coupling reaction
(94). CSLPHNPs containing attached folic acid on the surface can be prepared by using
pre-synthesized DSPE-PEG5k-Folic acid (97). Alternatively, CSLPHNPs can display a
cell death ligand such as tumor necrosis factor α (TNF α) on the outer surface which
mimics the bioactivity of membrane bound TNF α. In one study, the dual attachment of
TNF α in both the core and the shell showed strong and specific binding to TNF receptorexpressing cells (121).
Physicochemical characteristics of CSLPHNPs
Several physicochemical and biological techniques for the characterizing
CSLPHNPs are summarized in Table 1-2. Also included are discussions on mechanism
of hybrid particle formation, structure and stability of CSLPHNPs.
Interaction and mechanism of hybrid particle formation. The interactions
between lipids and polymer particles to form hybrid particles have not been well defined.
Generally, different mechanisms of lipid-polymer hybrid particle formation can be
distinguished based on the method of preparation. In the single-step method, polymer
particle formation involves the precipitation of polymer from an organic solution and the
diffusion of the organic solvent in an aqueous medium (93). Then, the lipid molecules
self-assemble spontaneously by hydrophobic interactions on the polymeric particle
surface to form a monolayer. In cases when the lipid-PEG component is incorporated, the
lipid moiety of the lipid-PEG conjugate is inserted into the lipid monolayer, and the polar
PEG moiety faces outward into the external media to form the stabilizing shell for the
hybrid particles.
The possible mechanism of hybrid particle formation in the two-step method can
be understood from a study by Carmona-Riberio and de Moraes Lessa (113). Their study
involved phospholipid adsorption by polystyrene particles. According to the authors, the
process occurs in two steps. First, the phospholipid forms a bilayer in aqueous solution
and attaches to the polystyrene particle surface by adsorption to form homodispersed and
stable phospholipid vesicle-covered particles. Second, after bilayer attachment,
hydrophobic attractions between the polystyrene surface and hydrocarbon chain of the
phospholipid bilayer collapses the bilayer structure and leaves a monolayer covering the
polymer particle. In the process, the lipid and polymer contact is favored by electrostatic
interactions, hydrophobic attractions, or van der Waals forces. In addition, the input of
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Table 1-2.
Summary of the techniques used for physicochemical and biological
characterization of lipid-polymer hybrid nanoparticles
Parameter/property
Particle size distribution
Surface charge
Morphology
Lipid shell thickness
Interface chemical
composition
Lipid shell fluidity
Lipid shell transition
Drug loading and
entrapment
Drug release
In vitro cellular uptake
Cell viability and
cytotoxicity

Method of characterization
Photon correlation spectroscopy (94, 102, 134, 141, 153)
Zeta potential by PCS (102, 134, 153)
TEM (86, 89, 102, 134), SEM (94, 141, 154), AFM (155),
CLSM (89, 123), fluorescence microscopy (89, 134)
SAXS (87), TEM (87)
XPS (89, 98)
FRAP (123), fluorescent probes (106)
NMR (87, 88, 96), FTIR (96), DSC (96), PXRD (96)
HPLC (98), dialysis (86, 134), centrifugation (141),
membrane filtration (102)
Dialysis followed by HPLC(86, 134)/UV-visible
spectrophotometry(96, 141), sample and separate method
(98, 102)
Fluorescence microscopy (94, 97, 134)
MTT cell viability assay (86, 98), MTS cell proliferation
assay (134), tryptan blue staining (102), clonogenic assay
(102), ATPLite 1-step luminescence ATP detection
assay(94)
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external energy such as heating, sonication or agitation helps to rearrange lipids onto the
polymer particles. Surface charges also play a major role in forming the lipid layer onto
polymer particles. Stable particles are formed by electrostatic interactions between a
negatively charged polymer and a cationic lipid. Moreover, affinity of the phospholipid
for the polymer particle depends on the hydrophilicity of the polystyrene surface. Surface
hydration of the polystyrene particles can shield the attractive forces and decreases
affinity for the lipid monolayer coverage.
Structure of CSLPHNPs. The morphology, two dimensional fluidity, lipid shell
permeability, and distribution of lipids in polymeric particles have been assessed using
confocal laser scanning microscopy and cryo-transmission electron microscopy (CryoTEM) (123). Often, samples in TEM are stained with uranyl acetate, osmium tetraoxide,
or phosphotungstic acid for better imaging contrast to differentiate the core-shell
structure. Zhang and co-workers deciphered the structure of the PLGA-lecithin-DSPEPEG LPHNs by TEM using negative staining of the low electron dense lipid layer (69).
Information about the structure of the hybrid particles are obtained by using conventional
fluorescence microscopy and confocal laser scanning microscopy (CLSM). For example,
the co-existence of a polymer core and lipid layer has been confirmed after overlay of the
fluorescent images of nitro-2-1,1-benzoxadiazol-4-yl phosphatidyl choline (NBD-PC) at
365 nm for the polymeric core and at 534 nm for the lipid layer (89). As indicated
previously, lipid composition and its concentration play a significant role in the formation
of various nanostructures of hybrid particles. Thus, the presence of excess lipid during
preparation leads to the formation of multilamellar lipid coatings on the particle or may
form free liposomal vesicles. Bershteyn et al (123) reported two distinct structures when
an excess concentration of lipid (DOPC) and lipid-PEG conjugate (DOPC-PEG) were
used to prepare lipid/PLGA hybrid NPs. In the first case when excess DOPC was used, it
formed an onion-like structure with multilamellar stacks of lipid packed together around
the polymer core. When 10% mole of DOPC was replaced by DOPC-PEG, lipid
“flowers” were formed with “petals” extruding from the polymer core.
Stability. Evaluation and optimization of physical or colloidal as well as chemical
stability are required for any nanoparticle based drug delivery system to prepare a stable
product with an acceptable shelf-life. The phospholipids that constitute the shell of the
CSLPHNPs may act as surfactants to stabilize the hybrid NPs (156-158). Often times, the
phospholipids alone are not enough to stabilize the system. For instance, the electrostatic
repulsion between colloidal particles failed to stabilize a hybrid nanoparticle based
system prepared from poly(lactic acid) core and lipid mixtures composed of
DPPC/DPTAP when incubated in high ionic salt concentration such as 10 mM aqueous
salt solution (159).
Four major factors that affect the colloidal stability of lipoparticles have been
identified. These include pH and ionic strength of the aqueous medium, temperature,
curvature of radius of lipoparticles, and vesicle-to-particle ratio (87). These factors are
discussed below.
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Lipoparticles usually become unstable with an increase in ionic strength of the
continuous phase. For lipoparticles composed of a poly-lactic acid (PLA) core and
DPPC/DPTAP lipid shell, a significant increase in particle aggregation was seen when
the ionic strength of the aqueous phase increased from 1 mM to150 mM of NaCl
solution. This phenomenon can be explained as ion screening of electrostatic charges on
the particle surface(160).The adsorption of lipid onto polymer particle is affected by
incubation temperature. When incubation occurs at temperature (T) below glass transition
temperature (Tg), the entire vesicle adheres onto particles without rupturing. However,
when T is greater than Tg, lipid reorganization onto the polymer particle is accelerated.
Sicchierolli and Carmona-Riberio (161) studied the adsorption of DPPC lipid on the
surface of polystyrene microspheres at two different temperatures (25°C and 65°C) for 1
h. High adsorption of DPPC at room temperature suggested entire vesicle adhesion on
latex particles. But at a temperature above Tg for the lipid, monolayer coverage on
polystyrene particles was observed because of a change in the physical state of the lipid
into a liquid-crystalline state. Spontaneous or intrinsic curvature of the lipid monolayer
assemblies arises from the geometric packing of the lipid molecules by intermolecular
interactions (162). Generally, small vesicles having a higher curvature radius tend to coat
the smaller polymer particles (163). For spherically shaped monolayers, intrinsic
curvature (R) of the lipid monolayer membrane can be derived from the Equation 1-1:
ͳΤܴ ൌ ሾʹሺܸ Τ ݈ܣെ ͳሻȀ݈ ሿΤሾͳ  ඥሺͶܸ Τ ݈ܣെ ͳሻȀ͵ሿ

(Eq. 1-1)

Where V is the volume of the entire lipid molecule, l is the length, and A is the
area of the lipid head group at the lipid-water interface.
The proportion of lipid vesicles with regard to polymeric particles is an important
parameter affecting overall size and stability of lipoparticles. Vesicle to particle ratio
(Av/Ap) can be expressed by the Equation 1-2:
 ݒܣΤ ܣൌ

ܶݏ݈݁ܿ݅ݏ݁ݒ݈݄݀݅݅݁ݐ݂ܽ݁ݎ݂ܽ݁ܿܽݎݑݏ݈ܽݐ
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(Eq. 1-2)

Where Ap can be determined from the particle number and mean diameter. Based
on the study by Troutier et al (90), it can be hypothesized that the stability of the
lipoparticles depends on the value of Av/Ap. For instance, a high Av/Ap value suggests
electrostatic stabilization of the lipoparticles; while a low Av/Ap value suggests
aggregation will occur. The aggregation behavior at low Av/Ap values can be attributed
to the formation of bridges between lipid and polymer and incomplete coating that
exposes the anionic zone of the polymer.
One approach to improve the colloidal stability of CSLPHNPs is by steric
repulsions between particles after incorporating a lipid- PEG conjugate into the
formulation (164, 165). It has been reported by Thevenot et al that lipoparticle
stabilization was improved drastically from 1 mM to at least up to 150 mM sodium
chloride solution for a period of 1 year at 4oC when 10 mol % lipid-PEG conjugate was
added into the formulation (159). In the process of stabilization by lipid-PEG conjugate,
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two important aspects were identified; PEG degree of polymerization (n) and molar
percentage of lipid-PEG conjugate, which affected the final stability of lipoparticles. The
stability of lipoparticles towards ionic strength revealed that longer the PEG degree of
polymerization (i.e. chain length), the greater the stability in polar salt solution. The
decreasing order of lipoparticle colloidal stability was reported as a function of PEG
degree of polymerization: PEG113> PEG45> PEG16. The molar percentage of lipid-PEG
conjugate also affected the amount of lipid adsorbed onto particles, thereby affecting the
surface coverage by PEG. The amount of lipid-PEG adsorbed decreased when n
increased. Due to the steric hindrance by long PEG chains, lipid-PEG45 conjugate
adsorption was 3 mol % compared to initial amount of 10 mol %.
Another approach to improve the colloidal stability of CSLPHNPs is to
incorporate suitable amounts of additional surfactants along with the phospholipids (141).
For example, addition of 10 % of D-α-tocopherol polyethylene glycol 1000 succinate,
TPGS (an amphiphilic biocompatible, biodegradable surfactant ) along with PC confers
stability of CSLPHNPs in phosphate buffered saline (141). Reasonably, the projection of
the long and bulky PEG chain of the TPGS enhances stability as compared to small
choline head group of PC (166). Finally, lyophilization may be used to further enhance
the colloidal stability of CSLPHNPs in storage (167).
Unlike the physical stability issue that is a common concern for CSLPHNPs
dispersions, the chemical stability is drug specific depending on the presence of
susceptible functional groups and also the aqueous solubility of the compound. For
example, drug molecules containing esters and amides are susceptible to hydrolytic
degradation, while oxidative degradation is common for amine compounds (168). For
poorly water soluble drug molecules, the possibility of chemical reactions in CSLPHNPs
is not as substantial as that in solution-based formulations. Considering the inactive
ingredients of CSLPHNPs, the phospholipids may degrade by hydrolysis and oxidation
reactions during their storage in aqueous dispersions (169). The common strategy to
enhance the chemical stability of CSLPHNPs is to transform the nanoparticles dispersion
into dry solid dosage form using lyophilization technique with suitable cryoprotectants
(167, 170).

Immunocompatibility of CSLPHNPs
Drug delivery systems including CSLPHNPs should be biocompatible,
hemocompatible and immunocompatible thus avoiding undesirable interactions with the
immune system (171). The recognition of therapeutic nanoparticles as foreign entities
may result in multilevel immunological responses (e.g. cytokine release, interferon
response and lymphocyte activation) leading to severe toxicity and/or lack of therapeutic
benefit (172).
Since a CSHLPNs system is composed of polymeric core nanoparticles and lipid
shell, the immunocompatibility properties of the individual components should be
considered. There is ample evidence showing the immunogenic properties of polymeric
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nanoparticles composed of synthetic polyesters and polyanhydrides (173, 174). Although,
the phospholipid bilayers are made up of natural phospholipids found in body, it has been
reported that therapeutic liposomes containing paclitaxel, or docetaxel activate the
complement system resulted in adverse immune phenomenon C activation-related
pseudoallergy (175, 176). Complement activation can be enhanced by the
physicochemical properties of liposomes including size (177, 178), charge (179),
aggregation (180), polyamino coating (181), presence of endotoxin contaminants (182),
drugs like doxorubicin (180), and PEGylation (183). Liposomes are vulnerable to
immune recognition since the vesicles mimic the size and shape of some pathogenic
microbes, ectosomes, nanobacteria, and viruses. Additionally, lack of self-discriminating
molecules (e.g. C control proteins) on the phospholipid bilayers makes them susceptible
to immune attack (171, 184-186). Currently there is scarcity of immunocompatibility
studies on the CSLPHNPs and detailed investigations are warranted. The pioneering
work on the immunological characteristics of CSLPHNPs including complement system
activation, plasma/serum protein binding and coagulation cascade activation was reported
by Salvadore-Morales et al (153). Among the three surface functional groups of
CSHLPNs tested, the methoxy group induced lowest level of complement activation
compared to the amine and carboxyl groups. They showed that the surface chemistry of
the CSLPHNPs also changed human plasma and serum protein adsorption profiles. The
findings of the complement activation and coagulation assay of their study provided
evidence for good biocompatibility of CSLPHNPs.
Based on the immunocompatibility issues of polymeric core NPs and liposomes,
it is necessary to evaluate the immunocompatibility properties of the CSLPHNPs. Several
in vitro and in vivo techniques such as complement activation assay, platelet count and
function test, plasma coagulation, and protein binding studies are available (171, 187).
Assessment of the complement activation proteins (e.g. SC5b-9, Bb, C4d) using enzymelinked immunosorbent assay is one of the most useful in vitro predictors of the
immunological reactions (188).
The immunocompatibility of a complex drug delivery system such as CSLPHNPs
is often challenging to predict based on their physicochemical properties due to the
composition of formulations that differs both in nature and percentage of lipids and
polymer. Moreover, the immunological response not only depends on the biomaterials
but also on the host innate immune reactivity. Therefore, detailed investigations
accounting for both delivery system and patient related factors should be performed to
assess the immunocompatibility.
Applications of CSLPHNPs
Various applications of the CSLPHNPs are summarized in Table 1-3. Among
their versatile applications, some major areas with significant clinical implications were
discussed. These major application areas include vaccine adjuvants, cancer targeting and.
gene delivery. In cancer targeting, the most widely investigated disease areas include
breast cancer, prostate cancer and pancreatic cancer.
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Table 1-3.

Summary of the application of CSLPHNPs in drug delivery

Encapsulant

Polymer

Lipid

Particle
size
122-142 nm

EE/DL

Application

Reference

siRNA and Gemcitabine

mPEG-PLGA

Curcumin and RGD

mPEG-PLGA

Lecithin,cholesterol,
DSPE-PEG2000
Lecithin, cholesterol,
RGD-PEG-Chol

EE 42 %

(190)

216 nm

EE 96 %
DL 5 %

SPC

200-300 nm
90-470 nm

Doxorubicin and
GG918
Doxorubicin

HPESO

Tristearin/ stearic acid

150-270 nm

HPESO

Stearic acid

290 nm

Doxorubicin

PLGA

DPPC

195 nm

Paclitaxel

PLGA

Lecithin

83-95 nm

Verapamil HCl
Paclitaxel
Paclitaxel
Docetaxel, indium
111 and yttrium 90

Dextran
PLGA
PLGA
PLGA

Decanoic acid
DLPC
OQLCS
Docetaxel, indium
111 and yttrium 90

342 nm
200-300 nm
184-194 nm
65 nm

Protein
delivery
EE 30 %
Gene
delivery
EE 70–90 % MDR breast
cancer
EE 76 %
MDR breast
cancer
DL 1 %
MDR breast
cancer
NR
Pancreatic
cancer
EE 90-99 % NR
EE 43-56 % Cancer
EE 84-88 % Cancer
EE 60 %
Prostate
cancer

(192)

PLGA

PC, glyceryl
tripalmitate
DOTAP

EE 37 %
DL 10 %
EE 45-90%

Pancreatic
cancer
Brain
targeting for
glioma
Cancer

Mitomycin C

PLA

Lysozyme

PCL

siRNA

213-286 nm

25

(70)
(191)

(193)
(99)
(100)
(138)
(94)
(96)
(98)
(135)
(134)

Table 1-3.

Continued

Encapsulant
AChE
Docetaxel
Docetaxel
Plasmid DNA

Polymer
PMOXAPDMSPMOXA
PLGA
PLGA
PEI

Plasmid DNA

PLGA

Soy lecithin
Lecithin/DSPE-PEG
Triolein/EPC/
DSPE-PEG
DOTAP/DC-Chol

Plasmid DNA

PLA

DPPC/DPTAP

325-340 nm

NR

mRNA

PBAE

DOPC/DOTAP

230-300 nm

NR

siRNA

PLGA

225 nm

NR

7α-APTADD

PLGA

170 nm

EE 78-82 %

Fluoroquinolone
antibiotics
5-Fluorouracil

PLGA

EPC/lecithin/DSPEPEG
Egg PC/DOPE/
TPGS
Phosphatidyl choline

260-420 nm

EE 37 %

600-1100 nm

EE 4-25 %

FITC-BSA

Protamine
sulfate

Cetyl alcohol
/Tripalmitin
Cholesterol/
DSPC/DHA

Lung biofilm
infection
Lung cancer

130-200 nm

EE 19-60 %
DL 5-18 %

Protein
delivery

PGA/ Dextran

Lipid
EPC/DPPC

Particle size
75 nm

EE/DL
NR

Application
Protein
delivery

Reference
(91)

60-70 nm
70-80 nm
128 nm

NR
EE 60 %
NR

(86)
(69)
(95)

100-400 nm

NR

Cancer
Cancer
Gene
delivery
Gene
delivery
Gene
delivery
mRNA based
vaccine
Tumor
suppression
Breast cancer

(141)

(104)

26

(154)
(103)
(194)
(124)
(136)

(130-132)

Vaccine adjuvants. NPs are promising adjuvant delivery systems for enhancing
and directing the adaptive immune response of vaccine antigens (189). Biodegradable
polymeric microparticles and NPs composed of PLGA have been investigated as
potential vaccine delivery systems due to their ability to control the release of antigens
and co-delivering immunostimulatory molecules along with antigens in the same particle
(195). However, low antigen EE and denaturation of the antigen during
nanoencapsulation have limited their development (196, 197). Antigens adsorbed or
covalently coupled onto the surface of pre-synthesized CSLPHNPs could be viable
strategies for vaccine delivery (105, 198). “Synthetic pathogens”, which are surfacemodified biodegradable CSLPHNPs, can be used to imitate structural features of
pathogens for designing vaccine adjuvants (137). In this context, polymeric core
nanoparticles (e.g. PLGA) are advantageous since they activate inflammasome in
antigen-presenting cells and enhance innate/adaptive immune responses (199). In
addition, lipid bilayers displaying protein antigens and molecular “danger signals” (such
as pathogen-associated molecular patterns) create pathogen-mimicking antigens and
related motifs to boost the immune response (105). The surface display of antigen onto
lipid-based NPs has been shown to induce robust antibody responses by mimicking the
structure and surface chemistry of microbial pathogens (200). For example, high IgG
titers (> 106) were observed with sustained levels over 100 days after immunization with
nanograms of ovalbumin antigen conjugated onto the surface of CSHLPNPs along with
monophosphoryl lipid A or α-galactosylceramide as molecular “danger signals” (105).
Moreover, the strategy allows the conjugation reaction to proceed under mild aqueous
conditions thus avoiding harsh processing during encapsulation (178). Additionally, the
immune response can be altered by the presence of heterogeneous surface functional
groups. It has been reported that the presence of amine terminal group of DSPE-PEG on
the PLGA-lecithin CSLPHNPs induced highest complement activation and could be
considered as vaccine adjuvants (153).
Cancer targeting. Recent advancements in nanotechnology have fuelled NPs
development of different sizes, shapes, core physicochemical properties, and surface
modifications for the potential treatment of cancers. CSLPHNPs are being developed for
tumor-selective delivery of anticancer agents to increase the cell-kill eơect while
protecting the healthy tissue from exposure to a cytotoxic agents, thereby reducing
systemic toxic eơects (142). The following section discusses selected studies dealing with
in vitro evaluation and in vivo evaluation. Most of the literature on CSLPHNPs has
focused on in vitro cell culture models as the means to proof of concept.
Breast cancer is the most common form of cancer and affected more than 200,000
females in 2010 in the United States. Multidrug resistance (MDR) is a common cause of
failure of chemotherapy in breast cancer patients (201). MDR is caused by
overexpression of membrane drug efflux transporter P-glycoprotein (P-gp), which
reduces intracellular uptake of anticancer drugs (202). Excellent reviews are available on
the cause and strategies for overcoming MDR (203, 204). For example, a CSLPHNPs
system containing doxorubicin was developed and evaluated for cytotoxicity against
MDR breast cancer cells by Wong et al (99-102). The particle size and EE of the
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CSLPHNPs were reported to be 50-200 nm and 65-80 %, respectively. Cell-kill and
cellular uptake were significantly enhanced in CSLPHNPs forms compared to the
solution formulation. Two possibilities for the mechanism of cytotoxicity of doxorubicinloaded CSLPHNPs were proposed: i) free drug was released from CSLPHNPs and acted
on the cells, and ii) drug-loaded CSLPHNPs entered and released the drug inside cells,
thereby evading the P-gp efflux pump. In a subsequent publication, the authors proposed
that the second mechanism was more likely to happen. Drugs in CSLPHNPs entered the
cells by a combination of diffusion and phagocytosis. Because of the physical association
of the drug with the anionic polymer, the drug was not easily removed by the P-gp efflux
pump. Therefore, chronic suppression of the MDR cell proliferation was observed
because of the continued buildup of drug inside cells (98).
Another potential strategy to overcome MDR of breast cancer cells is to
simultaneously use a combination of chemotherapeutic drug and P-gp inhibitor
/chemosensitizer such as verapamil in a single nanoparticle cargo (204). Similar strategy
using a CSLPHNPs capable of co-delivering doxorubicin and elacrider (chemosensitizer)
was developed and evaluated by Wong et al (99). The particle size was found to be 187272 nm. EE was 71-76 % for doxorubicin and 80-88 % for elacrider. In this study, the
dual agents co-encapsulated in CSLPHNPs showed greatest uptake and anticancer
activity in human MDR breast cancer cell line MDA435/LCC6/MDR.
In another study, a CSLPHNPs system having PLGA core and phosphatidyl
choline shell was designed for loading 7α-APTADD, an investigational aromatase
inhibitor for treatment of estrogen-responsive breast cancer (136). Transferrin, a natural
80 kDa glycoprotein, was conjugated to CSLPHN to target SKBR-3 breast cancer cells
with overexpressed transferrin receptors. EE and mean diameter were measured to be 37
% and 170 nm. Aromatase inhibition activity of the targeted CSLPHNPs was
significantly higher in SKBR-3 cells compared to non-targeted CSLPHNPs.
Prostate cancer is the second leading cause of cancer mortality in men over the
age of 40 in the United States (205). Prostate-specific membrane antigen (PSMA) is a
type II membrane integral glycoprotein overexpressed in prostate cancer cells and has
been identified as a biochemical marker (206). Several PNPs and liposomal targeted
delivery systems were developed for prostate cancer (207-209). A new CSLPHNPs
system composed of a PLGA core and lecithin/DMPE-DTPA lipid shell was developed
for prostate cancer by co-delivering chemotherapeutic drug docetaxel (Dtxl) and the
therapeutic radionuclide yttrium 90 (90Y) (134). The CSLPHNPs were termed as
“chemorad NPs”. They were prepared by the single-step nanoprecipitation method to
produce mean particle size of 65 nm. Oligonucleotide aptamer A10, which has high
affinity and selectivity to PSMA positive prostate cancer cells, was attached to the outer
surface of the CSLPHNPs via coupling reaction with DSPE-PEG to produce targeted
particles (Apt-Dtxl-90Y-NPs). An increase in uptake of chemorad NPs was observed in
the LNCaP prostate cancer cell lines. “Chemorad NPs” were able to kill 80 % of the
LNCaP cells (PSMA-positive) compared to the PC3 cell line (PSMA-negative) and
untargeted control groups. The experimental findings of this study suggested the potential
of chemorad NPs to improve chemoradiotherapy in prostate cancer patients.
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Pancreatic cancer, especially adenocarcinoma of the exocrine pancreas, is the
fourth leading cause of cancer death in the United States (210). However, the current
chemotherapeutic regimen showed little or modest improvement in patient survival
because of poor vascularization and inadequate perfusion of the tumor (211). Liposomal
paclitaxel and gemcitabine (212), cisplatin and gemcitabine (213), curcuminencapsulated PLGA NPs (214), and EGFR-targeted gemcitabine-loaded PLGA NPs (215)
showed promising efficacy in refractory pancreatic cancer in animal studies and clinical
trials. Anti-carcinoembryonic antigen (CEA) half- antibody was conjugated to paclitaxelloaded CSLPHNPs, which were investigated for targeting ability against BxPC-3 (CEApositive) and XPA-3 (CEA-negative) pancreatic cancer cells (94). Antibody conjugated
CSLPHNPs with particle size of 95 nm were prepared by nanoprecipitation via selfassembly of PLGA, lecithin, and DSPE-PEG. Monoclonal antibody was attached to
CSLPHNPs through a maleimide-thiol coupling reaction. Targeting specificity, as well as
enhanced cellular cytotoxicity of paclitaxel-loaded CSLPHNPs was observed in CEA
positive cells compared to their non-targeted counterparts. This can be explained by
occurrence of the receptor mediated endocytosis process which facilitated particle
internalization into cells. Thus, the delivery platform showed therapeutic potential of
CSLPHNPs in the targeting of pancreatic cancer.
There are few available studies reported in the literature based on in vivo
evaluation of drug loaded CSLPHNPs in animal cancer models (101, 131-133, 135). To
best of my knowledge, the pioneering research involving in vivo evaluation of dual drug
loaded CSLPHNPs, known as “nanocell”, was reported in 2005 by Sengupta et al (133).
The delivery system comprised of chemotherapeutic agent doxorubicin conjugated to
PLGA forming polymeric core (nucleus, similar to a cell) and the antiangiogenic agent
combretastatin entrapped within the lipid shell. Tumors were induced by implanting
GFP-positive BL6/F10 melanoma cells or lewis lung carcinoma cells in male c57/BL6
mice. Intravenous administration of different combinations of CSLPHNPs containing
doxorubicin and/ combretastatin showed that CSLPHNPs containing dual agents
exhibited distinctly greater reduction in tumor volume with increasing percent survival in
Kaplan-Meier survival graphs compared to CSLPHNPs with other combinations. The
study proved that the dual agent loaded-CSLPHNPs treatment induced inhibition of
tumor growth in a dose-dependent manner with more susceptibility towards melanoma
than lung carcinoma. In addition, white blood cell count assay indicated that the delivery
system resulted in least systemic toxicity compared with other combinations.
Another study dealt with the in vivo evaluation of the doxorubicin-loaded
CSLPHNPs in the solid tumor model induced by injecting EMT6 mouse mammary
cancer cells intramuscularly into the hind legs of BALB/c mice (101). The cationic
anticancer agent doxorubicin was complexed with anionic polymer HPESO to form a
core, which was then covered by the lipid mixture of stearic acid and tristearin. The mean
time for the tumor to reach the cutoff size was significantly prolonged by 7 days. The
tumor growth delay value was 100% in mice after receiving 0.2 mg of doxorubicin in the
form of CSLPHNPs compared to blank CSLPHNPs injected into the tumor. The normal
tissue toxicity of the particles was minimal after a single dose of intratumoral injection,
suggesting the usefulness of the delivery system for local treatment of breast cancer.
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Gene delivery. Delivery of nucleic acids represents a challenge and great
opportunities to treat chronic diseases, genetic disorders, and cancers (216). Cationic
liposomes and biodegradable PNPs have been investigated as gene delivery carriers
(217). Polymer-based non-viral carriers have received significant attention because of the
death of a patient in a clinical trial of viral-based gene therapy (218). Among various
non-viral based approaches, particularly polymer and lipid-based non-viral carriers have
several advantages: low immunogenicity, low toxicity, absence of viral recombination,
low production cost, and the possibility of repeated administration (219).
Cytotoxicity, stability in serum, duration of gene expression, and particle size of
the non-viral based carriers still remain major limitations of lipid and polymer-based
systems. Recently, CSLPHNPs have emerged as an alternative, biodegradable, stable,
and long-lived nanoparticle vector delivery system. Plasmid DNA encoding luciferase
reporter gene was entrapped in CSLPHNPs composed of PLGA and cationic lipids
DOTAP/DC-cholesterol (154). The CSLPHNPs (100-400 nm) were able to transfect the
luciferase gene in adherent 293 human prostate cancer cells 500-600 times more
efficiently than did unbound DNA after 48 h. Another CSLPHN was reported by Li et al
(95) for efficient non-viral gene delivery with higher transfection efficiency and lower
toxicity compared to commercial LipofectamineTM2000. In another study, CSLPHNPs
with a mean particle size of 128 nm were prepared by emulsion evaporation technique
using different combinations of triolein, polyethylenimine (PEI), egg yolk
phosphatidylcholine (EPC), and PEG-DSPE. Plasmid DNA was complexed with NPs by
adsorption. A green fluorescent protein intensity study revealed that the transfection
efficiencies of CSLPHNPs/DNA complexes were 37 % and 34 % for HEK293 and
MDA-MB-231 cells, respectively. Transfection efficiency was significantly higher than
that of commercial LipofectamineTM 2000. Additionally, the proton-sponge effect
destabilized the endosomal membrane and enhanced transfection. PEG helped as a
protective layer and reduced the degradation of plasmid DNA by lysosomal enzymes
after entering the lysosome.
For siRNA delivery, cationic nanoscale complexes such as lipoplexes or
polyplexes were used successfully to deliver siRNA (220). But some of these systems
have disadvantages such as toxicity, induction of inflammatory responses and instability
in serum. Shi and coworkers (124) designed a relatively neutral surface charged hybrid
nanostructure capable of protecting siRNA and lipoplexes from physiological
environments. This delivery system was termed “differentially charged hollow core/shell
lipid-polymer-lipid hybrid nanoparticles” which were composed of four functional
building blocks; a positively charged inner hollow core made up of cationic lipid, a
hydrophobic PLGA layer, with a neutral lipid layer having outer PEG chains.
Combination of a modified double emulsion solvent evaporation method and a selfassemble method yielded an average particle size of around 225 nm and neutral surface
charge. The hybrid system was capable of releasing siRNA in a sustained manner,
enhanced in vivo gene silencing and inhibited luciferase gene expression in murine
xenograft tumors. This strategy has opened another potential avenue for successful gene
delivery for the treatment of multidrug resistant cancers.
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Summary, future prospects and challenges of CSLPHNPs
CSLPHNPs are the alternative platform for drug delivery. These particles design
uses an integrative approach by combining two classes of nanocarriers, namely polymeric
NPs and liposomes. These particles have several beneficial features for treating various
diseases, particularly cancers. Often treatment of a single type of cancer requires
administering multiple drugs, and, in this aspect, CSLPHNPs are promising because they
have to the potential to deliver multiple drugs simultaneously from a single platform.
Specifically, incorporating two drugs into the core and lipid layer can offer a viable
approach to treat MDR and life-threatening diseases. Apart from small molecular weight
drugs, delivery of diagnostic agents such as quantum dots, macromolecules such as
proteins, and genes, offers other exciting strategies with CSLPHNPs. Because their
structural similarity to the viral architecture, CSLPHNPs offer potential as vaccine
adjuvants. Furthermore, recent advancements in the CSLPHNPs delivery system such as
coating PNPs with natural erythrocyte membrane, entrapping quantum dots inside these
hybrid particles and concurrent administration of chemotherapy/radiotherapy, have
shown potential for theranostic applications in the treatment of malignancies and other
diseases.
The design and development of CSHLPNPs as drug delivery platforms have been
concentrated in the architecture and in vitro efficacy. The complexities of these systems
afford new challenges in translating the in vitro efficacies into tangible therapeutic
options. More focused research is warranted, especially in key areas of development
including stability, scale-up, optimization of targeting ligand density, in vivo fate,
toxicity, and pharmacokinetic profiles.
Stability of new drug product is an essential prerequisite. Therefore, the long-term
physical and chemical stability of these hybrid nanoparticles in various environmental
stress conditions need to be systematically evaluated to have a shelf life assigned to the
marketed product. The critical parameters that should be evaluated include, but are not
limited to, particle size distribution, drug entrapment, retention of entrapped drug in the
system, physical robustness of the system, and effect of stressed environments on any of
the aforementioned parameters (221). As with any colloidal system, stability can be a
challenge in the liquid state. Thus, if instability is observed in aqueous states, other
strategies could be evaluated including lyophilization or other stabilization techniques to
address instability issues (170).
Active targeting has been considered to be a significant shift in the paradigm of
therapeutic efficacy of nanoparticulate drug delivery systems (41). Although, these
systems show potential in early in vitro or “proof-of-concept” studies, a number of
factors that can impact its efficacy need to be addressed. One such factor is the
optimization of the targeting ligand on the hybrid NPs surface. The selection of the
targeting ligands should additionally be evaluated because some of these targeting agents
possess pharmacological activity (222). Understanding of the targeting ligand is crucial to
address therapeutic outcomes and also address confounding outcomes due to
polypharmacological inconsistencies.
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The pharmacokinetic and pharmacodynamics (PK/PD) effects of these systems
should be critically evaluated. Traditional PK evaluations are dependent of the
availability of the free drug in the biological system to postulate its PD or metabolic fate.
When drugs encapsulated in CSLPHNPs are administered, the PK/PD profile may be
altered when compared to only the free drug due to altered release of the drug from these
systems. Therefore, the appreciation of this phenomenon is essential in understanding the
final therapeutic outcomes of these systems. A recent review by Li and Huang
specifically addresses this aspect of the PK/PD fate of NPs and should be a valuable
resource for the readers (46).
A primary requirement for any product entering the pharmaceutical market is the
availability of large scale production methods which need to be cost-effective and meet
the regulatory requirements. Current bench scale processes employed for the developing
CSLPHNPs systems are labor intensive and are not amenable to direct scale-up.
Moreover, most of these delivery systems are intended for parenteral administration and
thus directly impact its aseptic production. Although, significant advances in aseptic
processing have been utilized for the manufacturing of CSLPHNPs systems, it often
comes with a high price-tag and can be cost-prohibitive.
Central Hypothesis and Specific Aims
Lung cancer is the leading cause of cancer related death for both men and women
worldwide (1). NSCLC represents 85 to 90 % of all lung cancer cases. Lung cancer
patients are diagnosed at an advanced inoperable stage of the disease with the main
treatment option being chemotherapy with cytotoxic drugs. However, the 5-year survival
rate at advanced stages (III and IV) of NSCLC remains only about 15 % and 1 %
respectively (4). One of the main reasons for the poor survival rates among patients with
advanced stages of NSCLC is the limited efficacy of traditional chemotherapy along with
severe adverse effects of the high doses of cytotoxic anticancer drugs. Besides cytotoxic
chemotherapies, a number of molecularly targeted agents were developed exploiting two
major cancer cell pathways: EGFR and VEGFR (the vascular endothelial growth factor
receptor). EGFR has been identified as the effective molecular target and overexpressed
(50-90 %) in several cancer types including NSCLC (5). In 2004, US FDA approved the
drug, erlotinib (ETB) for the treatment of locally advanced or metastatic NSCLC after
failure of at least one chemotherapy regimen. ETB is a highly selective inhibitor of
HER1/EGFR-TK. The drug binds with the ATP binding site of the tyrosine kinase
domain of EGFR, which blocks the catalytic activity of the kinase, thereby inhibiting
downstream signaling of the pathways responsible for cell proliferation, cell survival,
angiogenesis, and metastasis (6). However, limited therapeutic efficacy along with
several toxicities was reported from the traditional oral delivery of ETB (7, 8).
Additionally, administration of oral ETB tablets is not convenient to cancer patients with
gastrointestinal disorders/abnormalities (27). Another major concern with ETB therapy is
the development of drug resistance by P-glycoprotein mediated efflux pump or other
pathways in NSCLC tumors (30).

32

The low survival rate in NSCLC patients demands the development of novel and
efficacious therapeutic approaches for the treatment of NSCLC. Nanoparticulate carriers
are attractive for cancer therapy due to their ability to enhance accumulation of anticancer
agents at the tumor site, resulting in increased tumor cell kill efficacy, reduction in dose
and dose-related adverse effects to healthy cells (41). There has been some investigations
on the ETB loaded NPs reported in the literature. ETB loaded polymeric NPs in mice has
shown improved efficacy and reduced toxicities associated with the drug (223). Another
study revealed polymeric NPs improved antitumor efficacy of ETB in A549 human lung
adenocarcinoma cells (224). Formulation of reverse micelles containing ETB showed
improved in vitro efficacy of ETB in pancreatic cancer cells (225). Huang and coworkers
examined the inhibition of HER1/EGFR-TK signaling using an anti-EGFR monoclonal
antibody (mAb) and tyrosine kinase inhibitor, which target extracellular and intracellular
domains of the receptor (14). This approach suggests potential new strategy to maximize
effective target inhibition, which may improve the therapeutic efficacy for the treatment
of NSCLC. Recently, our group has published a review on core–shell-type lipid–polymer
hybrid nanoparticles as drug delivery platform (65). This unique platform combines the
mechanical advantages of biodegradable polymeric nanoparticles and biomimetic
advantages of liposomes into a single, integrated platform. The system provides
advantages such as controllable particle size, surface functionality, high drug loading,
potential for entrapment of multiple therapeutic agents, tunable drug release profile, and
good serum stability (65). For the proposed study, core-shell type lipid-albumin hybrid
nanoparticles (CSLAHNPs) were utilized as a novel and unique nanoparticulate carrier
for the delivery of ETB in NSCLC. The schematic diagram of the proposed delivery
system was shown in Figure 1-6. The core was composed of albumin which is a natural
protein present in blood. The shell were composed of 1,2-dipalmitoyl-sn-glycero-3phosphocholine (DPPC) which is a major lung surfactant phospholipid. Both albumin and
phospholipid are biocompatible and biodegradable. Finally, anti-EGFR monoclonal halfantibody (hAb) were conjugated to the CSLAHNPs.
The central hypothesis of my project is that permeability and uptake of anti-EGFR
half-antibody (hAb) conjugated erlotinib (ETB)-loaded CSLAHNPs (targeted) and
erlotinib (ETB)-loaded CSLAHNPs in NSCLC tumor cells is expected to improve the
therapeutic efficacy of ETB while reducing off-toxicities of the drug in the treatment of
EGFR positive NSCLC compared to free ETB in solution (Figure 1-7). Therefore, in
order to test the hypothesis, the following specific aims were proposed:
Aim 1. To design, develop, characterize and optimize CSLAHNPs
The purpose of this specific aim was to prepare and characterize blank
CSLAHNPs without encapsulation of drug ETB to understand the CSLAHNPs delivery
platform. Formulation and process parameters that influence physicochemical properties
including mean size, polydispersity index (PDI), zeta potential, morphology, and related
critical quality attributes CSLAHNPs were identified and optimized to guide subsequent
design, preparation and optimization of ETB-loaded CSLAHNPs.
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Figure 1-6. Schematic representations of albumin nanoparticles (A), liposomes
(B), and CSLAHNPs (C)

34

Figure 1-7.

Schematic representation of the central hypothesis

Targeted anti-EGFR half-antibody conjugated ETB-loaded CSLAHNPs bind to the
extracellular domain of EGFR overexpressed on human NSCLC cells. After receptor
binding and internalization, the drug is released in the cytoplasm and binds with
intracellular tyrosine kinase domain of EGFR and prevents subsequent downstream
signaling pathways.
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Aim 2. To develop, characterize and optimize erlotinib loaded CSLAHNPs
The purpose of this specific aim was to prepare and characterize erlotinib loaded
CSLAHNPs (ETB-CSLAHNPs). Various strategies were used for drug loading in
CSLAHNPs. Formulation and process parameters that influence mean size, PDI, zeta
potential, drug loading, drug entrapment efficiency, morphology, drug release, storage
and serum stability CSLAHNPs were identified and optimized.
Aim 3. To develop, characterize and optimize targeted erlotinib-loaded CSLAHNPs
Anti-EGFR monoclonal antibody (mAb) was selectively reduced to half-antibody
(hAb) fragments and conjugated to ETB-CSLAHNPs via maleimide-thiol conjugation
for the preparation of targeted anti-EGFR hAb conjugated erlotinib-loaded CSLAHNPs
(hAb-ETB-CSLAHNPs). The hAb-ETB-CSLAHNPs were characterized for mean size,
PDI, zeta potential, drug loading, drug entrapment efficiency, morphology, drug release,
storage and serum stability CSLAHNPs.
Aim 4. To evaluate cellular uptake, and efficacy of CSLAHNPs in human NSCLC
cells
The cellular uptake, efficacy, mechanism of uptake, intracellular trafficking, and
up/downregulation of p-EGFR after the treatment of the targeted and
untargeted ETB-CSLAHNPs were evaluated in human lung cancer cells (A549 and
HCC827).
Aim 5. To lyophilize and develop stable CSLAHNPs
The purpose of this specific aim was to improve the shelf-life of the CSLAHNPs
via lyophilization process. The untargeted and targeted liquid formulations were
subjected to lyophilization process to preserve CSLAHNPs as dry powder. The stability
of liquid dispersion and lyophilized dry powder were evaluated after stored at different
storage conditions for various lengths of time.
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CHAPTER 2. PREPARATION, CHARACTERIZATION, AND
OPTIMIZATION OF CORE SHELL TYPE LIPID ALBUMIN HYBRID
NANOPARTICLES
Introduction
Protein based colloidal drug delivery systems prepared from plasma proteins have
attracted much attention because they offer several advantages: biodegradability,
biocompatibility, non-antigenic, easy to prepare, controlled particle size distribution,
various possibilities for surface modification, greater stability, relatively easy to scale up
and binding ability for a number of hydrophilic and lipophilic drug molecules (226, 227).
Among various plasma proteins, albumin has been widely used in versatile drug delivery
systems including microparticles, nanoparticles (NPs), and micelles for various drugs and
diagnostic agents (226, 228). Three different types of albumins can be used in drug
delivery purposes: ovalbumin (229), bovine serum albumin (230), and human serum
albumin (231). Significant amount of drug can be loaded into albumin matrix due to the
presence of drug binding sites (232). Additionally, presence of high quantity of charged
amino acids allow electrostatic attraction and loading of charged drug molecules and
oligonucleotides into albumin matrix (233-236). A significant advantage of albumin NPs
includes its accumulation to the tumor and inflamed site. This is due to the passive
targeting or enhanced permeation and retention (EPR) effect and its active targeting
ability mediated by binding with endothelial gp60 receptors overexpressed on these
tissues (237, 238). Marketed products include albumin NP bound paclitaxel
(AbraxaneTM) which was approved by the US Food and Drug Administration in 2006 for
the treatment of metastatic breast cancer (237, 239, 240). For diagnostic applications, two
albumin NPs based products (Nanocoll® and Albures®) were approved for the detection
of cancer and rheumatoid arthritis respectively (228). Among different types of albumin,
bovine serum albumin (BSA) has been widely used to prepare drug delivery systems
including NPs because of its defined primary structure, non-antigenicity (241), stability,
abundance, low cost, ease of purification, and ligand binding properties (226). It is a
globular protein with molecular weight of ~ 66 kDa and isoelectric point (pI) of 4.7 in
water at 25oC (230, 242). It has a single polypeptide chain consisting of about 583 amino
acids residues, 17 intrachain disulfide bridges, and 1 sulfhydryl group (243). BSA based
albumin NPs (ANPs) are produced by desolvation or coacervation (244-248),
emulsification (249, 250), thermal gelation (251, 252), nanospray drying (253), nabtechnology (254), disulfide bond reduction (255, 256), and self-assembly methods (257).
Desolvation is the most widely used method for the preparation of ANPs. Detailed
investigations on the formulation and process variables of the desolvation method were
reported in the literature (244-246, 258).
NPs can broadly be classified as simple NPs and composite or core-shell NPs
based on the number of materials used and the structural features (259). Simple NPs as
the name implies are composed of a single material whereas composite NPs are made up
of two or more materials. The focus of nanoparticle design over the years has evolved
towards more complex nanoscopic core-shell architecture to combine multiple
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functionalities (116, 260, 261). Core-shell NPs can broadly be described as NPs
comprising of a core (inner material) and shell (outer layer material) (259). A wide range
of combinations of inner and outer materials were used such as organic/organic,
organic/inorganic, inorganic/organic, and inorganic/inorganic (259). Significant
advancement in nanotechnology has enabled to produce not only core-shell NPs with
spherical or symmetric shapes but also other non-spherical shapes (259).
Core-shell type lipid-polymer hybrid nanoparticles (CSLPHNPs), which combine
the mechanical advantages of biodegradable polymeric NPs and biomimetic advantages
of liposomes, have emerged as a robust and promising delivery platform (65, 82, 262). In
CSLPHNPs, a biodegradable polymeric core is surrounded by a shell composed of
layer(s) of phospholipids. Various bioactive molecules such as drugs, genes, proteins, and
targeting ligands can be entrapped, adsorbed, or covalently attached in the hybrid system.
The common choices of biodegradable polymers include polylactic-co-glycolic acid
(PLGA), polycaprolactone (PCL), dextran due to their biocompatibility,
biodegradability, non-toxicity and previous use in approved products (83, 84). Lipids
used are often zwitterionic, cationic, anionic and neutral phospholipids. The examples
include lecithin, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl3-trimethylammonium-propane (DPTAP), 1,2-dioleoyl-3-trimethylammonium-propane
(DOTAP) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). The hybrid
architecture can provide advantages such as controllable particle size, surface
functionality, high drug loading, entrapment of multiple therapeutic agents, tunable drug
release profile, and good serum stability (134). Besides passive targeting of CSLPHNPs
based on particle size, they can be conjugated with appropriate targeting ligands such as
aptamers (134), folic acid (97, 135), transferrin (136), antibody (94), and single-chain
tumor necrosis factor (121) to deliver NPs at the target tissues for treating cancers.
In this project, a unique drug delivery system known as core-shell type lipid
albumin hybrid nanoparticles (CSLAHNPs) was proposed. The delivery system was
comprised of albumin core surrounded by phospholipid layer for the delivery of ETB, a
small-molecule EGFR tyrosine kinase inhibitor for the therapy of NSCLC (previously
described in Chapter 1. Core-shell type hybrid NPs comprising of albumin core is a
unique strategy which has not been reported in the literature till date. BSA was selected
as the biodegradable polymer to: i) form the core of the CSLPHNPs, ii) to support the
phospholipid layer, and iii) to bind the hydrophobic drug molecules. The shell of
CSLAHNPs was composed of DPPC, cholesterol, and DSPE-PEG2000 with a molar
ratio of 60:30:10 respectively. DPPC is the major lung surfactant phospholipid having a
polar head group and two non-polar hydrocarbon tails of palmitic acid (263).
Incorporation of DSPE-PEG2000 has become a preferred strategy to reduce NPs uptake
by RES organs and to increase NPs circulation time (264). All the components (BSA,
DPPC and DSPE-PEG2000) have been approved by the Food and Drug Administration
(FDA) for medical applications. CSLAHNPs were expected to be biocompatible,
biodegradable, and potentially safe as a drug carrier for clinical use.
Particle size and surface characteristics are the two important physicochemical
properties of any nanoparticle based delivery system for intravenous administration.
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These properties mainly affect their transport across biological membranes, body
distribution, and cellular uptake (265-267). The functional or physiologic pore size of the
renal glomerular capillary was found to be 4.5-5 nm in diameter (268). Hepatobiliary
clearance eliminates viruses and other small particles of size 10-20 nm (269). In addition
to size, surface characteristics of NPs influence opsonization process by which proteins
are adsorbed on the particle surface and leads to elimination of the particles from
systemic circulation (264). The mean diameter of blood capillaries or microvessels which
connect arterioles and venules was found to be around 5-10 μm (270). Uncoated bare
NPs of size in the range 2-300 nm are taken up by the liver sinusoidal endothelial cells
while greater than 2-300 nm sized particles are taken up by the Kupffer cells. Therefore,
prolonged circulation of NPs in the blood is desired because it would increase the
probability of extravasation of NPs into the target tissues. For intravenously injected NPs,
a size range of 100-300 nm with a hydrophilic particle surface is expected to be optimum
for drug delivery applications. Majority of the marketed therapeutic and diagnostic NPbased products falls into the size range of 100-300nm. Apart from size, the size
distribution of NPs is another important parameter. It is measured by a parameter called
polydispersity index (PDI). Conceptually, PDI is the measure of the width of particle size
distribution and expressed by a dimensionless number between 0 to 1 (271). If PDI value
is lesser than 0.1, it is considered monodispered size distribution (272). For the present
study, PDI below 0.2 was considered acceptable. Another important NP property is the
surface charge which is measured by zeta potential. The electrostatic potential at the
electrical double layer surrounding the NPs in solution is known as zeta potential. NPs
with zeta potential close to ± 10 mV is considered neutral whereas zeta potential greater
than ± 30 mV indicates strong electropositvity or electronegativity (273). NPs with near
neutral zeta potential or mildly charged surfaces tend to aggregate faster, which may
enhance clearance by the RES. Stronger the surface charge, better is the colloidal stability
of NPs and hence a longer shelf life on storage as well (274). Cationic NPs was found to
interact more with the negatively charged cell membranes thereby enhancing toxicity to
healthy tissues whereas anionic NPs was found to be non-toxic (275). NPs with negative
zeta potential with a magnitude lesser than -30 mV are desirable for in vivo stability and
also for colloidal stability on storage. Therefore, optimization of formulation and process
parameters which control the particle size and surface characteristics would be a rational
approach to improve the efficacy of NPs in biological system. Therefore, the objective of
this study was to identify and optimize formulation and process parameters, and to
develop a prototype formulation to prepare blank CSLAHNPs which could be utilized
subsequently for drug loading and antibody conjugation.
Experimental Section
Materials
Bovine serum albumin (BSA, Cohn fraction V, lyophilized powder, MW ̴ 66000,
purity 95-99%) was obtained from Sigma-Aldrich (St. Louis, MO). The lipids used in this
work were all of research grade. 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)
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and 1,2-distearoyl-sn-glycero-3-hoshoethanolamine-N (poly(ethylene glycol)2000)
[DSPE-PEG2000] were purchased from Avanti Polar Lipids (Alabaster, AL).
Cholesterol, ferric chloride hexahydrate, and ammonium thiocynate were purchased from
Sigma (St. Louis, MO). High performance liquid chromatography (HPLC) grade water,
ethanol, and methanol were obtained from Fisher Scientific (Fair Lawn, NJ). HPLC grade
chloroform and 1N sodium hydroxide solution were purchased from Acros Organics
(Morris Plains, NJ). All other chemicals and reagents were of analytical grade and used
without further purification or characterization.
Preparation of CSLAHNPs
CSLAHNPs were prepared using a two-step method which combined desolvation
method (245) and lipid film hydration method (133, 159). The schematic representation
of the two-step method was shown in Figure 2-1.
In the first step, albumin nanoparticles (ANPs) were prepared by the desolvation
(also known as pH-coacervation) method widely reported (244, 258, 276-278). Briefly,
BSA was dissolved in 10 mM sodium chloride solution and pH was adjusted to 6- 9 with
1N sodium hydroxide solution. Ethanol was added dropwise at 0.5-2 mL/min into the
aqueous phase (water/ethanol volume ratio 1:2 ) until turbidity appeared. The coacervates
formed were hardened for 12 h after adding glutaraldehyde solution and the resulting
albumin nanoparticles were purified by centrifugation at 12000 rpm for 30 min, washed 3
times and reconstituted in 1x PBS.
In the second step, lipids (DPPC, cholesterol, DSPE-PEG2000; molar ratio
60:30:10) dissolved in methanol: ethanol (50:50 v/v) was evaporated in vacuum
evaporator in a round-bottom flask. The dry lipid film was hydrated with ANPs
dispersion (1x PBS) for 15-30 min at 45-50oC. After hydration, two separate methods
were utilized for CSLAHNPs preparation; sonication and extrusion. The dispersion was
sonicated in water bath for 10 min. In parallel, another batch was hydrated with ANPs
dispersion (1x PBS) for 15-30 min at 45-50oC and extruded through a stack of
polycarbonate membranes (0.8 μm/0.4 μm/ 0.2 μm) using mini-extruder. The free
vesicles and micelles were removed by ultracentrifugation at 10000-14000 rpm for 20-30
min, followed by washing thrice. The unbound free drug and other small molecular
weight species were removed by gel filtration column (sepharose CL 4B) by spinning the
sample at 400 g for 5 min with 1x PBS as the elution buffer. The final product was
reconstituted in 1x PBS.
Optimization of ANPs
A number of formulation and process variables were selected to produce optimum
core ANPs with size (100-250 nm), PDI lesser than 0.2 and zeta potential lesser than -30
mV. These variables included the pH of albumin solution (6-9), albumin concentration
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Figure 2-1. Schematic representation of the two-step method for the preparation
of blank CSLAHNPs
In the step I, blank core ANPs were prepared by adding ethanol dropwise, followed by
hardening with gluteraldehyde. In step II, mixture of lipids (DPPC, cholesterol, DSPEPEG2000 at a molar ratio of 60:30:10) were dissolved in ethanol:methanol (50:50 v/v),
followed by evaporation of organic solvents to form a dry lipid film. Finally, the film was
hydrated with ANPs to from blank CSLAHNPs.

41

(5-40 mg/mL), rate of addition of ethanol (0.5-2 mL/min), concentration of the crosslinker gluteraldehyde (0.188-0.97 % w/w), and water-to-ethanol volume ratio (1:1-1:4).
Optimization of CSLAHNPs
Since preparation of CSLAHNPs required incubation of ANPs at or above the
transition temperature of lipids, the thermal stability of ANPs was determined. Briefly,
ANPs were incubated at 45-50oC for 30 min, followed by determination of the
physicochemical properties (size, PDI, and zeta potential). The best method to prepare
CSLAHNPs was selected; either sonication or extrusion. The most important factor that
influenced the physicochemical properties of CSLAHNPs was total lipid-to-albumin ratio
(WLipid/WANPs). An empirical calculation was performed to predict the WLipid/WANPs based
on the assumptions; the spherical ANPs, 100 % DPPC in the bilayer, 5 nm lipid bilayer
thickness. In parallel, different WLipid/WANPs ratios were selected (0, 5, 10, 15, 20, and 30
%) to prepare blank CSLAHNPs.
Characterization of ANPs and CSLAHNPs
The mean hydrodynamic size (Z-average) of ANPs and CSLAHNPs was
determined by dynamic light scattering (also known as photon correlation spectroscopy)
principle using Zetasizer Nano ZS90 (Malvern Instruments, Westborough, MA) equipped
with 50 mW diode laser as a source of light operating at 532/633 nm. Particle scattered
photons were detected at an angle of 90°. The samples were suitably diluted with HPLC
grade water for the determination of Z-avg. Three independent measurements were
performed for each sample. Zeta potential was determined by electrophoretic light
scattering (also known as laser doppler micro-electrophoresis) technique in the Zetasizer
Nano ZS (Malvern Instruments, Westborough, MA). Samples were suitably diluted in
HPLC grade water or 1x PBS, filled into the disposable capillary cell (DTS1070), and
analyzed in triplicate.
The phospholipid (DPPC) that were coated onto ANPs at various WLipid/WANPs %
were quantified by colorimetric assay previously published (279). Briefly, a 2 mL portion
of 0.1 N ammonium ferrithiocynate solution was added to 1 mL of DPPC in chloroform
at various concentrations (0-80 μg/mL). The mixture was vortexed for 2 min, chloroform
layer collected, and optical density was read at 464 nm. A calibration curve of DPPC was
prepared by plotting optical density versus concentrations of DPPC. To determine DPPC
content in CSLAHNPs, an aliquot was added to chloroform, agitated for 2-5 min and
optical density of the chloroform layer was measured after addition of 2 mL of
ammonium ferrithiocynate solution.
Morphology of the ANPs and CSLAHNPs was characterized by transmission
electron microscopy using a negative staining technique. Sequential two droplet method
was used for staining samples with 1% w/v sodium silicotungstate on 400-mesh formvar
support film on copper specimen grid (Electron Microscopy Sciences, Hartfield, PA) and
42

dried. The TEM images were acquired using JEOL 2000EX transmission electron
microscope (JEOL USA, Inc., Peabody, MA) equipped with high resolution digital
camera.
Results and Discussion
In the two-step, ANPs (core) were prepared by desolvation (coacervation) method
in the first step (245). In the second step, the lipid film was hydrated with the ANPs
dispersion at or above the transition temperature of phospholipids, followed by sonication
to obtain CSLAHNPs (87, 88, 133). In the desolvation method, ANPs were prepared by
dropwise addition of a desolvating agent (ethanol or acetone) into aqueous albumin
solution (adjusted to a particular pH) until the solution became turbid. The turbidity was
caused addition of desolvating agent which leads to conformational change in protein
structure by reducing the aqueous solubility of albumin which was phase separated to
form NPs. At this point, NPs were hardened by addition of gluteraldehyde which
crosslinked between ɛ-amino groups of lysine and arginine residues (280, 281). The
hydrophilic surface of the ANPs favors formation of phospholipid bilayer with the
hydrophilic polar head groups facing towards the hydrophilic albumin core. The process
was governed by the ratio of lipids and ANPs (also expressed as WLipid/WANPs). In
addition, the input of external thermal and vibrational energy by heat, sonication and
agitation increased the mobility and rearrangement of lipids onto the ANPs to form
CSLAHNPs.
A number of formulation and process variables were studied during the
preparation ANPs by the desolvation method. As mentioned in the introduction, the
desired physicochemical properties of blank CSLAHNPs include hydrodynamic mean
size around 100-250 nm, PDI < 0.2, and zeta potential < -30 mV. The pH of the albumin
solution prior to ethanol addition significantly influenced mean size of the final ANPs
(Figure 2-2). The mean size drastically decreased from greater than 1μm at pH 6 to 485
nm at pH 7. At pH 8, the mean size further reduced to around 183 nm. However, further
increase in pH to 9 increased size to about 294 nm. The isoelectric point (pI) of the BSA
was reported to be 4.7 to 5.4 (242, 282). When pH was closer to the pI of BSA, ANPs
became unstable as indicated by mean size of greater than 1 μm. When pH was increased
further, carboxyl groups on BSA were ionized to a higher extent. The higher charge
density in the ANPs increased the electrostatic repulsion and decreased the particle size at
elevated pH (245). The high electronegative charge density was evident from the
increased negative zeta potential of ANPs from -15 mV at pH 6 to around -50 mV at pH
9. Similar findings were reported for the optimization of ANPs by the desolvation method
(245). Next, the effect of initial albumin concentration on the mean size and
polydispersity index (PDI) was studied at pH 8 (Figure 2-3). No significant difference in
mean size was observed for 5 mg/mL and 20 mg/mL albumin concentrations while size
increased at 40mg/mL albumin concentration. At a high albumin concentration, ANPs
were close to one another which enhanced coalescence and increase in size. Another
possible explanation is the increased viscosity of the solution at higher albumin
concentration, which caused increased droplet size after ethanol addition and ultimately
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Figure 2-2.

Influence of the pH on the mean size and zeta potential of ANPs

The smallest mean size was obtained at pH 8. Values were presented as mean ±SD (n=3);
albumin concentration: 20 mg/mL; ethanol addition rate: 1 mL/min; water/ethanol (v/v):
1:2; gluteraldehyde-to-albumin ratio: 0.47 % w/w; mean size and zeta potential were
measured in pure HPLC grade water.
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Figure 2-3. Influence of albumin concentration on the mean size and
polydispersity index of ANPs
The smallest mean size was obtained at albumin concentration of 20 mg/mL. Values were
presented as mean ±SD (n=3); albumin solution pH: 8; ethanol addition rate: 1 mL/min;
water/ethanol (v/v): 1:2; gluteraldehyde-to-albumin ratio: 0.47 % w/w; mean size and
PDI were measured in pure HPLC grade water.
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leads to increased mean size. of ANPs. Addition of a chemical cross-linker such as
gluteraldehyde provides better stability, shape, insolubility at high temperatures, and
reduced swelling. In order to study the effect of crosslinking degree on the size and PDI
of ANPs, different gluteraldehyde-to-albumin ratios (% w/w) were used during
preparation of ANPs (Figure 2-4). The gluteraldehyde-to-albumin ratios of 0.188 %, 0.47
%, and 0.94 % w/w corresponded to the 40, 100, and 200 % of the calculated amount
necessary for quantitative cross-linking of 59 episilon amino groups of the lysine in the
albumin molecule (230). It was observed that 0.47 % w/w of gluteraldehyde-to-albumin
ratio produced smallest mean size of ANPs. The effect of rate of ethanol addition on
mean size revealed a higher size at low rate (0.5 mL/min) while reduced size was
obtained from higher flow rates of 1 mL/min and 2 mL/min (Figure 2-5). Finally the
volume ratio of water-to-ethanol showed smallest mean size of ANPs at 1:2 while size
increased at 1:3 and 1:4 ratios (Figure 2-6).
The thermal stability of the ANPs was performed at 45-50oC since this is above
the phase transition temperature of the major lipid component (Tm[DPPC] 41.4oC) present
in the lipid bilayer (283). Thermal stability data showed no significant change in mean
size, PDI, and zeta potential before and after incubation (data not shown). DSC data also
confirmed the thermal stability of serum albumin at 45-50oC (284). No significant
difference in the physicochemical properties of CSLAHNPs was observed for
CSLAHNPs prepared by sonication or extrusion. Sonication was chosen as the preferred
method compared to extrusion for the preparation of CSLAHNPs. This is because a
significant amount of CSLAHNPs were lost during extrusion method. Unlike liposomes
which could deform and pass through the pores of the polycarbonate membrane, the rigid
structure of CSLAHNPs possibly clogged the membrane pores and resulted in poor yield.
The proportion of total lipids with regard to core ANPs (expressed by lipid-to-ANPs
weight ratio or WLipid/WANPs) was an important parameter influencing the overall size and
stability of CSLAHNPs. At high concentrations of phospholipids, free multilamellar
vesicles formed to a greater extent. As a result, the mean size and PDI of CSLAHNPs
increased. Furthermore, the purification of final CSLPHNPs was difficult at a very high
phospholipid concentration. At low or suboptimal lipid concentrations, there would be
insufficient coating on the polymeric core particles, resulting in instability. The number
of phospholipid molecules per unilamellar liposome was calculated based on assumptions
of spherical geometry of liposomes, 5 nm lipid bilayer thickness, and 0.71nm2 surface
area of phospholipid head group (139). Based on the similar assumptions, the
WDPPC/WANPs ratio was calculated to be ~10 % based on the theoretical assumptions of 5
nm DPPC lipid bilayer around spherical 190nm ANPs (core) taking into account the
DPPC molecular surface area of the head group (0.628 nm2) (285) and density of BSA
(1.32 gm/cc). The effect of WLipid/WANPs on the mean size and zeta potential of
CSLAHNPs was studied experimentally to validate the calculated value. When
WLipid/WANPs was increased to 5, 10, 15, 20, 30 %, the mean particle size also increased
gradually from 190 nm to around 300 nm (Figure 2-7). This can be explained by the
formation of multiple lipid layers around the core which increased the mean size of
CSLAHNPs. At around 15 % WLipid/WANPs (equivalent to ~8 % WDPPC/WANPs), mean size
was around 200 nm which was 10 nm higher compared to the ANPs. Zeta potential value
also reduced from -30 mV to about -10mV when WLipid/WANPs increased from 0 to 30 %.
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Figure 2-4. Influence of gluteraldehyde-to-albumin ratio on the mean size and
polydispersity index of ANPs
The smallest mean size was obtained at 0.47 % w/w of gluteraldehyde to albumin. Values
were presented as mean ±SD (n=3); albumin concentration: 20 mg/mL; albumin solution
pH: 8; ethanol addition rate: 1 mL/min; water/ethanol (v/v): 1:2; mean size and PDI were
measured in pure HPLC grade water.

47

Figure 2-5. Influence of ethanol addition rate on the mean size and polydispersity
index of ANPs
The smallest mean size was obtained at ethanol addition rate of 1 mL/min. Values were
presented as mean ±SD (n=3); albumin concentration: 20 mg/mL; albumin solution pH:
8; water/ethanol (v/v): 1:2; gluteraldehyde-to-albumin ratio: 0.47 % w/w; mean size and
PDI were measured in pure grade water.
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Figure 2-6. Influence of water-to-ethanol ratio on the mean size and
polydispersity index of ANPs
The smallest mean size was obtained at water/ethanol volume ratio 1:2. Values were
presented as mean ±SD (n=3); albumin concentration: 20 mg/mL; albumin solution pH:
8; ethanol addition rate: 1 mL/min; gluteraldehyde-to-albumin ratio: 0.47 % w/w; mean
size and PDI were measured in pure grade water.
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Figure 2-7. Effect of lipid-to-albumin nanoparticles weight ratio on the mean size
and zeta potential of CSLAHNPs
The optimum weight ratio of total lipid to the ANPs was found at 15 % to form the lipid
bilayer around core ANPs. Values were presented as mean ±SD (n=3); mean size and
PDI were measured in pure grade water.
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The change in zeta potential was indicative of the formation of lipid shell around the
ANPs. About 60 mol % of the lipid bilayer was composed on DPPC which is a
zwitterionic phospholipid with negative charge on the phosphate group and a positive
charge on the amine (286). The net charge of DPPC molecule is close to zero at pH 7.4.
Therefore with the increase in lipid concentration, the zeta potential of the CSLAHNPs
gradually dropped from -30 mV to -10 mV due to the coating of neutral DPPC around
core ANPs. As shown in Figure 2-7, the WLipid/WANPs of ~ 15 % resulted in CSLAHNPs
with favorable combination of size (200 ± 4 nm) and zeta potential (-15± 2 mV) for drug
delivery application. The optimized WLipid/WANPs of 15 % (which was equivalent to
WDPPC/WANPs of ~8 %) obtained experimentally were also in conformity with the
calculated WDPPC/WANPs of ~10 %. The concentration of the DPPC adsorbed onto
CSLAHNPs was quantified using a colorimetric assay. The data suggested that
WDPPC/WANPs of 4.47 ± 1.12 % w/w were adsorbed out of the initial WDPPC/WANPs of 8 %.
The difference could be explained by the heterogeneity of ANPs population with various
mean sizes which required varied amounts of DPPC to coat the core.
To characterize the structure of CSLAHNPs, they were imaged by transmission
electron microscopy (TEM) with negative staining by sodium silicotungstate. Sodium
silicotungstate stained the lipid bilayer membrane with high electron density compared to
ANPs (core). The TEM image of the ANPs (core) was shown in Figure 2-8. The ANPs
were smooth and spherical in shape with the absence of dark corona at the edges of
particles. Figure 2-9 showed TEM image of CSLAHNPs with distinct dark corona
around the periphery of each CSLAHNP. The thickness of the layer was measured
around 5 nm which confirmed the presence of phospholipid bilayer (shell) around the
core (287). The CSLAHNPs were smooth and spherical in shape with some degree of
polydispersity as seen with core ANPs in Figure 2-8. The particle size observed in TEM
was in good agreement with that obtained by DLS. A slight reduction in size was
observed in TEM compared to DLS. This is because DLS provides the statistical Zaverage hydrodynamic size based on the diffusion coefficient of particles in the liquid
phase using the Stokes-Einstein equation whereas TEM provides estimation of the
projected area diameter of particles in the dried state under high vacuum (288).
Summary and Conclusion
Blank CSLAHNPs with albumin core and phospholipid bilayer shell were
successfully designed, prepared and optimized by the two step method using bovine
serum albumin, DPPC, cholesterol, and DSPE-PEG2000 as the formulation ingredients.
All the ingredients used were biodegradable, biocompatible, non-immunogenic or mildly
immunogenic and approved by FDA for human use. The formulation and process
variables were identified and optimized in thepreparation of CSLAHNPs by the twostep method. Various factors influenced the physicochemical properties including mean
size, polydispersity index, and zeta potential of both ANPs (core) and CSLAHNPs. In the
two-step method, the a number of variables were identified and optimized for the
preparation of ANPs (core) by the desolvation method (first step); albumin concentration
20 mg/mL, pH of the albumin solution at 8, ethanol addition rate 1mL/min, volume ratio
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Figure 2-8.

Transmission electron micrograph of the ANPs (core)

ANPs were spherical and uniform with a low population of smaller particles.
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Figure 2-9.

Transmission electron micrograph of CSLAHNPs

The sample was stained with 1 % sodium silicotungstate. The particles showed smooth
and spherical shapes with moderate degree of polydisersity. The lipid shell appeared as a
dark corona around each particle.
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of water to ethanol 1:2, and gluteraldehyde-to-albumin ratio 0.47 %w/w. In the second
step, DPPC, cholesterol, and DSPE-PEG2000 were used at a molar ratio of 60:30:10 for
the preparation of CSLAHNPs by the lipid film hydration method. The critical parameter
was identified as the weight ratio of lipid-to-ANPs (WLipid/WANPs) during the
optimization of CSLAHNPs. The experimental WLipid/WANPs was found around 15 %
w/w (equivalent WDPPC/WANPs ~ 8 % w/w) which was close to the calculated value (̴ 10%
w/w) based on the theoretical assumptions. TEM images showed smooth and spherical
particles of both ANPs (core) and CSLAHNPs with some degree of polydispersity. A
distinct electron dense corona around periphery of the CSLAHNPs was visible which was
absent in ANPs.
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CHAPTER 3. PREPARATION, CHARACTERIZATION, AND
OPTIMIZATION OF ERLOTINIB LOADED CORE SHELL TYPE LIPID
ALBUMIN HYBRID NANOPARTICLES
Introduction
Lung cancer, particularly non-small cell lung cancer (NSCLC) is the leading
cause of cancer related mortality in both men and women worldwide (2). Erlotinib
hydrochloride (ETB), an EFGR tyrosine-kinase inhibitor, promotes cell cycle arrest and
apoptosis, and leads to the inhibition of angiogenesis and cell invasion (16). ETB was
approved as the second or third line therapy in patients with locally advanced or
metastatic NSCLC after failure of at least one chemotherapy regimen (17). ETB is
available on the market as oral film-coated tablet 25-150 mg, sold under the trade name
Tarceva®, and showed oral bioavailability of 60 % (289). NSCLC treatment requires
long-term administration with a minimum of 4-6 cycles and the drug is likely to attack
both cancerous and normal cells. As a consequence of long term therapy, toxic effects
were observed including severe skin rash and diarrhea. No injectable formulation of ETB
is available in the market, although such a form would be useful for patients with
gastrointestinal abnormalities (27).
The development of an injectable formulation of ETB would be useful for
administering the drug in patients with NSCLC. Nanoencapsulation of anticancer drugs
in colloidal nanocarriers offers the advantages of more favorable pharmacokinetics, drug
protection, the enhancement of therapeutic efficacy, the reduction of potential toxic side
effects and the increase of patient comfort by avoiding repetitive bolus injections (40,
290-292). A recent study showed a reduction in sub-acute toxicity in mice after
intravenous administration of ETB loaded in PLGA NPs (223). Among various
nanoparticulate drug delivery systems, CSLAHNPs have emerged as a promising drug
delivery platform effective for anticancer agents, antibiotics, proteins, and genes. The
system showed advantages of encapsulation of multiple drugs, increased overall drug
payload, controlled drug release profiles, and improved stability (65). Many small
molecular weight chemotherapeutic drugs (135, 138), antibiotics (141), proteins (91) and
nucleotides (103, 194) have been encapsulated or entrapped in CSLPHNPs (70, 277, 293300). CSLPHNPs can be loaded with either a single drug or two drugs (133, 145, 301).
For single drug loaded CSLPHNPs, the drug can be loaded into both the polymeric core
as well as in the lipid shell, thereby increasing the total drug payload in the system. For
two drugs, CSLAHNPs can also be co-loaded with one drug in the core and the other one
in the shell (145). This is a unique feature of CSLPHNPs which can combine multiple
functionalities in a single delivery platform. There are two commonly used strategies for
drug loading in CSLPHNPs; incorporation method and ad/absorption method. In the
incorporation method, drug(s) is/are incorporated during the preparation step i.e. in the
core and/or in the lipid film. Another option is to adsorb or absorb the drug with the cores
and lipid vesicles separately before combining to form CSLPHNPs. However, the DL is
generally expected to be better in the incorporation approach than the adsorption
approach (146). The adsorption method has been used to load DNA into lipoparticles
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composed of PLA core/DPPC-DPTAP lipid shell (103). The macromolecules or proteins
show greatest loading efficiency near its isoelectric point when it has minimum solubility
and maximum adsorption (147). For small molecules, the use of ionic interactions
between the drug and polymer can be an effective way to increase the drug loading (96).
Examples of the factors which may influence the DL and EE are aqueous solubility of the
drug, affinity and miscibility of the drug in both polymer and lipid phases (96), amount of
lipid (144), drug-lipid charge interactions (141), aqueous phase pH (148), and methods of
preparation. Often it is required to carry out in-depth physicochemical characterization
during preformulation studies to optimize LC and EE (149). For instance, Li et al have
analyzed the combined solubility parameters and partition coefficients for screening the
best lipid and polymer for the highest LC and the maximum binding capacity to the
cationic drug verapamil (149). Based on the approach, they have reported drug EE
greater than 90 % and DL between 5 to 36.1 % (96). The amount of the lipid is also a
decisive factor for EE of lipophilic drugs in CSLPHNPs. Liu et al reported the decrease
in EE from 42 % to 15% when the lipid component was lowered from 0.1 % to 0.01 %
for paclitaxel particles (144). Drug lipid charge interactions may be important for
encapsulation of drugs. Cheow et al reported successful encapsulation of zwitterionic
levofloxacin and ofloxacin when PLGA polymer and phosphatidyl choline (PC) lipid
were used, whereas formation and loading of cationic ciprofloxacin into the CSLPHNPs
was unsuccessful (141). When PC was replaced with non-ionic polyvinyl alcohol,
ciprofloxacin loaded CSLPHNPs were successfully produced. The results suggested the
possibility of unfavorable ionic interactions between the anionic PC and cationic
ciprofloxacin for the failed formulation. The method of preparation also affects the DL
and EE. The method used during core PNPs preparation, such as solvent displacement
method leads to poor DL and EE for hydrophilic compounds (150). Another problem of
the two-step method is that encapsulated drugs leak out before the lipid coat is formed
(141).
For the present work, bovine serum albumin (BSA) was selected as the core
material with phospholipids (DPPC, cholesterol, DSPE-PEG2000) as the shell for the
loading of ETB in CSLAHNPs. Serum proteins including albumin offer several
advantages; biodegradability, biocompatibility, non-antigenic, easy to prepare, controlled
particle size distribution, various possibilities for surface modification, greater stability,
relatively easy to scale up and binding ability for a number of hydrophilic and lipophilic
drug molecules (226, 227). BSA is a well-known globular protein which has been wellinvestigated over the past 40 years (302). The molecule consists of three intrinsic
fluorophores; tryptophan (trp), tyrosine, and phenylalanine with two trp residues; trp-212
and trp-134 (243). Trp-212 is located within a hydrophobic binding pocket and Trp-134
on the surface of a molecule(243). The interaction and binding of drugs with albumin is
of great importance in various biomedical applications, particularly drug delivery and
receptor targeting. ETB-loaded CSLAHNPs (ETB-CSLAHNPs) with high drug payload
would be advantageous in maximizing the therapeutic efficacy of ETB for the therapy of
NSCLC. The objective of the study was to optimize drug loading strategies in
CSLAHNPs along with investigation of the formulation and process variables that
influence physicochemical properties of ETB CSLAHNPs.
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Experimental Section
Materials
Bovine serum albumin (BSA, Cohn fraction V, lyophilized powder, MW ̴ 66000,
purity 95-99 %) and glutaraldehyde solution (25 % in water) were obtained from SigmaAldrich (St. Louis, MO). Erlotinib hydrochloride (purity 99 %) was obtained from LC
Laboratories (Woburn, MA). The lipids used in this work were all of research grade. 1,2dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3phoshoethanolamine-N (poly(ethylene glycol)2000) [DSPE-PEG2000] were purchased
from Avanti Polar Lipids (Alabaster, AL). Cholesterol, ferric chloride hexahydrate, and
ammonium thiocynate were purchased from Sigma (St. Louis, MO). High performance
liquid chromatography (HPLC) grade water, ethanol, and methanol were obtained from
Fisher Scientific (Fair Lawn, NJ). HPLC grade chloroform and 1N sodium hydroxide
solution were purchased from Acros Organics (Morris Plains, NJ). All other chemicals
and reagents were of analytical grade and used without further purification or
characterization.
Quantification of erlotinib
A sensitive reversed phase HPLC method was developed and validated to
quantitate ETB in the CSLAHNPs. HPLC system consisted of a Waters 600 controller,
Waters 717 plus auto sampler and a Waters 2996 photodiode array detector. Data were
acquired and processed with Waters Millennium 32 software (version 4.0).
Chromatographic separation was achieved on a NovaPak® C18 reverse phase column
(3.9 X 150 mm) from Waters (Milford, MA). The isocratic mobile phase consisting of
acetonitrile and acidified water pH 2.6 (40:60, v/v) was pumped at a flow rate of 1.0
mL/min with an injection volume of 20 μL. ETB (retention time, 5.0 min) was monitored
at 346 nm with a photodiode array detector.
Optimization of drug binding to albumin
The drug binding capacity of albumin was determined experimentally. The
various parameters or variables that affect drug binding with BSA were investigated and
optimized to obtain ETB-ANPs with highest drug loading capacity. Briefly, albumin
solution (1 mg/mL) and aliquots of ETB (drug) in DMSO were added and incubated in
various pH conditions for 0-24 h at both room temperature (RT) and at 37oC. At
predefined time intervals, the sample was filtered through Amicon® Ultrafiltation device
(MWCO 30 kDa) after addition of twice the volume of acetonitrile/water (40:60) mixture
to extract the unbound drug in the filtrate. Drug concentration in the filtrate was
determined by HPLC method stated above.
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Preparation of ETB-ANPs
Erlotinib loaded ANPs (ETB-ANPs) were prepared by two different methods:
incorporation method and absorption method. The method that provided highest drug
loading efficiency was chosen.
In the incorporation method, albumin was dissolved in water and drug dissolved
in DMSO as cosolvent. Then, albumin solution and drug solution were incubated together
at various ratios of drug to albumin: 2, 4, 8, 12 or 24 h at different pH conditions (3.4, 5.4
or 7.4) and at different temperature conditions (20 oC or 37oC). Drug loaded ANPs were
prepared by first adjusting the pH of the albumin drug mixture to pH 8-9, followed by
addition of ethanol dropwise at 1 mL/min until turbidity appeared. The nanosized
droplets or coacervates formed were hardened for 12 h after adding glutaraldehyde
solution (0.47 % w/w of BSA) and the resulting ETB-ANPs were purified by
centrifugation at 12000 rpm for 30 min (159). ETB-ANPs were also washed thrice.
Drug loading in ANPs can be accomplished by ad/absorption method because of
the presence of drug binding sites in albumin molecules (303, 304). In the ad/absorption
method, ANPs (core) was first prepared by desolvation method as discussed in the
previous chapter. Then, ANPs and drug solution in DMSO were incubated together at
various drug to albumin ratios, 12 or 24 h, at different pH conditions (3.4, 5.4 or 7.4) and
at different temperature conditions (20 or 37oC). The ETB-ANPs were purified by
centrifugation at 12000 rpm for 30 min (159).
Preparation of ETB-CSLAHNPs
ETB-ANPs that were prepared in the previous step were used in the preparation
of ETB-CSLAHNPs. About 5 % w/w of additional drug/lipids was incorporated into the
lipid film. Drug and lipids (DPPC, cholesterol, DSPE-PEG2000; molar ratio 60:30:10)
were dissolved in a small quantity of methanol/ethanol (50:50 v/v) in a round bottom
flask and evaporated in vacuum evaporator for 1-2 h to form dry lipid film. The lipid film
was hydrated with ANPs dispersion in1x PBS) for 15-30 min at 45-50oC. The dispersion
was sonicated in a bath sonication for 10 min. The optimized lipids to ETB-ANPs ratio of
15 % w/w was used as described in Chapter 2.
Purification of ETB-CSLAHNPs
The free vesicles and micelles were removed by ultracentrifugation cycle at
10000-14000 rpm for 20-30 min, followed by washing thrice. The unbound free drug and
other small molecular weight species were removed by gel filtration column (Sepharose
CL 4B) by spinning the sample at 400 g for 5 min with 1x PBS as the elution buffer. The
final product was reconstituted in 1x PBS.
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Characterization of ETB CSLAHNPs
The mean diameter, PDI, and zeta potential of the ETB-CSLAHNPs were
determined using the methods reported in Chapter 2. Particle surface morphology and
shape of the ETB-CSLAHNPs were characterized by TEM as mentioned in Chapter 2.
In order to examine the particle surface morphology and shape, scanning electron
microscopy (SEM) was also used. A concentrated aqueous suspension was spread over a
slab and dried under vacuum. The sample was shadowed in a cathodic evaporator (also
known as “sputter coater”) with a gold layer of 20 nm thick in an argon gas environment
at 45 mA current for 5 seconds. Photographs were taken using a JSM-5200 Scanning
Electron Microscope (Tokyo, Japan) operated at 10 kV.
Yield of CSLAHNPs was determined by microgravimetry analysis (305). An
aliquot (50-100 μL) of the CSLAHNPs dispersion was put in an aluminium pan, dried for
2h at 80oC, and cooled off. Subsequently, the pans were weighed with a microbalance.
The yield (mg/mL) was calculated from the difference in weight of the empty and
CSLAHNPs filled pan.
Drug entrapment efficiency (DEE) and drug loading (DL) of ETB-CSLAHNPs
were quantified by HPLC method as reported earlier in this chapter. For comparison,
DEE and DL of ETB-ANPs (core) were also quantified by HPLC method. The drug was
extracted from CSLAHNPs/ANPs using acetonitrile/water (40:60 v/v) as solvent under
sonication for 30-45 min. After centrifugation, the supernatant was injected in HPLC
system to determine the quantity of ETB using the method previously reported. DEE and
DL were calculated by the Equation 3-1 and Equation 3-2 respectively.
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(Eq. 3-1)

(Eq. 3-2)

Transmission infrared spectra were recorded on a Fourier transform infrared
(FTIR) spectrophotometer (Perkin-Elmer Spectrum BX, Perkin-Elmer Inc., Norwalk, CT,
USA). The FT-IR spectra were obtained by averaging 32 scans at a resolution of 2 cm−1.
Thermal analysis was conducted using DSC 2010 differential scanning
calorimeter (TA Instruments, New Castle, DE). The temperature and heat flow
calibrations were performed at a heating rate of 5°C/min from 0 to 200°C with indium as
a standard substance. Powder samples, 1–5 mg each, were analyzed at the same settings
under a purge of nitrogen (50 mL/min). Each analysis was performed in triplicate.
Drug release was quantified in 4000 mL of dissolution media (PBS pH 7.4 and
acetate buffer pH 5.4) using dialysis method previously reported (69). The in-house set
up for in vitro drug release experiment was shown in Figure 3-1. A 100μL portion of the
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Figure 3-1. Schematic diagram of the in-house experimental setup for in vitro
drug release study
The ETB-CSLAHNPs liquid dispersion was equally divided and placed in minidialysis
tubes (MWCO 3.5 k Da). The tubes were put inside the floater and placed in a beaker
containing dissolution medium kept on a magnetic stirrer to agitate the medium. The
beaker and the magnetic stirrer were kept inside an environmental chamber maintained at
37oC.
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ETB-CSLAHNPs dispersion in 1x PBS were pipetted out and added into each Slide-ALyzer MINI dialysis microtubes with a molecular weight cutoff of 3500 Da (Pierce,
Rockford, IL). Minidialysis tubes were kept in a floater which was placed in a beaker
containing 4000 mL of the dissolution medium (PBS pH 7.4 or acetate buffer pH 5.4)
under magnetic magnetic stirring at 75 rpm at 37oC. The entire set up was kept inside a
temperature controlled oven. At predefined time point, dialysis tubes containing samples
were taken out, extracted in acetonitrile/water (40:60 v/v) with sonication or vortexing
for 0.5-1 h at room temperature. After centrifugation, the samples were injected in HPLC
to quantify the amount of drug released in specified time points. Data of the ETB release
from ETB-CSLAHNPs were analyzed for release kinetics by zero-order, first order,
Higuchi, Hixon-Crowell, and Korsemeyer-Peppas model (306, 307).
The colloidal stability of CSLPHNPs in serum was performed according to the
previously published absorbance (93, 125). CSLAHNPs were suspended in 50 % fetal
bovine serum (FBS) with a final nanoparticle concentration of 1 mg/mL (dispersed in 1x
PBS). In order to do this, particles were washed in PBS using Amicon® Ultrafilter and
concentrated to 2 mg/mL. An equal volume of FBS was then added. Samples were
incubated at 37oC with periodic light shaking. At each time point, an aliquot of NP
solutions was at predetermined time points (0, 0.5, 1, 2, 3, 4, and 6 h). Due to interference
of high concentration of plasma proteins at 50 % FBS, absorbance measurements were
conducted at 560 nm for each time point using a UV-Visible Spectrophotometer. The
measurements were performed in triplicate at room temperature.
Results and Discussion
For the purpose of rational design of ETB-CSLAHNPs, preformulation
characterization studies were performed. ETB is a quinazolinamine derivative with the
molecular weight of 429.9, pKa of 5.42 at 25oC with pH dependent solubility profile (9).
Increased aqueous solubility was observed at a pH of less than 5 due to protonation of the
secondary amine (9). The pH of maximum solubility occurs at pH 2. Pharmacokinetics
data showed 95 % binding with plasma proteins in humans (9). Binding of ETB with
bovine serum albumin (BSA) was studied (308, 309). BSA has three homologues
domains (I, II, III) with each domain having two sub-domains (A and B) and 17 disulfide
bonds (310). Human serum albumin (HSA) also has three domains (I, II, III) with each
having two subdomains and stabilized by 17 disulfide bridges (243). The major drug
binding sites in BSA and HSA are located in the hydrophobic cavities in subdomains IIA
and IIIA (311, 312). Because of the structural similarities with HSA, BSA has been
frequently used as a model protein for drug binding studies (313). The binding of ETB
with BSA was investigated by Liu et al (308). Using NMR, spectroscopic,
thermodynamic and molecular modeling methods, they reported that ETB was bound to
domain II of BSA with high affinity through hydrogen bond and van der Waals forces.
Rasoulzadeh et al also reported the formation of ETB-BSA complex through
hydrophobic interaction and the presence of single ETB binding site on BSA (309).
Therefore, BSA was selected as the core forming material of the CSLAHNPs for the
loading and delivery of ETB.
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The ETB binding study was performed to select and optimize the formulation and
process variables for the subsequent preparation of ETB-ANPs. The unbound ETB was
quantified by HPLC method using the standard curve which was linear between 0.625
and 80 μg/mL with a coefficient of determination (r2) value of 0.9999. The effect of pH
of the incubation medium was studied at room temperature (RT ̴ 20oC) and at 37oC for 4h
(Figure 3-2). The results exhibited highest ETB binding with BSA at pH 7.4 and pH 5.4
while binding capacity decreased at acidic pH 3.4. No significant difference was
observed for RT and 37oC incubation. This observation could be explained by pHionization hypothesis. The isoelectric point (pI) of BSA is ~ 4.7-5.4 at 25oC. ETB has a
pKa of ~ 5.4. BSA molecules exist as predominantly cationic below its pI. ETB is a
weakly basic compound and exists as highly ionized (cationic) with protonation of
secondary amine. Therefore, electrostatic repulsion of ETB and BSA molecules reduced
their interaction at pH 3.4. At pH 5.4, 50 % of ETB would ionize while remaining 50 %
would be unionized. Therefore, the hydrophobic interaction and ionic interaction between
ETB and BSA lead to increased drug binding capacity. At pH 7.4, ETB would be
maximally unionized and the hydrophobic interaction between drug and BSA was
predominant. The influence of incubation time on drug binding to albumin was studied at
RT and 37oC while keeping the pH of the incubation medium at 7.4 (Figure 3-3). Higher
drug binding was observed at RT compared to 37oC for 1 h to 24 h. Maximum drug was
bound to albumin at 8 h, pH 7.4 and at RT condition. The effect of drug-to-albumin
molar ratio on the drug binding capacity was shown in Figure 3-4. Maximum drug
binding occurred at drug-to-albumin molar ratio of 10:1 after 8h at pH 7.4.
ETB was encapsulated in the CSLAHNPs to develop a prototype formulation for
drug delivery to NSCLC. The preparation, characterization and optimization of
CSLAHNPs (without ETB) were described in detail in Chapter 2. ETB-CSLAHNPs were
also prepared by the two-step method with two different strategies for loading the drug
(ETB) into CSLAHNPs; incorporation and sorption method. In the incorporation method,
ETB was added to BSA solution prior to addition of ethanol to form ETB-loaded ANPs.
In the sorption method, ANPs were first prepared by desolvation method, followed by
incubation with ETB to form ETB-ANPs. Figure 3-5 showed the drug loading (DL %)
and mean size of ANPs as a function of incubation time using incorporation method.
However, DL was poor with no significant difference observed between two incubation
times (4 h, 8 h, and 12 h) and two temperatures (RT and 37oC). The addition of high
volume of ethanol might have solubilized ETB during particle formation and significant
amount of drug was lost in the subsequent purification of ANPs. Sorption method showed
higher DL in ANPs at 12 h and RT incubation (Figure 3-6). This is because the drug was
added after the preparation of ANPs and the desolvating agent (ethanol) did not interfere
with DL of ANPs. In the method, a part of the drug was absorbed while other parts were
adsorbed on the surface of ANPs, increasing the final DL. Therefore, sorption method
was selected for the preparation of ETB-ANPs.
After the preparation of ETB-ANPs, additional ETB (5 % w/w ETB/lipid) was
also incorporated in the lipid bilayer (composed of DPPC, cholesterol, DSPE-PEG2000
molar ratio 60:30:10) to increase DL and DEE of the final ETB-CSLAHNPs. The
physicochemical properties of the optimized ETB-ANPs and ETB-CSLAHNPs were
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Figure 3-2. The influence of pH on the drug binding to albumin in solution at
room temperature (RT ̴ 20oC) and at 37oC for 4h
The data were presented as mean ± SD (n =3). The highest ETB binding with BSA at pH
7.4 and pH 5.4 while binding capacity decreased at acidic pH 3.4. No significant
difference was observed for RT and 37oC incubation.
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Figure 3-3.

The effect of incubation time on drug binding to albumin in solution

The pH of the solution was kept at 7.4. The study was performed at two temperature
conditions: RT (20oC) and 37oC. The data were presented as mean ± SD (n =3). Higher
drug binding was observed at RT compared to 37oC for 1 h to 24 h. Maximum drug was
bound to albumin after 8 h, pH 7.4 and at RT condition.
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Figure 3-4. The influence of drug-to-albumin molar ratio on drug binding to
albumin in solution after 8 h. at pH 7.4
The data were presented as mean ± SD (n =3). Maximum drug binding occurred at drugto-albumin molar ratio of 10:1 after 8 h at pH 7.4.
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Figure 3-5. Influence of drug loading and mean size of ETB-ANPs prepared by
incorporation method as a function of incubation time at RT and 37oC
The data were presented as mean ± SD (n =3). In the incorporation method, DL was poor
with no significant difference observed among 4, 8, and 12 h at two temperatures (RT
and 37oC).
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Figure 3-6. Influence of drug loading and mean size of ETB-ANPs prepared by
sorption method as a function of incubation time at RT and 37oC
The data were presented as mean ± SD (n =3). Sorption method showed higher DL in
ANPs at 12 h and RT incubation.
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shown in Table 3-1. ETB-CSLAHNPs were 194 nm in size with PDI 0.16, zeta potential
-15.6 mV, yield 83.5 % w/w, DL 2.08 % w/w, and DEE 32.75 % w/w.
TEM photomicrograph of ETB-CSLAHNPs was shown in Figure 3-7. Sodium
silicotungstate was used for negative staining. ETB-CSLAHNPs were smooth and
spherical in shape with distinct dark lipid corona around core. Similar observation was
reported for TEM image of CSLAHNPs in chapter 2. Additionally, SEM image was
taken for these particles which also showed spherical particles with low to moderate
degree of polydispersity (Figure 3-8). As mentioned in Chapter 2, a reduction in size was
observed in both TEM and SEM images compared to DLS. This is because DLS provides
the statistical Z-average hydrodynamic mean size based on the diffusion coefficient of
particles in the liquid phase using the Stokes-Einstein equation whereas TEM and SEM
provide estimation of the projected area diameter of particles in the dried state under high
vacuum (288).
FT-IR analysis was used to characterize any chemical interaction that occurred in
the hybrid NPs system among the drug, albumin and lipids. The FT-IR spectra of ETB,
BSA, DPPC, cholesterol, DSPE-PEG2000, physical mixture of ETB and BSA, ETBANPs and ETB-CSLAHNPs were shown in Figure 3-9. ETB peaks found at 649, 867,
901, 948, 1029, 1073, 1213, 1242, 1355, 1431, 1484, 1624, and 3401 cm−1.. The FT-IR
spectra of native ETB illustrated characteristic bands due to different functional groups
such as 3495, 1637, 1509 and 1024 cm−1, corresponding to OH stretching vibration, NH
stretching, aromatic C-C stretching and C=O stretching, respectively. The spectra of
ETB-CSLAHNPs showed the presence of bands similar to the physical mixture of ETB
and BSA. Therefore, it can be inferred that ETB-CSLAHNPs system showed no
significant adverse chemical interaction among the constituents.
DSC studies were carried out to determine whether the drug was incorporated in
the CSLAHNPs as crystalline, amorphous, or bound form. In Figure 3-10, the DSC
thermograms demonstrated that pure ETB had a sharp endothermic melting peak at
235oC. Pure BSA powder showed two endothermic peaks: smaller peak at ~150oC and
bigger peak around 200oC. DPPC melted around 65oC and pure DSPE-PEG2000 showed
dual endothermic peaks (40oC and 50oC). ETB-CSLAHNPs showed endothermic peaks
corresponding to BSA and lipids with no peak for ETB. This suggested that the
encapsulated ETB might exist in the BSA and lipid matrix as either amorphous form or in
disordered crystalline phase (314).
Figure 3-11 showed the plot of the drug release data expressed as percentage
drug released from ETB-CSLAHNPs in two dissolution media (PBS pH 7.4 and acetate
buffer pH 5.2) as a function of time. The encapsulated ETB was released from the
CSLAHNPs at a sustained rate over 96 h. When PBS pH 7.4 was used as the dissolution
medium, ETB-CSLAHNPs showed a biphasic release pattern with initial fast release
medium, ETB-CSLAHNPs showed a biphasic release pattern with initial fast release
followed by slower release up to 96 h. The initial faster release of around 60 % of the
encapsulated drug was observed in 24 h, followed by slower release of drug from
CSLPHNPs up to about 100 % in 96 h. The initial faster drug release could be attributed
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Table 3-1.
Physicochemical properties of the optimized ETB-ANPs and ETBCSLAHNPs
Batch
ETB-ANPs

Mean
Size
(nm)
185 ±8

ETB194 ±6
CSLAHNPs

PDI

Zeta
potential
(mV)
0.13±0.01 -25.1±3.9

Yield
(%
w/w)
71.3±3.5

DL
DEE
(%
(% w/w)
w/w)
1.42±0.5 24.95±7.73

0.16±0.02 -15.6±4.1

83.5±5.9 2.08±0.7 32.75±5.34

Data presented as mean ±standard deviation (n=3). In ETB-CSLAHNPs, lipids were
composed of DPPC, cholesterol, DSPE-PEG2000 (molar ratio 60:30:10). In ETB-ANPs,
initial drug-to-albumin molar ratio was kept at 10:1 (6.45% w/w drug/albumin).
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Figure 3-7.

TEM image of ETB-CSLAHNPs

Scale bar represents 100 nm. TEM image revealed spherical and smooth shape of ETB
(drug) loaded CSLAHNPs with dark corona of lipid bilayer. The image was similar to
TEM image of the blank CSLAHNPs as shown in Chapter 2.
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Figure 3-8.

SEM image of ETB-CSLAHNPs

Scale bar represents 200 nm. SEM image revealed spherical and smooth shape of ETB
(drug) loaded CSLAHNPs.
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Figure 3-9.

FTIR spectra of CSLAHNPs and its components

(A) physical mixture of ETB and BSA, (B) ETB, (C) ETB-ANPs, (D) ETB.HCl, (E)
ETB-ANPs, (F) ETB-CSLAHNPs, (G) BSA, (H) Cholesterol, (I) DPPC, and (J) DSPEPEG2000. FTIR revealed no adverse chemical interaction was present in the CSLAHNPs
containing drug.
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Figure 3-10. DSC thermograms of CSLAHNPs and its components
(A) ETB. HCl, (B) ETB-CSLAHNPs, (C) BSA, (D) DPPC, (E) DSPE-PEG2000, and (F)
Cholesterol. DSC results indicated the existence of drug in the CSLAHNPs as amorphous
or molecularly dispersed solid solution state.
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Figure 3-11. In vitro drug release profiles of ETB-CSLAHNPs in pH 7.4 and
acetate buffer pH 5.2
The data were presented as mean ± SD (n=3). Sustained release of drug from
CSLAHNPs was observed for about 72-96 h. Drug release rate was faster in pH 5.2
compared to pH 7.4.
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to the presence of drug at or near the surface of CSLPHNPs. The burst release effect was
absent probably due to the presence of hydrophobic lipid bilayer around the ANPs which
acted as the diffusion controlled membrane. The biphasic drug release pattern was
reported for ANPs and surfactant coated ANPs in the literature (234, 315). BSA was used
as the core forming biodegradable polymer which was reported to be highly permeable
for low molecular weight drugs. The predominant mechanism of drug release from BSA
matrix occurred through diffusion rather than polymer degradation. However, the burst
release effect was absent due to the presence of hydrophobic lipid bilayer which acted as
the diffusion controlled membrane. When acetate buffer pH 5.2 was used as the
dissolution medium, the drug release rate was faster compared to PBS pH 7.4, indicating
pH sensitive release of ETB-CSLAHNPs (Figure 3-11). After 24 h, ETB-CSLAHNPs
released about 80 % drug in pH 5.2 while about 60 % drug release was observed at pH
7.4. After 48 h, drug release was around 100 % at pH 5.2 while only about 66 % drug
was release at pH 7.4. Significant difference between drug release profiles at two
different pH media was observed from after 6 h up to 96 h. The pH sensitivity of ETBCSLAHNPs might be beneficial for enhanced drug release in the acidic
microenvironment of tumors and also the acidic endosome/lysosome compartments of
cells (316-318). Table 3-2 showed the coefficient of determination and release rate
constants calculated from in vitro drug release data using various drug release kinetic
models (zero order, first order, Higuchi, Hixon-Crowell, and Korsmeyer-Peppas). From
the drug release profiles at pH 7.4, Higuchi and 1st order kinetic models fitted best (r2 ̴
0.97). This indicated that the drug release from CSLAHNPs occurred through diffusion
controlled mechanism. Drug release profile at pH 5.2 fitted best with 1st order kinetics
(r2 ̴ 0.92). Therefore, it can be interpreted from first order release kinetics that the drug
release rate was dependent on the concentration of drug in CSLAHNPs. Similar findings
were reported for biphasic release of 5-fluorouracil loaded ANPs (319). Moreover, the
Korsmeyer-Peppas release model showed high correlation for drug release from ETBCSLAHNPs at both pH values. The diffusion exponent, ݊, was about 0.8, which
confirmed that the anomalous diffusion or non-fickian diffusion was the controlling
factor in drug release. Therefore, drug release from CSLAHNPs was governed by both
diffusion and erosion of matrix as indicated by non-fickian diffusion mechanism (320).
Stability of CSLAHNPs in serum is an important consideration for their
usefulness of CSLAHNPs as the drug delivery system in vivo where dilution after
intravenous administration could result in NPs aggregation, disassembly and/or drug
leakage. CSLAHNPs were incubated in 50 % serum at 37oC with gentle stirring followed
by determination of the absorbance at 560 nm. Absorption method was used since
CSLAHNPs cannot be accurately detected in dense serum solution by dynamic light
scattering technique due to the matrix protein interference from serum (321).Aggregation
phenomena were characterized by increased absorbance to higher values. The interaction
of CSLPHNPs with various serum proteins in the incubation media would cause
neutralization of zeta potential of NPs. The process subsequently would reduce repulsion
energy between particles and progressively facilitate agglomeration process and the
formation of larger particles. As shown in Figure 3-12, ETB-CSLAHNPs were stable in
serum retaining the integrity up to 6 h as indicated by no significant change in absorbance
values at 560 nm similar to ETB-ANPs.
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Table 3-2.

In vitro release kinetics of ETB-CSLAHNPs
Release model
Zero Order
First Order
Higuchi
Hixon-Crowell
KorsmeyerPeppas

r2/K
r2
K0
r2
K1
r2
KH
r2
KHC
r2
n

pH 7.4
0.8874
0.9127
0.9795
-0.0099
0.97
9.9221
0.9619
-0.0252
0.9626
0.7841

pH 5.2
0.7156
0.9789
0.9214
-0.0183
0.8816
11.298
0.857
-0.0361
0.9652
0.8073

r2 = Coefficient of determination. K0 = Zero-order release rate constant. K1 = First-order
release rate constant. KH = Higuchi release rate constant. KHC = Hixon-Crowell release
rate constant. n = diffusion exponent.
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Figure 3-12. In vitro stability of ETB-CSLAHNPs and ETB-ANPs in 50% fetal
bovine serum
The data were presented as mean ± SD (n=3). Particles retained their physicochemical
properties without aggregation for a prolonged period of time (6 h).
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Summary and Conclusion
The drug binding capacity of albumin in solution was studied and optimized at
various pH conditions, durations of incubation, incubation temperatures, and drug-toalbumin molar ratios. The maximum drug binding capacity of albumin was observed at 6
h incubation in pH 7.4 at room temperature with drug-to-albumin molar ratio 10:1. ETBCSLAHNPs were successfully designed, prepared and optimized by the two step method
as described in Chapter 2. Two strategies for drug loading in ANPs were studied;
incorporation and sorption method. Sorption method provided better drug loading and
entrapment efficiency in ETB-ANPs compared to incorporation method. Additional ETB
was incorporated in the lipid bilayer to maximize the drug loading and entrapment
efficiency of ETB-CSLAHNPs. ETB-CSLAHNPs were ~194 nm in size with PDI ~0.16,
zeta potential -15.6 mV, yield 83.5 % w/w, DL 2.08 % w/w, and DEE 32.75 % w/w.
SEM and TEM images showed smooth and spherical particles of ETB-CSLAHNPs. Drug
release from ETB-CSLAHNPs occurred in a sustained manner up to 96 h with a biphasic
release pattern in pH 7.4. Drug release was faster in acidic pH of 5.2. Drug release
kinetics analysis showed a first order release kinetics with non-fickian diffusion
mechanism. ETB-CSLAHNPs were stable in serum for up to 6 h. Therefore, the
optimized ETB-CSLAHNPs would be utilized for the conjugation of monoclonal
antibodies for the preparation of targeted ETB-CSLAHNPs as described in the following
chapter.
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CHAPTER 4. DEVELOPMENT OF HALF-ANTIBODY CONJUGATED
ERLOTINIB LOADED CORE SHELL TYPE LIPID ALBUMIN HYBRID
NANOPARTICLES
Introduction
Conventional chemotherapy of cancer has often exhibited limited therapeutic
efficacy along with severe systemic toxicities (322). As an alternative, small molecule
EGFR tyrosine kinase inhibitors (TKI) such as ETB that target overexpressed EGFR
present on the NSCLC tumor blood vessels endothelial membranes have been used
clinically as the molecularly targeted therapy (323). However, EGFR TKI therapy can
cause serious toxicities because they are not organ or tissue specific (324). After binding
with growth factors such as EGF, EGFR elicits the internalization and intracellular
sorting of receptor-ligand complexes and activates signaling pathways (325). The
endocytosis of ligand-activated EGFR was found to be EGF concentration dependent. At
low concentration of ligand (EGF), it involved clathrin-mediated endocytosis (326). At
high EGF concentration, caveolae-mediated endocytosis was prevalent (327). The ligandEGFR complex undergoes intracellular trafficking and finally degrades in lysomes after
ubiquitin-dependent sorting in early endosomes (325). The internalization and lysosomal
trafficking phenomena can be utilized by directing TKI to specific tumor cells via passive
targeting and/or active targeting strategies. Therefore, the efficacy of TKI could be
improved by targeted delivery and release of small molecule EGFR TKI inside the tumor
cells using anti-EGFR antibody conjugated NPs.
In tumor pathogenesis, multiple factors such as increased metabolic function,
decreased oxygen supply or hypoxia, and depletion of glucose triggers the formation of
new blood vessels, a process also known as angiogenesis (328-330). Angiogenesis plays
an important role in the proliferation, migration and maintenance of healthy tissues.
Imbalance between pro-angiogenic and physiological anti-angiogenic signaling leads to
the formation of the tumor vessels which are heterogeneous, immature and leakier than
normal vessels (330-333). This leakiness is present because of the impaired recruitment
of pericytes which are support cells of normal vessels (334). The intercellular openings
between endothelial cells become larger than normal transcellular fenestrations. There is
a significant heterogeneity in pore size within and between tumor types with nominal size
range between 100 nm to 2 μm (51, 335, 336). The physical pressure arising from cancer
cell proliferation causes compression of the intratumoral lymphatics which leads to poor
lymphatic drainage or clearance. As a consequence, NPs which are smaller than the
fenestrations can extravasate to the surrounding tumor tissues and entrapped in the tumor.
This phenomenon is known as enhanced permeability and retention (EPR) effect. EPR
effect is also known as passive targeting which has also been exploited by various drug
delivery systems including NPs (50).Unlike passive targeting by EPR effect, active
targeting utilizes peripherally conjugated targeting moieties such as monoclonal
antibodies, proteins, peptides, vitamins or aptamers to direct drug loaded NPs to the
specific tumor tissues (337). Targeting ligands can be attached to the surface of NPs by
covalent and non-covalent conjugation chemistry techniques (152). Covalent coupling
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techniques employ various covalent linkages such as thioether (338), disulfide (339),
carboxamide (340), amide (341), and hydrazine bonds (342) to bind ligands to NPs. Noncovalent coupling method used to bind ligands to NPs include simple adsorption.
However, the non-covalent method has limitations such as low ligand binding efficiency,
incorrect orientation of ligands, difficulty in controlling amount of ligands, and
detachment of ligands in vivo (343).
Most NSCLC tumors (50-90%) overexpress EGFR or HER1 which are associated
with tumor cell proliferation, metastasis, and angiogenesis. Small molecule EGFR
tyrosine kinase inhibitors (e.g. erlotinib and gefitinib) inhibit autophosphorylation by
binding to the ATP binding site of the intracellular tyrosine kinase domains of EGFR.
Alternatively, therapeutic EGFR directed monoclonal antibodies such as Cetuximab
(marketed as Erbitux®, Bristol-Myers Squibb company) were used to prevent ligand
binding to the extracellular domain of the receptor(344-346). EGFR specific monoclonal
antibodies (mAb) were investigated as the targeting ligand in nanoparticulate drug
delivery systems in NSCLC (347-353). Whole mAbs (molecular weight 150 kDa) which
are immunoglobulins (IgG) have two identical heavy (H) chains and two identical light
(L) chains of amino acids held together by disulfide bridges between the cysteine
residues (354). The mAbs conjugated onto NPs have several limitations such as shorter
circulation half-life because of the large hydrodynamic size of mAbs increases nonspecific uptake by RES. Large hydrodynamic size of mAbs also limit both intratumoral
uptake and homogeneous distribution in the tumor, thus adversely affecting
pharmacokinetic properties of mAb-conjugated NPs (355). In addition, binding
orientation is important for maximizing the functionality of mAbs for targeting (356).
However, non-specific conjugation of nanoparticle to mAb via amide bond may hinder
the binding sites of mAb (357). Antibody fragments can penetrate tissue more rapidly
than whole mAbs due to their smaller size than mAbs (358, 359). Antibody fragments
such as single chain variable fragments (scFv), diabodies, and nanobodies have been used
to replace mAbs (360, 361). Peng et al reported a significant increase in intracellular
cisplatin concentration and enhanced antitumor efficacy of the single-chain variable
fragment (ScFv) EGFR conjugated heparin NPs (362). A ScFvEGFR functionalized
quantum dots (QDs were reported to bind and internalize by EGFR-expressing cancer
cells (363).
Half-antibodies (hAb) or reduced IgG were synthesized by TCEP induced
cleavage of the disulfide bridges in the hinge region between two heavy chains of mAb
(94, 364). The hAbs possess intact binding site and retain their receptor binding affinity
(364, 365). NPs can be conjugated through the readily available thiol functional groups
that are present in the constant region of hAb (94, 365). The other advantages compared
to mAbs include relatively smaller hydrodynamic size, longer circulation half-life, and
rapid extravasation to tumor tissues. For the present study, ETB-CSLAHNPs were
conjugated to anti-EGFR hAb via thioether bonds between maleimide terminated
CSLAHNPs and thiol groups of hAb. The objective of this study was to prepare and
characterize prototype anti-EGFR hAb-conjugated ETB-CSLAHNPs for the purpose of
active targeting to NSCLC.
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Experimental Section
Materials
Bovine serum albumin (BSA, Cohn fraction V, lyophilized powder, MW ̴ 66000,
purity 95-99 %), glutaraldehyde solution (25 % in water), 2-mercaptoethanesulfonic acid
sodium salt (MESNA), sodium chloride, and Ellman's reagent (5,5'-dithiobis-(2nitrobenzoic acid) or DTNB) were obtained from Sigma-Aldrich (St. Louis, MO).
Erlotinib hydrochloride (purity 99 %) was obtained from LC Laboratories (Woburn,
MA). The lipids used in this work were all of research grade. 1,2-dipalmitoyl-sn-glycero3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-hoshoethanolamine-N
(poly(ethylene glycol)2000) [DSPE-PEG(2000)], and 1,2-distearoyl-sn-glycero-3phoshoethanolamine-N-(maleimide poly(ethylene glycol)2000) [DSPE-PEG2000maleimide] were purchased from Avanti Polar Lipids (Alabaster, AL). Cholesterol was
purchased from Sigma (St. Louis, MO). High performance liquid chromatography
(HPLC) grade water, ethanol, and methanol were obtained from Fisher Scientific (Fair
Lawn, NJ). HPLC grade chloroform and 1N sodium hydroxide solution were purchased
from Acros Organics (Morris Plains, NJ). Mouse monoclonal EGFR antibody (D-8) was
obtained from Santa Cruz (Dallas, TX). Tris(2-carboxyethyl)phosphine hydrochloride
[TCEP] was supplied by Thermo Scientific (Rockford, IL). All other chemicals and
reagents were of analytical grade and used without further purification or
characterization.
Preparation of maleimide terminated ETB-CSLAHNPs
Maleimide terminated ETB-CSLAHNPs were prepared and purified using the
method previously reported in Chapter 2 and 3 with the replacement of 1 mol % DSPEPEG2000 with DSPE-PEG2000-maleimide.
Assay of maleimide
Maleimide content of ETB-CSLAHNPs after incorporation of DSPE-PEG2000maleimide was quantified using the modified Ellman’s assay (366). Briefly, a standard
curve was prepared by adding the Ellman’s reagents to different concentrations of a water
soluble thiol MESNA in 100 mM PBS pH 8. The absorbance was read at 412 nm using a
UV-visible spectrophotometer and thiol concentration was quantified from the standard
curve. An aliquot of maleimide terminated ETB-CSLAHNPs in PBS was reacted with
excess molar concentration of MESNA for 5 min at room temperature, followed by
addition of Ellman’s reagent and absorbance was read at 412 nm. The concentration of
maleimide was calculated by subtracting unreacted MESNA from initial concentration of
MESNA added.

81

Synthesis of anti-EGFR half antibody
For antibody conjugation, anti-EGFR half-antibody (hAb) were synthesized from
anti-EGFR intact monoclonal antibody (mAb) by reducing the disulfide linkages between
the heavy chains of mAb (94). Briefly, mAb in 1xPBS (50 μg/mL) was mixed with 50:1
molar ratio of [tris(2-carboxyethyl)phosphine] (TCEP) to mAb and incubated for 1h at
room temperature(364). The samples were passed through Amicon® Ultra-0.4 filters
MWCO 100 kDa, followed by 50 kDa. The sample retained in 50 kDa was collected.
Total cell proteins from each sample (25-50 μg) were added to Laemmli 5x loading
buffer and incubated at 37oC for 10 min. The samples were loaded into the wells of 4-15
% SDS-PAGE gels immersed in running buffer (tris-glycine/SDS) and resolved at 150V
for 45 min using standard molecular weight ladder. Finally, the gel was stained with
water soluble colloidal CoomassieTM blue stain for 12 h. A calibration curve was
constructed using standard concentrations of BSA resolved by SDS-PAGE as described
above. The Coomassie-stained gels were used for densitometric measurements using
ImageJ 1.39u software (National Institutes of Health, Bethesda, MD). Using a calibration
curve, the densitometric units of the samples were converted into concentrations.
Preparation of half-antibody conjugated ETB-CSLAHNPs
The molar ratio of hAb to DSPE-PEG2000-maleimide used was 8.6 nM/μM as
reported by Meel et al (367). CSLAHNPs with maleimide moieties (1 mL) were
incubated with selectively reduced anti-EGFR hAb (1mL) for 4h at 4oC. The samples
were assayed for maleimide content by modified Ellman’s assay as reported previously.
The unconjugated antibodies, TCEP and other small molecular weight species were
removed by spinning the dispersion in Sepharose Cl-4B packed gel filtration column. To
confirm the presence of hAb on targeted CSLAHNPs, the samples were resolved by
SDS-PAGE and hAb concentration was determined by the method described above.
Characterization of half-antibody conjugated ETB-CSLAHNPs
The mean diameter, polydispersity index (PDI), zeta potential, morphology, drug
loading, drug release, and in vitro serum stability of the targeted CSLAHNPs were
determined using the methods reported in Chapter 2 and 3.
Results and Discussion
The schematic diagram of the preparation of targeted ETB-CSLAHNPs was
shown in Figure 4-1.To prepare targeted ETB-CSLAHNPs, anti-EGFR half-antibody
(hAb) was conjugated to maleimide-terminated ETB-CSLAHNPs. The preparation of
hAb from monoclonal antibody (mAb) via disulfide bond reduction method was the
critical step in the preparation of targeted hAb-ETB-CSLAHNPs. A number of protein
disulfide reducing agents are available such as β-mercaptoethanol (BME) (368), cysteine,
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Figure 4-1. Schematic diagram of the preparation of anti-EGFR half antibody
(hAb) conjugated ETB-CSLAHNPs
Anti-EGFR monoclonal antibody (mAb) was selectively reduced to half-antibody (hAb)
with thiol groups. Maleimide-PEG-DSPE incorporated ETB-CSLAHNPs were
conjugated with hAbs to produce hAb-ETB-CSLAHNPs.
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dithiothreitol (DTT) (369), tris(2-carboxyethyl)phosphine (TCEP). In this study, TCEP
was used as the reducing agent because it is stable, specific, and effective at wide range
of pH (370). Anti-EGFR mAb was selectively reduced by using TCEP which breaks the
disulfide bonds between the two heavy chains of the mAb to form hAb or reduced IgG.
The extent of mAb reduction was controlled by TCEP concentration and duration of
reaction (94, 364). Normally, the reduction products include half-antibody or hAb
fragments (75kDa), heavy chain fragments ( 50 kDa), light chain fragments (25
kDa) along with unreacted mAb ( 150 kDa) (371). Various molar ratios of mAb: TECP
were incubated at room temperature for 1 h (364). The samples were resolved in SDSPAGE and visualized by staining with CoomasieTM blue (Figure 4-2). It was observed
that 1:100 or higher molar ratio of mAb:TCEP completely cleaved to heavy-chain and
light-chain fragments. The optimized molar ratio of 1:50 of mAb:TCEP maximized the
yield of hAb and minimize the production of non-targeting fragments.
Maleimide-terminated ETB-CSLAHNPs (Mal-ETB-CSLHANPs) were prepared
by the previously described two-step method using 1 mole % DSPE-PEG2000maleimide. The final composition of the lipids used was DPPC, cholesterol, DSPEPEG2000, and DSPE-PEG2000-maleimide at a molar ratio of 60:30:9:1 respectively.
Since the incorporation of lipids in the Mal-ETB-CSLAHNPs was not 100%, the molar
concentration of maleimide groups on the particles were determined by modified
Ellman’s assay (366). The Ellman’s assay showed actual amount of DSPE-PEG2000maleimide in CSLAHNPs was ~ 30-40% of the theoretical amount added. The ratio of
hAb to DSPE-PEG2000-maleimide was kept at 8.6 nM/μM of DSPE-PEG 2000maleimide as reported previously (367). Based on the theoretical assumptions, it was
estimated to be ~ 30 hAb molecules per CSLAHNPs (372).The anti-EGFR mAbs were
reduced by TCEP at 1:50 molar ratio for 1 h to produce hAbs with readily available
sulfahydryl groups (-SH). Mal-ETB-CSLAHNPs and hAbs were incubated together at
4oC overnight to obtain hAb-conjugated ETB-CSLAHNPs or targeted CSLAHNPs (hAbETB-CSLAHNPs). The conjugation of hAbs and CSLAHNPs were accomplished
through the formation of thioether linkages between sulfahydryl groups and maleimide
groups present on the distal end of PEG chains on the Mal-ETB-CSLAHNPs. To confirm
that hAb was successfully conjugated to ETB-CSLAHNPs, samples were run through
SDS-PAGE and visualized by staining in comparison with standard molecular weight
ladder (Figure 4-2). The physicochemical properties of hAb-ETB-CSLAHNPs were
reported in Table 4-1. Targeted hAb-ETB-CSLAHNPs were ~ 200 nm in mean
hydrodynamic size with PDI ~ 0.13, zeta potential ~ -13mV, DL ~ 2 % w/w, and DEE ~
31% w/w.
The TEM image of hAb-ETB-CSLAHNPs was shown in Figure 4-3. It showed
that targeted CSLAHNPs were spherical in shape with moderate degree of polydispersity.
The conjugation of hAb onto ETB-CSLAHNPs did not significantly change the
morphology and shape of the particles compared to ETB-CSLAHNPs without hAb (as
shown in Chapter 3).
The drug release data expressed as percentage of drug released from hAb-ETBCSLAHNPs in two dissolution media (PBS pH 7.4 and acetate buffer pH 5.2) as a
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Figure 4-2.

Analysis of proteins by SDS/PAGE with coomassie staining

Lane 1 represents ETB-CSLAHNP without targeting half-antibody (hAb) which did not
show any protein band. Lane 2 represents ETB-CSLAHNPs conjugated with hAb which
showed a distinct band at ~75 kDa. Lane 3 represents TCEP reduced mAb at 1:50 molar
ratio of mAb: TCEP. It showed three distinct bands at~75 kDa, 45 kDa, and 25kDa. Lane
4 represents anti-EGFR mAb which showed a sharp band at ~150 kDa. The rightmost
lane represents a standard molecular weight proteins marker.
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Table 4-1.

Physicochemical properties of targeted CSLAHNPs

Batch

Mean
Size
(nm)

PDI

Zeta
potential
(mV)

DL
(% w/w)

DEE
(% w/w)

Mal-ETB-CSLAHNPs

196 ±5

0.11±0.01 -19.1±5.1

2.12±0.3

31.95±3.34

hAb-ETB-CSLAHNPs

199 ±7

0.13±0.02 -12.6±4.1

2.01±0.2

30.95±4.37

The data were presented as mean ± SD (n=3). Mal-ETB-CSLAHNPs represent 5 mol %
DSPE-PEG2000-maleimide incorporated ETB-CSLAHNPs. hAb-ETB-CSLAHNPs
represent anti-EGFR half-antibody (hAb) conjugated ETB-CSLAHNPs.
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Figure 4-3.

TEM images of targeted hAb-ETB-CSLAHNPs

Scale bar represents 100 nm. The sample was stained with 1% sodium silicotungstate.
The particles showed smooth and spherical shapes with moderate degree of polydisersity.
The lipid shell appeared as a dark corona around each particle.
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function of time (Figure 4-4). The hAb-conjugated CSLAHNPs showed similar release
profiles in pH 7.4 and pH 5.2 compared to ETB-CSLAHNPs without targeting antibody
(as shown in chapter 3). The encapsulated ETB was released from the hAb-ETBCSLAHNPs at a sustained rate over 96 h in PBS pH 7.4 with a biphasic release pattern.
In acetate buffer pH 5.2, the drug release rate was faster compared to PBS pH 7.4,
indicating pH sensitive release of hAb-ETB-CSLAHNPs (Figure 4-4).
NP-serum protein interactions are related to the particular physicochemical
characteristics of the particles, such as their colloidal stability, and this significantly
influences the subsequent NP-cell interaction. The colloidal stability of hAb-ETBCSLAHNPs in 50 % fetal bovine serum showed by measuring absorbance at 560nm for
various incubation time points (Figure 4-5).There was no perceptible change in
absorbance values for up to 6 h. After prolonged incubation for 24 h, the absorbance
value increased indicating aggregation due to the adsorption of serum proteins. Lipid
coating around polymeric core particles also showed enhanced serum stability compared
to bare PNPs (373). Surface charge was identified as the critical parameter which
influenced the colloidal stability of NPs. It was reported that positively charged NPs
displayed a significantly lower colloidal stability than neutral and negatively charged
particles (374). The targeted CSLAHNPs possessed negative zeta potential which
increased colloidal stability by electrostatic repulsive forces. In addition, the presence of
PEG chains on the particle surface provided increased colloidal stability via steric
repulsion by reducing serum protein adsorption (375).
Summary and Conclusion
Targeted hAb-ETB-CSLAHNPs were prepared by the maleimide-thiol
conjugation reaction after incorporating 1 mol % DSPE-PEG2000-maleimide in ETBCSLAHNPs during preparation. Anti-EGFR mouse monoclonal antibody (mAb) was
reduced to half-antibodies (hAb) using TCEP at 50:1 molar ratio of TCEP:mAb and
coupled to maleimide-terminated ETB-CSLAHNPs. Targeted hAb-ETB-CSLAHNPs
were ~ 200 nm in hydrodynamic mean size with PDI ~ 0.13, zeta potential ~ -13 mV, DL
~ 2 % w/w, and DEE ~ 31 % w/w. TEM image showed smooth and spherical particles
with moderate degree of polydispersity. Drug release from hAb-ETB-CSLAHNPs
occurred in a sustained manner up to 72-96 h with a biphasic release pattern in pH 7.4. A
faster rate of drug release was observed in acidic pH of 5.2. The hAb-ETB-CSLAHNPs
were stable in 50% serum for up to 6 h. Therefore, the hAb-ETB-CSLAHNPs were used
for the cell-based assays.
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Figure 4-4. In vitro drug release profiles of targeted hAb-ETB-CSLAHNPs in pH
7.4 and acetate buffer pH 5.2 at 37oC
The data were presented as mean ± SD (n=3). Sustained release of drug from
CSLAHNPs was observed for about 72-96h. Drug release rate was faster in pH 5.2
compared to pH 7.4.
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Figure 4-5. In vitro stability of targeted hAb-ETB-CSLAHNPs in 50% fetal
bovine serum at 37oC
The data were presented as mean ± SD (n=3). Particles retained their physicochemical
properties without aggregation for a prolonged period of time.
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CHAPTER 5. IN VITRO UPTAKE, TRAFFICKING, AND EFFICACY OF
TARGETED AND UNTARGETED ERLOTINIB LOADED CORE SHELL TYPE
LIPID ALBUMIN HYBRID NANOPARTICLES IN NSCLC CELLS
Introduction
A detailed understanding of the involved processes of NPs to cell interaction is an
important aspect for developing NPs for anticancer drug delivery (376, 377). Cell
membrane acts as a barrier impermeable to many large particles while allowing very
small particles of size 10-30 nm (378, 379). One of the mechanisms to overcome the
barrier for larger particles is known as endocytosis. It is a process utilized by viruses
when they invade cells. Endocytosis has been described as the uptake of particulate
matter such as proteins, nutrients, cell debris, and foreign cells via formation of
invagination of the cell membranes (380). Phagocytosis is a type of endocytosis in which
cells (e.g. macrophages, monocytes, and neutrophils) engulf larger particles (e.g. bacteria,
cell debris) of diameter between 0.5 to 10 μm as a response of body’s immune defense.
In addition to phagocytosis, cells also utilize the pinocytosis process for the uptake of
soluble substances. There are two major pinocytic mechanisms currently known:
micropinocytosis and receptor-mediated endocytosis (RME). Macropinocytosis is the
process of uptake of particles via formation of larger vesicles (0.3 – 5 μm) mediated by
membrane ruffling driven by actin cytoskeleton (381). There are different pathways
observed in RME: clathrin-mediated endocytosis, caveolae-mediated endocytosis,
clathrin- and caveolin-independent endocytosis. Clathrin-mediated endocytosis is the
uptake of particles through the formation of clathrin coated pit. The process involves five
stages: nucleation, cargo selection, clathrin coat assembly, vesicle scission, and
uncoating/clathrin component recycling. The size of the clathrin-coated pits varies from
species to species in the range of 15 - 200 nm (382). Caveolae mediated endocytosis
involves uptake of particles via the formation of invaginated, flask-shaped plasma
membrane domains, known as caveolae. These vesicles are typically 50-80 nm in
diameter and are enriched with cholesterol and sphingolipids. After internalization,
caveolae- or lipid raft-derived vesicles travel to caveosomes. Caveosomes have neutral
pH compared to endosomes which have an acidic pH. In caveosomes, internalized cargo
could reside, sorted to the Golgi complex, or to the endoplasmic reticulum. In addition to
active endocytotic processes, NPs may also enter the cells by non-endocytotic
mechanisms such as diffusion or active transport.
NPs interact with biomolecules including proteins, carbohydrates, and lipids
present in the extracellular fluids prior to association with the cell membrane. A protein
corona forms around the NPs and subsequently triggers activation of cell surface
receptors (383). Plasma protein such as immunoglobulin binding caused opsonization and
receptor-mediated phagocytosis of carboxyl-functionalized NPs (264). Cellular uptake
and internalization of NPs are strongly influenced by physico-chemical properties of NPs
including size (384, 385), shape (386, 387), surface charge (388, 389), surface functional
groups (390) and hydrophilicity (391).
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Apart from quality, the biological safety and efficacy of nanomedicines have to be
fully investigated to comply with the rules and regulations set forth by regulatory
agencies such as Food and Drug Administration. For the biological testing of
nanomedicines, cell culture models have been widely used as an exceptionally powerful
and economic tool before moving to expensive in vivo models (392). Cell based models
offer unique platform to test the efficacy and safety of nanomedicines under controlled
and reproducible conditions (393). In addition, a number of experimental variables can be
easily manipulated to simulate the in vivo conditions (394).
The objective of this work was to investigate the cellular binding, uptake and
internalization of fluorescently labeled ETB-CSLAHNPs (untargeted) and hAb-ETBCSLAHNPs (targeted) in two human lung adenocarcinoma cells (A549 and HCC827). In
addition, in vitro efficacy of CSLAHNPs was determined by cell viability assay and
clonogenic assay. Finally, the expression levels of biomarker (p-EGFR) with and without
treatment of CSLAHNPs were assessed by western blot.
Experimental Section
Materials
Bovine serum albumin (BSA, Cohn fraction V, lyophilized powder, MW ̴ 66000,
purity 95-99%), and cholesterol were obtained from Sigma-Aldrich (St. Louis, MO). The
lipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-snglycero-3-hoshoethanolamine-N (poly(ethylene glycol)2000) [DSPE-PEG2000], 1,2distearoyl-sn-glycero-3-phoshoethanolamine-N-(maleimide poly(ethylene glycol)2000)
[maleimide DSPE-PEG2000], and 1-palmitoyl-2-[6-[(7-nitro-2-1,3-benzoxadiazol-4yl)amino]hexanoyl]-sn- glycero-3-phosphocholine (NBD-PC) were purchased from
Avanti Polar Lipids (Alabaster, AL). Mouse monoclonal EGFR antibody (D-8) was
obtained from Santa Cruz (Dallas, TX). Tris(2-carboxyethyl)phosphine hydrochloride
[TCEP] was supplied by Thermo Scientific (Rockford, IL). CellTiter-Glo® Luminescent
cell viability assay substrate and buffer was purchased from Promega (Madison, WI).
High performance liquid chromatography (HPLC) grade water, ethanol, and methanol
were obtained from Fisher Scientific (Fair Lawn, NJ). All other chemicals and reagents
were of analytical grade and used without further purification or characterization
Preparation of fluorescently labeled CSLAHNPs for imaging
For imaging cellular uptake and intracellular localization , fluorescently labeled
ETB-CSLAHNPs (untargeted) and hAb-ETB-CSLAHNPs (targeted) were prepared and
purified using the methods reported in Chapter 3 and Chapter 4 respectively with the
replacement of 1 mol % DPPC with NBD-PC, a fluorescent phospholipid (Ex/Em
460/530 nm).
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Preparation of CSLAHNPs
For in vitro cellular viability, colony-forming assay, and western blots, ETBCSLAHNPs (untargeted) and hAb-ETB-CSLAHNPs (targeted) were prepared and
purified using the methods reported in Chapter 3 and Chapter 4 respectively.
Culture of human lung cancer cell lines
Two cell lines, A549 (human lung adenocarcinoma; ATCC® CCL-185TM,
Manassas, VA, USA) and HCC827 (human lung adenocarcinoma; ATCC® CRL-2868TM,
Manassas, VA, USA) were used for this project. HCC827 cells have an acquired
mutation in the EGFR tyrosine kinase domain (E746 - A750 deletion).
A549 cells were cultured in Ham’s F12K (Kaighn’s) medium containing 10%
foetal bovine serum (FBS), 1% penicillin streptomycin (Penstrep) (all purchased from
ATCC, VA, USA). HCC827 cells were cultured in RPMI 1640 medium containing 10%
FBS, 1% Penstrep. Cells were grown under standard conditions (37oC and 5% CO2) to
reach a confluency of 70% to 80% before being subjected to any further experimentation.
In vitro cellular uptake of fluorescently labeled CSLAHNPs
To study the cellular uptake of fluorescently labeled CSLAHNPs, two techniques
were utilized as given below.
Visualization and qualitative uptake of CSLAHNPs were studied by using
confocal laser scanning microscopy (CLSM) technique (392). Cells were seeded in LabTek® II chamber slides (4 wells) at a density of 5 x 104 cells per well and incubated at
37oC, 5 % CO2 in complete growth medium until 80-90 % confluence. Appropriate
volume (50-100 μL) of fluorescent CSLAHNPs were added in each well and incubated
for 0-4 h. Following the incubation, cells were washed with 1x PBS and fixed in 4%
paraformaldehyde for 10 min at room temperature. Following fixation, cells were washed
with 1X PBS thrice 3 min each time. The upper chamber was separated from the slide.
The cells were counterstained with a drop of VECTASHIELD® mounting medium
containing DAPI to visualize nuclei. A coverslip was placed over the slide containing
fixed cells. The cover slip was immobilized by placing clear nail polish around the edges.
Finally, the slides were examined on a Zeiss LSM 710 confocal laser scanning
microscope (carl Zeiss SMT Inc., USA) by using a Plan-Apochromat 60×/1.4o na Oil
DIC objective. Images were processed using the Zeiss LSM Zen software 2010.
For quantitative estimation of cellular uptake, flow cytometry (FCM) was used
(395). Cells were seeded into 6-well plates at a density of 5x104 cells per well in 2 mL of
complete medium and cultured at 37oC in a 5 % CO2 humidified atmosphere until 80-90
% confluence. The growth medium was replenished, followed by addition of appropriate
volume of fluorescently labeled CSLAHNPs. The cells were incubated for 0-4 h at 37oC,
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followed by rinsing with ice-cold 1x PBS three times. The cells were detached by
trypsinized, centrifuged at 130 g for 7 min and washed with 1x PBS. The mean
fluorescence intensity (MFI) was determined using a BD AccuriTM C6 flow cytometer
(Becton Dickinson Inc., NJ, USA) with FITC channel. Generally 10,000 events were
acquired per sample, and samples were run in triplicates. Data were analyzed using BD
AccuriTM CFlow Plus analysis software.
Cell association study of fluorescently labeled CSLAHNPs
To determine the target binding specificity of hAb-ETB-CSLAHNPs on EGFR
cell surface receptors, cell association studies at 4oC were performed as reported by
Oliviera et al (396). Cells at a density of (1x105) were incubated with fluorescently
labeled CSLAHNPs (untargeted and targeted) in the dark for 1h at 4oC at a final
concentration of 0.05-10 μM. Thereafter, cells were washed three times with 1% BSA in
1X PBS and the mean fluorescence intensity (MFI) was determined using a BD
AccuriTM C6 flow cytometer (Becton Dickinson Inc., NJ, USA) with FITC channel.
Generally 10,000 events were acquired per sample, and samples were run in triplicates.
Data were analyzed using BD AccuriTM CFlow Plus analysis software. The cell
association of targeted and untargeted CSLAHNPs was also conducted by CLSM as
described under the section “In vitro cellular uptake of CSLAHNPs”.
Cellular uptake mechanism of CSLAHNPs
To elucidate potential cellular uptake pathways of CSLAHNPs, cells were pretreated with following endocytosis inhibitors at a concentration that were not toxic to
cells. Genistein (200 μM) (397), chlorpromazine (10 μg/mL)(398), amiloride (10 mM)
and methyl-β-cyclodextrin (10 mM)(399) were added to block caveola-mediated
endocytosis, clathrin-mediated endocytosis, micropinocytosis, lipid rafts and lipid-raftmediated endocytosis respectively. Following pre-incubation with inhibitors for 1h,
fluorescently labeled CSLAHNPs were added for further 1 h. Subsequently, the cells
were washed thrice with 1xPBS and analyzed using a BD AccuriTM C6 flow cytometer
(Becton Dickinson Inc., NJ, USA) with FITC channel. Generally 10,000 events were
acquired per sample, and samples were run in triplicates. Data were analyzed using BD
AccuriTM CFlow Plus analysis software. CSLAHNPs without any inhibitor treatment
were used as control, and the mean fluorescence intensity (MFI) of controls was
expressed as 100 %.
Intracellular trafficking of CSLAHNPs
Endolysosomal trafficking of CSLAHNPs was studied in cells using confocal
laser scanning microscopy (CSLM) and transmission electron microscopy (TEM).
For CLSM, cells were grown on Lab-Tek® II 4-chambered slides with complete growth
medium until 70-80 % confluence. The cells were replenished with complete growth
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medium containing fluorescently labeled CSLAHNPs. LysoTracker® deep red (a specific
marker for secondary endosome and lysosome) at a final concentration of 50nM was
added into the medium 15 min prior to the experimental endpoint. Following the
incubation, cells were washed with 1x PBS and fixed in 4% paraformaldehyde for 10 min
at room temperature. Following fixation, cells were washed with 1X PBS thrice 3 min
each time. The upper chamber was separated from the slide. The cells were
counterstained with a drop of VECTASHIELD® mounting medium containing DAPI to
visualize nuclei. A coverslip was placed over the slide containing fixed cells. The cover
slip was immobilized by placing clear nail polish around the edges. Finally, the slides
were examined using confocal microscopy (Zeiss LSM 710, Jena, Germany) by using a
Plan-Apochromat 60×/1.4o na Oil DIC objective. Images were processed using the Zeiss
LSM Zen software 2010.
For TEM, CSLAHNPs loaded with 10% water soluble iron-oxide NPs with
carboxyl group (IONPs, size 15 ± 2.5 nm, Ocean NanoTech, Springdale, AR) were
prepared by the two-step method described in Chapter 4. Cells were seeded in BioFlex®
Collagen type I 6-well plates at a density of 1 × 105 cells/mL. After 24 h incubation, cells
were treated with 200 μg/mL IONP-loaded CSLAHNPs for 0-4h. The cells were washed
with cold 1X PBS for 3 times and fixed in 4 % paraformaldehyde solution in 1x PBS
overnight. The cells were rinsed with 0.1M cacodylate buffer, 3 x 20 min at RT on rotator
and dehydrated with successive 50, 70, 80, 90, 95, 100 % ethanol for 30 min at RT on
rotator. The cells were infiltrated with 1:1 ethanol:Spurr’s resin, overnight at RT on
rotator, followed by 100 % Spurr’s resin for 2 h at RT on rotator. The cells were
embedded in an epoxy resin molds with appropriate labels, the plastic was cured in oven
for 48 h at 70° C, cut into ultra-thin sections with an ultramicrotome using a diamond
knife, and mounted on 150 mesh copper grids. The cell ultrastructures were stained with
uranyl acetate and lead citrate and then observed under TEM.
In vitro efficacy of CSLAHNPs in NSCLC cells
The CellTiter-Glo®Luminescent cell viability assay was used for the
determination of the number of viable cells in culture based on the quantitation of ATP,
an indicator of metabolically active cells. The cells were seeded in 96 well opaque
(white) plates at a density of 5000 cells per well and incubated for 24 hours at 37oC, 5%
CO2 in complete medium. Then, the culture medium was replenished with 100 μL of
CSLAHNPs at different concentrations (0-15 μM) in complete medium and incubated for
24-72 h. The CellTiter-Glo® buffer and lyophilized CellTiter-Glo®Substrate were
equilibrated at room temperature. The substrate was reconstituted with the buffer to form
the CellTiter-Glo® reagent. , The plate contents were equilibrated at room temperature for
approximately 30 min. A 100 μL portion of CellTiter-Glo® reagent were added to each
well and mixed for 2 min on an orbital shaker to induce cell lysis. Control wells
containing complete growth medium without cells were prepared to measure the
background luminescence. The plates were equilibrated at room temperature for 10 min
to stabilize the luminescent signal. Finally, luminescence was recorded using
SpectraMax® M2e microplate reader (Molecular devices, Sunnyvale, CA).
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Colony-formation assay
Colony formation assay, also known as clonogenic assay were performed by the
previously reported method (400). The cells were plated at a density of 500 to 1000 cells
on 6-well tissue culture treated plates and allowed to attach for 24 h. After that, cells were
treated with CSLAHNPs or controls and allowed to grow for 10-14 days. The cell
colonies were washed with 1x PBS thrice, followed by fixing with -20oC methanol in
freezer for 5-15 min. The colonies were washed with 1x PBS thrice and stained with
hematoxylin. The photographs were taken using GelDoc-it imaging system (UVP,
Upland, CA). The efficacy of the CSLAHNPs was determined by counting the number of
colonies and comparing with controls.
Expression of phosphorylated EGFR
Expression of phosphorylated EGFR was investigated by western blotting. Cells
were seeded into 6-well plates at a concentration of 2 × 105 cells per well. When 90-95%
confluency reached, cells were treated with ETB/ ETB-CSLAHNPs/hAb-ETBCSLAHNPs at the corresponding IC50 values and incubated for 6 h, followed by
stimulation using 60 ng/mL EGF for 15 min. Cells were washed with ice cold 1X PBS
thrice and lysed with 0.2% Triton X-100 in 1X PBS on the shaker at 4oC for 1 h. The
lysates were scraped out, placed in Eppendorf tubes and centrifuged at 13000 rpm for 15
min. Protein contents in the lysates were estimated by Pierce BCA protein assay kit by
optical absorbance method using BSA as the standard. Total cell proteins from each
sample (25-50 μg) were added to Laemmli 5x loading buffer and incubated at 37oC for
10 min. The samples were loaded into the wells of 4-15% SDS-PAGE gels (MiniPROTEAN® TGX Gels, Bio-Rad, Hercules, CA) immersed in running buffer (trisglycine/SDS) and resolved at 150V for 45 min using standard molecular weight ladder.
The transfer stacks were prepared with the order sponge-3 filter papers-PVDF
membrane-gel-3 filter papers-sponge. The PVDF membrane was soaked with methanol
before placing in the transfer stack. The gel bands were transferred to PVDF membrane
at 4oC, 90 V for 1.5 h, followed by blocking in blocking buffer (5% non-fat milk in
TBST) and probed using appropriate dilutions of primary monoclonal antibodies directed
against phospho-specific EGFR (p-EGFR) and β-actin as control at 4oC overnight. The
membrane was washed thrice with TBST 5 min each, followed by recommended dilution
of labeled secondary antibody in 5 % blocking buffer in TBST at room temperature for 1
h. The membrane was washed thrice with TBST 5 min each. Immunoreactive bands were
detected by enhanced chemiluminescence reagents (Amersham Biosciences).
Statistical analysis
Student’s t-test (two tailed) was performed to compare the mean values of
different groups; p values less than 0.05 were considered to be significant. All the results
are represented as mean ± SD, with n equaling the number of experiments.
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Results and Discussion
EGFR is a tumor specific receptor overexpressed in various NSCLCs (401). Two
representative human lung cell lines, A549 and HCC827, were used to test the cellular
uptake and efficacy of targeted and untargeted CSLAHNPs. A549 is a lung carcinoma
cell line which expresses wild type EGFR. Constitutive upregulation of
autocrine/paracrine secretion of EGFR ligands, particularly ARG, results in an increase in
active phosphorylated-EGFR in A549 cells (402). HCC827 is a human lung
adenocarcinoma cell line that has an acquired mutation in the EGFR tyrosine kinase
domain (exon 19 deletion or the del E746-A750 mutation) (403). Literature reports
support that HCC827 and A549 cells overexpress EGFR (404, 405).
To study the cellular uptake of CSLAHNPs, both confocal laser scanning
microscopy (CLSM) and flow cytometry (FCM) techniques were utilized. CLSM
visualized the localization of CSLAHNPs in the cellular compartments, while FCM gave
quantitative analysis of the mean fluorescence intensity (MFI) of the treated cells. The
application of these two techniques in parallel helped to visualize as well as quantify the
uptake of CSLAHNPs in human lung adenocarcinoma cells. Both hAb-ETB-CSLAHNPs
(targeted) and ETB-CSLAHNPs (untargeted) were labeled with 1 mol % of a
fluorescently labeled phospholipid, NBD-PC for visualization and quantification. The
physicochemical properties of fluorescent targeted and untargeted CSLAHNPs such as
size, PDI and zeta potential were almost similar to the non-fluorescent targeted and
untargeted CSLAHNPs (data not reported).
CLSM images of the cellular uptake of CSLAHNPs at two time points were
shown in Figure 5-1 for HCC827 cells and in Figure 5-2 for A549 cells. Upon excitation
at 460 nm, the NBD-PC tagged CSLAHNPs appeared green under CLSM (emission
wavelength of NBD-PC at 534 nm). DAPI (Ex/Em 358/461 nm) was used for nuclear
staining (blue color). The appearance of green color surrounding the blue colored nucleus
indicated that the CSLAHNPs were extensively present in the cytoplasm of the cells. In
both cells, significantly higher uptake of targeted and untargeted CSLAHNPs was
observed at 3.5 h compared to 0.5 h. Higher uptake was observed with hAb-ETBCSLAHNPs in HCC827 cells compared to untargeted ETB-CSLAHNPs.
As shown by FCM, NSCLC tumor cells treated with 1 mol % fluorescent NBDPC lipid loaded CSLAHNPs exhibited a time dependent increase of their mean
fluorescence intensity (MFI) which indicated enhanced intracellular uptake of
CSLAHNPs. It was significantly different from the control only after 30 min of exposure
in both the cells A549 and HCC827 (Figure 5-3). Overall, a higher cellular uptake was
observed in HCC827 cells compared to A549 cells. Targeted NBD-hAb-ETBCSLAHNPs were taken up significantly higher in HCC cells after 4h compare to
untargeted ETB-CSLAHNPs. As observed by CLSM, CSLAHNPs were found inside the
cytoplasm of cells. Observation of treated cultures revealed that CSLAHNPs were almost
entirely internalized after 4 h suggesting that the MFI measured by FCM mainly reflected
internalized CSLAHNPs. Therefore, the results of both FCM and CLSM confirmed the
uptake of CSLAHNPs.
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Figure 5-1. Confocal microscopy images of CSLAHNPs uptake in HCC827 cells
after 0.5 h (A) and 3.5 h (B)
DAPI stained nucleus, NBD represents fluorescent NBD-PC loaded CSLAHNPs.
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Figure 5-2.

Confocal microscopy images of CSLAHNPs uptake in A549 cells

(A) 0.5 h and (B) 3.5 h . DAPI stained nucleus, NBD represents fluorescent NBD-PC
loaded CSLAHNPs.
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Figure 5-3.
cells

Flow cytometric analysis of cellular uptake of CSLAHNPs in HCC827

(A) and A549 cells (B). The data were presented as mean ± SD (n=3). * represents pvalue of <0.05.
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Cell association studies at 4oC were performed to determine whether hAb-ETBCSLAHNPs could specifically interact with EGFR expressed on the cell surface. For
comparison, control sets were run at 37oC. After 1h incubation at 4oC, cell associations of
fluorescent CSLAHNPs were determined by measuring MFI using FCM (Figure 5-4).
A549 cells showed no significant difference in MFI between targeted and untargeted
CSLAHNPs. As expected, HCC827 cells incubated with targeted CSLAHNPs presented
4 fold higher MFI than untargeted CSLAHNPs. CLSM images confirmed the observed
anti-EGFR hAb medicated cell association of targeted CSLAHNPs compared to
untargeted particles (Figure 5-5). A higher degree of association was observed for both
targeted and untargeted in HCC827 cells compared to A549 cells. This could be
explained by a higher level of EGFR expression in HCC827 compared to A549. The
presence of anti-EGFR hAb on the surface of CSLAHNPs resulted in a specific cell
association, and enhanced signal compared to control groups. At 37oC, targeted and
untargeted CSLAHNPs were taken up by both the cells.
The process of cellular uptake of NPs via endocytosis pathway can involve
clathrin mediated endocytosis, caveolae mediated endocytosis, micropinocytosis, and
clathrin/caveolae independent endocytosis (377). The flow cytometry results of the effect
of endocytosis inhibitors on the uptake of fluorescently labeled CSLAHNPs in both A549
and HCC827 cells were shown in Figure 5-6. Macropinocytosis is a non-specific, ligand
independent mechanism which involves formation of large irregular vesicles known as
macropinosomes (406). Amiloride is an inhibitor of micropinocytosis by inhibiting
Na+/H+ exchange (407). It had no significant inhibitory effect on the CSLAHNPs uptake
compared to control in both A549 and HCC827 cells. Chlorpromazine is known to block
assembly of clathrin-coated pit formation at the plasma membrane and causes clathrin
lattices to assemble on endosomal membranes (408). The treatment with chlorpromazine
did not decrease cellular uptake of CSLAHNPs compared to control group in both A549
and HCC827 cells. Caveolae mediated endocytosis involves the formation of 50-100 nm
invaginated plasma membranes known as caveolae (409). Caveolae are rich in caveolin,
glycolipids, and cholesterol. Genistein is a specific inhibitor of caveolae-mediated
endocytosis (410). It showed a significant inhibition of cellular uptake of CSLHANPs in
both cells. Methyl-β-cyclodextrin was used to block cholesterol depletion and lipid-raft
mediated endocytosis (399). It did not inhibit the cellular uptake of CSLAHNPs.
Therefore, the results showed that the caveolae-mediated endocytosis played a major role
in the cellular uptake of CSLAHNPs in human lung adenocarcinoma cells. One of the
major components of CSLAHNPs was the albumin NPs. Albumin NPs were reported to
bind to protein on the endothelial cell surface localized on caveolae and activate
gp60/caveolae receptor medicated endocystosis (411). Therefore, the literature report
confirmed the present finding.
In vitro cellular internalization, localization and intracellular trafficking were
investigated by TEM. Figure 5-7 showed the TEM image of the cells incubated with
IONPs-loaded CSLAHNPs for 4h. IONPs were loaded into CSLAHNPs to track them
inside the cells. IONPs were observed at or near cell membranes, inside the cytoplasm
and also into the endolysomal vesicles. Figure 5-8 showed the confocal microscopy
images of cells incubated with fluorescently labeled CSLAHNPs for various time
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Figure 5-4. Cell association study using flow cytometric analysis of cellular
uptake of CSLAHNPs in HCC827 cells and A549 cells at 4oC and 37oC
The data were presented as mean ± SD (n=3). * represents p-value of <0.05.
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Figure 5-5. Confocal microscopy images of the cell association of CSLAHNPs
after 1 h incubation at 4oC
DAPI stained nucleus, NBD represents fluorescent NBD-PC loaded CSLAHNPs.
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Figure 5-6. Effect of endocytosis inhibitors on the cellular uptake of CSLAHNPs
using flow cytometric analysis
The data were presented as mean ± SD (n=3). * represents p-value of <0.05. Inhibitors
were treated with cells for 1 h, followed by CSLAHNPs incubation for 1 h.
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Figure 5-7. TEM image of a single HCC827 cell after incubation of IONPs-loaded
targeted CSLAHNPs
The image revealed intracellular localization of 15 nm iron-oxide nanoparticles (IONPs)
loaded targeted hAb-ETB-CSLAHNPs after 4h incubation at 37oC.
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Figure 5-8. Confocal microscopy image of a single HCC827 cell after 1 h
incubation with fluorescent hAb-ETB-CSLAHNPs
The images showed the endolysosomal localization using colocalization of NBD (green)
and lyosotracker (red) signals in the merged image. The nucleus was stained with blue
color.
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intervals. The confocal microscopy revealed that the CSLAHNPs were co-localized with
endosomes and lysosomes, which were marked by LysoTracker Deep Red.
After confirmation of the binding and internalization of the hAb-ETBCSLAHNPs and ETB-CSLAHNPs to deliver ETB to target cells, in vitro cellular
viability of ETB solution, ETB-CSLAHNPs, and hAb-ETB-CSLAHNPs were tested
against both A549 and HCC827 cells using CellTitre Glo®Luminescent cell viability
assay. Cells were treated with CSLAHNPs or ETB solution for 72h, followed by the
determination of cell viability. The plots of ETB concentration versus in vitro cellular
viability were shown in Figure 5-9 for HCC827 cells and in Figure 5-10 for A549 cells.
Overall the dose-response curves showed higher sensitivity to ETB, hAb-ETBCSLAHNPs, and ETB-CSLAHNPs treatments in HCC827 cells compared to A549 cells.
The ETB concentrations were in nanomolar (nM) range for HCC cells where high
micromolar (μM) ETB concentrations were required for A549 cells. This could be
explained by EGFR expression in both the cells. HCC827 cells express EGFR at a much
higher level due to the presence of acquired mutation in the EGFR tyrosine kinase
domain (403). A549 cells express a lower level of total and phosphorylated EGFR
compared to HCC827 cells (412). In HCC827 cells, hAb-ETB-CSLAHNPs were more
effective compared to ETB-CALSHNPs and ETB-solution . The IC50 values (the
concentration required to kill 50 % of the cells) were ~ 20 nM for hAb-ETB-CSLAHNPs,
~45 nM for ETB-CSLAHNPs and ~51 nM for ETB-solution. The comparison of IC50
values demonstrated that anti-EGFR hAb conjugated CSLAHNPs were about 2.5 folds
more efficacious in reducing viability of HCC cells after 72 h compared to ETB-solution.
This could be explained by higher cellular uptake of hAb-CSLAHNPs via receptor
mediated endocytosis pathways compared to free ETB in solution form. The untargeted
particles showed no significant difference in viability of HCC827 cells compared to ETBsolution form due to the absence of targeting ligands in ETB-CSLAHNPs. In contrast, the
A549 cells were less sensitive to ETB, hAb-ETB-CSLAHNPs, and ETB-CSLAHNPs
treatments as concentrations of ETB to 1 did not result in a significant decrease in
proliferation
The clonogenic assay or colony formation assay is an in vitro long-term cell
survival assay based on the ability of a single cell to grow into a colony consisting of at
least 50 cells (400) . The assay has been essentially used to test the efficacy and toxicity
of anticancer drugs, drug delivery systems and radiation therapies (413). The colony
formation assay results are shown in Figure 5-11. In HCC827 cells, treatment of ETBCSLAHNPs and hAb-ETB-CSLAHNPs at a concentration close to IC50 (10 nM)
significantly decreased the formation of colonies compared to control groups. The ETB
solution form also showed decreased number of colonies at 10 nM concentration but not
to the same extent as CSLAHNPs. Control and blank CSLAHNPs showed very high
colony counts as expected. In A549 cell, reduced number of colonies was observed after
treatment of ETB-CSLAHNPs and hAb-ETB-CSLAHNPs at 5 mM compared to control
group and blank CSLAHNPs. The ETB-solution form had significantly higher number of
colonies compared to hAb-ETB-CSLAHNPs and ETB-CSLAHNPs groups. Therefore,
overall increased efficacy was observed in both untargeted and targeted CSLAHNPs
compared to ETB solution and controls.
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Figure 5-9. Plot of the in vitro HCC827 cell viability as a function of ETB (drug)
concentration after 72 h
CellTiter-Glo®Luminescent cell viability assay was used. The data were presented as
mean ± SD (n=3). * represents p-value of <0.05. IC50 targeted CSLAHNPs was ~20 nM
which was lower than the IC50 of untargeted CSLAHNPs (~45 nM) and ETB-solution
(~51 nM).
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Figure 5-10. Plot of the in vitro A549 cell viability as a function of ETB (drug)
concentration after 72 h
CellTiter-Glo®Luminescent cell viability assay was used. The data were presented as
mean ± SD (n=3). * represents p-value of < 0.05. IC50 of targeted and untargeted
CSLAHNPs ~5μM which was lower than the IC50 of ETB-solution > 20μM.
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Figure 5-11. Colony formation assay results after in (A) HCC827 cells and (B)
A549 cells
ETB dose was 50nM for HCC cells and 5μM for A549 cells.
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The phosphorylated EGFR (active form) expression by western blotting was
showed in Figure 5-12. The drug (ETB) binds with the ATP binding site in the
intracellular tyrosine kinase domain of EGFR. Thus, it inhibits phosphorylation of EGFR
to its active form, thereby preventing downstream signaling cascade leading to cell
proliferation and angiogenesis. In HCC827 cells, the treatment of ETB-CSLAHNPs at 50
nM showed significant down regulation of p-EGFR expression compared to control.
Treatment with only ETB-solution did not show significant downregulation of p-EGFR
compared to control. Blank CSLAHNPs had no effect on p-EGFR expression in HCC827
cells. A549 showed lesser sensitivity to ETB or ETB-CSLAHNPs treatments. At 5 μM
ETB-CSLAHNPs, slight reduction in p-EGFR expression was observed compared to
control.
Summary and Conclusion
In summary, cellular uptake, intracellular trafficking, and cellular viability of
ETH-CSLAHNPs and targeted hAb-ETB-CSLAHNPs were investigated in A549 and
HCC827 cells. For intracellular imaging, 1 mol % of NBD-PC was incorporated into
CSLAHNPs. The targeting ability of hAb-ETB-CSLAHNPs was confirmed by cell
association study. Confocal microscopy and flow cytometry results showed higher uptake
of hAb-ETB-CSLAHNPs and ETB-CSLAHNPs in HCC827 cells compared to A549
cells up to 4 h. Endocytosis inhibitor assay showed major mechanism of particle uptake
was via caveolae-mediated endocytosis. Significantly higher reduction in cell viability
was observed for both targeted and untargeted ETB-CSLAHNPs compared to ETBsolution form in HCC827 compared to A549 cells. Similar results were observed for
colony formation assay. Western blot results showed significant downregulation of
phosphorylated EGFR after ETB-CSLAHNPs treatment compared to control. The results
suggest the potential therapeutic advantages of targeted and untargeted ETB-CSLAHNPs
over ETB in solution in EGFR-overexpressing NSCLC.
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Figure 5-12. Expression of phosphorylated-EGFR by western blot
(1) ETB-solution, (2) control, (3) hAb-ETB-CSLAHNPs, and (4) blank hAbCSLAHNPs. ETB dose was 50 nM for HCC cells and 5 μM for A549 cells. All
treatments were incubated with the cells for 6 h. The blots showed higher downregulation
of phosphorylated EGFR (active form) after ETB-CSLAHNPs treatment in HCC827
cells.
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CHAPTER 6. LYOPHILIZATION OF TARGETED AND UNTARGETED
ERLOTINIB LOADED CORE SHELL TYPE LIPID ALBUMIN HYBRID
NANOPARTICLES
Introduction
Physical and chemical stability of the colloidal drug delivery systems including
CSLAHNPs in aqueous dispersion is a major concern in the development of a drug
product with acceptable shelf-life (344). Phospholipids which constitute the shell of the
CSLAHNPs can undergo hydrolysis and/or oxidation and lead to degradation when
stored as aqueous dispersions (414). As a result, the encapsulated drug tends to leak from
the bilayer which surrounds the core of CSLAHNPs (415). Apart from drug leakage, the
CSLAHNPs may aggregate or fuse together resulting in an increase in particle size
distribution. The albumin core and the targeting antibody conjugated to the CSLAHNPs
are also susceptible to chemical and physical degradation pathways, such as oxidation,
deamidation, aspartate isomerization, peptide bond hydrolysis and aggregation (416-419).
The long-term stability of colloidal drug delivery systems including CSLAHNPs can be
improved by various techniques such as freezing-drying, lyophilization, spray drying, and
supercritical fluid technology. Lyophilization is one of the preferred methods to improve
long-term stability of NPs containing thermosensitive drugs and proteins (170). It can
prevent a number of physical and chemical degradation pathways during storage (170).
By removing water by lyophilization process, the physicochemical characteristics of
CSLAHNPs can be retained with improved storage stability.
Lyophilization is the process of removing water from a frozen sample by
sublimation and desorption to increase the shelf-life of materials (420-422). It combines
three separate and interdependent processes; freezing, primary drying (sublimation), and
secondary drying (desorption). The first step is the freezing which is initiated by cooling
the shelves to the desired freezing temperature and holding the temperature to equilibrate
and create a solid matrix. The key process parameters for freezing step include freezing
temperature, freezing rate and hold time at the freezing temperature. The freezing
temperature should be below the glass transition temperature (Tg´) of the formulation. A
slow cooling rate results in relatively homogenous ice crystal formation. The majority of
water is removed in the primary drying by the process of sublimation. There are two
critical process parameters; shelf temperature and chamber pressure. The shelf
temperature is maintained 2-5oC below Tg´ of the frozen product to maintain structural
integrity of the maximally frozen amorphous phase and prevent collapse. For crystalline
materials, product temperature must be kept below the eutectic melting temperature (Te)
of the crystalline component in the formulation to prevent meltback. The chamber
pressure is kept below the saturated vapor pressure of the ice at frozen product
temperature to provide driving force for sublimation process to occur. The final stage is
the secondary drying, the bound unfrozen water is removed via desorption by raising the
shelf temperature at ambient or higher values while maintaining low chamber pressure.
To characterize the frozen samples, subambient analytical techniques are utilized such as
differential scanning calorimetry (DSC) and freeze-drying microscopy (170).
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Lyophilization may generate various stresses such as cryo/freezing and
lyo(sublimation) stresses which could destabilize NPs. In order to minimize the stresses
and subsequent destabilization, excipients are added before the lyophilization process.
The excipients include cryoprotectant, lyoprotectant, bulking agents, buffers, tonicity
adjusters, and collapse temperature modifiers. Cryoprotectants are used to protect the
product from freezing stress while lyoprotectants are added to protect the product from
sublimation stress (423). Cryoprotectants stabilize NPs by preferential “exclusion”
mechanism (424). The examples of cryoprotectants include polyethylene glycol, glycerol,
and dimethylsulfoxide (425). A number of excipients are available as lyoprotectants such
as glucose, sucrose, trehalose, mannitol, lactose, sorbitol, glycine, dextran, fructose,
maltose, glycerol, polyvinyl alcohol (426). They stabilize the NPs by either “water
substitution” or “vitrification” mechanism (427). In vitrification mechanism, the glassy
sugar matrix below Tg´ immobilizes NPs and prevents aggregation.
The specific aim of this study was to develop lyophilized hAb-ETB-CSLAHNPs
(targeted) and ETB-CSLAHNPs (untargeted) CSLAHNPs of ETB to improve the shelflife of the CSLAHNPs during storage. The cryo/lyoprotective ability of sucrose and
trehalose at various concentrations during the process of lyophilization was investigated
to optimize the better protectant and it’s concentration. Finally, the stability of liquid
dispersion and lyophilized dry powder were evaluated after stored at different storage
conditions for various lengths of time.
Experimental Section
Materials
Bovine serum albumin (BSA, Cohn fraction V, lyophilized powder, MW ̴ 66000,
purity 95-99%), glutaraldehyde solution (25% in water), sucrose, and trehalose were
obtained from Sigma-Aldrich (St. Louis, MO). Erlotinib hydrochloride (purity 99%) was
obtained from LC Laboratories (Woburn, MA). The lipids used in this work were all of
research grade. 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoylsn-glycero-3-hoshoethanolamine-N (poly(ethylene glycol)2000) [DSPE-PEG(2000)], and
1,2-distearoyl-sn-glycero-3-phoshoethanolamine-N-(maleimide poly(ethylene
glycol)2000) [maleimide DSPE-PEG(2000)] were purchased from Avanti Polar Lipids
(Alabaster, AL). Cholesterol was purchased from Sigma (St. Louis, MO). High
performance liquid chromatography (HPLC) grade water, ethanol, and methanol were
obtained from Fisher Scientific (Fair Lawn, NJ). HPLC grade chloroform and 1N sodium
hydroxide solution were purchased from Acros Organics (Morris Plains, NJ). Mouse
monoclonal EGFR antibody (D-8) was obtained from Santa Cruz (Dallas, TX). Tris(2carboxyethyl)phosphine hydrochloride [TCEP] was supplied by Thermo Scientific
(Rockford, IL). All other chemicals and reagents were of analytical grade and used
without further purification or characterization.

114

Preparation of ETB-CSLAHNPs and hAb-ETB-CSLAHNPs
ETB-CSLAHNPs (untargeted) and hAb-ETB-CSLAHNPs (targeted) were
prepared by the methods as described in Chapter 3 and Chapter 4.
Determination of Tg
Two lyoprotectants were used; sucrose and trehalose. The effect of lyoprotectant
on glass transition temperature (Tg´) was monitored by DSC using a Q2000 differential
scanning calorimeter equipped with refrigerated cooling system (TA Instruments, New
Castle, DE). About 10-20 μL of the CSLAHNPs and lyoprotectant mixture was placed
into T-Zero aluminum pans and hermetically sealed. An empty pan prepared in a similar
manner was used as reference. The samples were equilibrated at 25°C and then cooled at
5°C/min to -70°C. After equilibration, the samples were heated at the rate of 10°C/min to
30°C. The Tg′ was also determined from these thermograms.
Lyophilization of CSLAHNPs
ETB-CSLAHNPs and hAb-ETB-CSLAHNPs dispersions were mixed with
sucrose or trehalose solution. Different weight ratios of CSLAHNPs to lyoprotectant
were used (1:1, 1:4, 1:8, and 1:16). The samples (1 mL) were filled into 5cc glass lyo
vials. Rubber lyo stoppers placed in the vials with partial opening to allow water vapor
escape. The vials containing stoppers were placed into the tray and loaded into the
benchtop lyophilizer (VirTis adVantage Plus, SP Scientific, Gardiner, NY). The
lyophilization cycle was designed based on the Tg′ of maximally freeze-concentrated
amorphous phase as determined by DSC. The following parameters were selected:
freezing shelf temperature -45oC (duration 6h), primary drying shelf temperature -35oC
(duration 12 h), and secondary drying shelf temperature 15oC (duration 6 h), primary
drying chamber pressure 100 mTorr, secondary drying chamber pressure 50mTorr. The
product temperature, shelf temperature, and condenser temperature were controlled and
monitored using Wizard 2.0 software. On completion of the drying cycle, the vials were
sealed after filling nitrogen in the headspace of the vials at atmospheric pressure.
Characterization of lyophilized CSLAHNPs
The lyophilized powders were inspected for cake volume and cake appearance
including collapse or meltback and skin formation.
The moisture content of the lyophilized cake was determined using Mettler
Toledo DL31 Karl Fischer Titrator (Mettler Toledo Inc., Boston, MA). The titrator was
calibrated on each day of analysis with a known quantity of water. About 10-20 mg of the
lyophilized powder was weighed accurately and added to the titration vessel. The titration
was started after allowing one minute for extraction. Triplicate measurements were
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recorded. The residual moisture content in the lyophilized cake was expressed in % w/w.
The lyophilized powders were reconstituted with HPLC grade water. The
hydrodynamic mean size (Z-avg) of the reconstituted CSLAHNPs was determined using
dynamic light scattering using Zetasizer Nano ZS (Malvern Instruments, Westborough,
MA) equipped with 4.5 mW diode laser as a source of light operating at 670 nm. The
samples were suitably diluted with HPLC grade water. Three independent measurements
were performed for each sample. Zeta potential was determined from electrophoretic
mobility using samples suitably diluted with HPLC grade water.
Stability evaluation of liquid and lyophilized CSLAHNPs
Short-term stability was assessed for 3 months by after storage of ETBCSLAHNPs and hAb-ETB-CSLAHNPs (targeted). The different batches of targeted and
untargeted CSLAHNPs (aqueous dispersion and lyophilized powder) were stored at two
temperatures 2-8oC and 25oC in glass vials for up to 3 months. After predetermined time
intervals, liquid samples were characterized for the physicochemical properties including
mean size, PDI, zeta potential. For lyophilized batches, powders were reconstituted with
water and evaluated for physicochemical properties. The total and free ETB in the
CSLAHNPs before and after lyophilization were determined using an HPLC method.
Briefly, a centrifugal ultrafiltration device (Amicon® Ultra-4, MWCO 100 KD, Millipore,
Bedford, MA) was used to separate free drug from the ETB-CSLAHNPs. Drug
entrapment efficiency (DEE) and drug loading (DL) of ETB-CSLAHNPs and hAb-ETBCSLAHNPs were quantified by HPLC method previously described in chapter 3. Finally,
the characteristics of CSLAHNPs were compared with that of the initial values.
Results and Discussion
Lyophilization was used to remove water from CSLAHNPs to obtain lyophilized
powders for storage stability. The determination of the glass transition temperature (Tgʹ)
of the maximally frozen concentrated mixture of the formulation components is a critical
parameter which helps to set the freezing and the primary drying temperatures of the
lyophilization cycle. To dry the product with retention of the structure of materials, the
product is maintained in the solid state below the collapse temperature. The collapse
temperature is also known as Tgʹ for amorphous materials. To determine Tgʹ, DSC was
performed using four different weight ratios of CSLAHNPs and lyoprotectant (1:1, 1:4,
1:8, and 1:16). The DSC thermograms were shown in Figure 6-1. The Tgʹ values
decreased with an increase in sucrose weight ratio in the mixture (428). The Tgʹ value
was around -33oC. Therefore, primary drying temperature was set 2-5oC below the Tgʹ to
prevent collapse. For the lyophilization cycle, freezing step was performed at -45oC. The
cooling rate was ~ 0.4oC/minute, followed by holding at -45oC for 4 h. The primary
drying was performed at -35oC to prevent collapse. The end of primary drying process
was determined by the rise in product temperature which matched with the shelf
temperature. The total hold time was found to be around 12 h at around -35oC. The
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Figure 6-1.

DSC thermograms of CSLAHNPs and sucrose mixture

CSLAHNPs to sucrose weight ratio used were (A) 1:0, (B) 1:1, (C) 1:4, (D) 1:8, and (E)
1:16. The Tg´ was determined using Universal Analysis 2000 software (TA instruments,
New Castle, DE). Blank CSLAHNPs without drug and targeting ligand were used for the
DSC studies. Tg´ was found to be around -33oC.
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chamber pressure was set at 100 mTorr which was below the vapor pressure of ice at subzero temperature (423, 429). The difference between the ice vapor pressure at -35oC and
the chamber pressure was the driving force for the sublimation process at primary drying
phase. For the secondary drying, the temperature was slowly ramped to 15ºC and hold for
4 h with maximum vacuum of 50 mTorr. The end of secondary drying was monitored by
measuring the moisture content of the lyophilized cake.
Two disaccharides, sucrose and trehalose were used as lyoprotectants in the
lyophilization of CSLAHNPs. Four different weight ratios of CSLAHNPs to
lyoprotectant (sucrose or trehalose) were lyophilized. The effect of lyoprotectant sucrose
on the mean size and PDI of reconstituted CSLAHNPs dispersions were compared to
their mean size and PDI before lyophilization (Figure 6-2). Sucrose was able to retain the
physicochemical characteristics of CSLAHNPs at the selected ratios of CSLAHNPs to
lyoprotectant. Trehalose showed slight increase in mean size at 1:1, 1:4 but maintained
the mean size at 1:8 and 1:16 (Figure 6-3). The possible explanation could be the
presence of core albumin which acted a support to prevent the lipid bilayer shell collapse
during lyophilization. Albumin NPs were shown to be stable for 6 months in liquid form
without affecting physical stability (305, 430). Therefore, the structural integrity of the
CSLAHNPs at lower lyoprotectant ratios could be justified. In addition, the presence of
PEG chains on the surface of CSLAHNPs provided additional protection during the
freezing phase. PEG has been widely used as a cryoprotectant which prevents the NPs
aggregation during the freezing phase. Evaluation of the cake properties of the
lyophilized powders with trehalose and sucrose revealed that sucrose was better as
lyoprotectant than trehalose (Figure 6-4). The major limitation of trehalose is it’s
tendency to crystallize during lyophilization (431-433). Crystallization of the
lyoprotectant trehalose could alter the structural integrity of CSLAHNPs during
lyophilization or after the storage. Therefore, sucrose was selected as the lyoprotectant
for further studies. At 1:16 weight ratio of CSLAHNPs to sucrose, the cake volume was
equal to the initial fill volume. In addition, the cake was immediately reconstituted with
gentle shaking. The mean size, PDI and zeta potential of CSLAHNPs were retained after
lyophilization at 1:16 weight ratio of CSLAHNPs to sucrose. At lower ratios, although
physicochemical properties of CSLAHNPs were retained, shrinkage of the cake volume
was observed. One of the quality control parameters for any lyophilized product is the
measurement of the residual water content of the lyophilized cake. Higher moisture
content might lead to poor stability and loss of biological activity (434). The low residual
moisture content of 0.5-3% w/w was recommended for lyophilized powders containing
both small molecular weight drugs and monoclonal antibodies (435). The moisture
content of the lyophilized powders of CSLAHNPs containing 16 times higher sucrose
content was in the range of 1.85 ± 0.25% w/w which is acceptable for storage stability.
Therefore, 1:16 weight ratio of CSLAHNPs to sucrose was the optimum ratio used to
prepare lyophilized CSLAHNPs.
To further evaluate short-term stability, liquid dispersion and lyophilized ETBCSLAHNPs and hAb-ETB-CSLAHNPs (containing 1:16 weight ratio of CSLAHNPs to
sucrose) were stored at 2–8oC (refrigerated conditions) as well as 25oC (accelerated
condition) for up to 60 days. Physicochemical properties including mean size, PDI, and
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Figure 6-2. Influence of CSLAHNPs to sucrose weight ratio on mean size(A) and
polydispersity index (B) of CSLAHNPs before and after lyophilization
The data were presented as mean ± SD (n=3). Blank CSLAHNPs without drug and
targeting ligand were used and indicated as HNPs.
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Figure 6-3. Influence of CSLAHNPs to trehalose weight ratio on mean size (A)
and polydispersity index (B) of CSLAHNPs before and after lyophilization
The data were presented as mean ± SD (n=3). Blank CSLAHNPs without drug and
targeting ligand were used and indicated as HNPs.
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Figure 6-4. Physical appearance of the lyophilized cakes at various weight ratios
of CSLAHNPs to lyoprotectant (A) sucrose and (B) trehalose
At 1:16 weight ratio of CSLAHNPs to sucrose, the cake volume was equal to the initial
liquid fill volume and the cake appeared uniform.
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zeta potential were analyzed immediately after lyophilization and at various time points
up to 60 days. Residual moisture content of the formulations was determined directly
after freeze drying and after a storage time of 60 days. Directly after the freeze-drying
process, the CSLAHNPs showed residual water content 1.85 ± 0.25%. After a storage
period of 60 days, the samples stored at 2–8oC showed no significant increase in the
residual water content. Samples stored at 25oC showed shrinkage and change in
appearance of cake after storage for 1-2 weeks. The determination of residual moisture
content using Karl Fisher titration method showed an increase in moisture level to 4-5 %
w/w after 1-2 weeks. This may be caused by ingress of moisture in the vials from
stoppers or inappropriate container-closure integrity (436). The lyophilized samples
stored at 25oC showed shrinkage and change in appearance of cake. Therefore, it can be
concluded that storage at 25oC showed significant instability of CSLAHNPs. The
lyophilized targeted and untargeted CSLAHNPs showed acceptable long-term storage
stability at 2-8oC with regard to mean size and PDI after reconstitution (Figure 6-5). For
comparison, liquid CSLAHNPs dispersions were also analyzed for their physicochemical
properties at two conditions. At 2-8oC storage of the liquid dispersion, the mean size and
PDI changed gradually over storage time of 30 days (Figure 6-6). The liquid samples
stored at 25oC showed aggregation and formation of sediments within 3-5 days of
storage. Therefore, the stability study at 25oC was discontinued.
In the case of drug loaded CSLAHNPs a further aspect, which needs
consideration, is the drug loading stability after freeze drying. Freeze-drying process may
influence the drug loading efficiency of CSLAHNPs since the process might result in
drug loss due to change or loss of the particle structures. Therefore, the samples were also
investigated for potentially released or leaked drug after reconstitution. After redispersion
the resulting particle suspensions were centrifuged through Amicon® ultrafiltration
device with MWCO 100 kDa, followed by HPLC analysis of both filtrate and retained
particles. Figure 6-7 showed the influence of storage time on retention of ETB in
lyophilized CSLAHNPs. Immediately after lyophilization, the amount of free drug was
low and the percent drug retained in the CSLAHNPs was approximately 90 %. The
lyophilized CSLAHNPs were able to retain about 80 % of the drug for up to 60 days at 28oC. However, the liquid dispersion stored at 2-8oC showed much higher leakage and
lower drug retention about 60 % in CSLAHNPs for up to 30 days (Figure 6-8).
Therefore, it has to be concluded that the freeze-drying process exerted no significant
influence on drug loading stability of CSLAHNPs.


Summary and Conclusion
The present study showed that targeted and untargeted ETB-CSLAHNPs can be
stabilized both during the lyophilization process as well as for long-term storage using
adequate concentrations of suitable excipients. Among the two disaccharides (sucrose
and trehalose) used as lyoprotectants, sucrose was the best in preserving the acceptable
physicochemical characteristics at 1:16 weight ratio of CSLAHNPs to sucrose. Storage at
room temperature (25oC) had a negative influence on both physical and chemical stability
of both lyophilized cake and liquid dispersion form of CSLAHNPs. The study also
122

Figure 6-5. Effect of storage time on the mean size (A) and polydispersity index
(B) of the lyophilized CSLAHNPs at 2-8oC
The data were presented as mean ± SD (n=3).
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Figure 6-6. Effect of storage time on the mean size and polydispersity index of the
liquid dispersion of CSLAHNPs at 2-8oC
The data were presented as mean ± SD (n=3).

124

Figure 6-7.
8oC

Influence of storage time on the % drug retention in CSLAHNPs at 2-

The data were presented as mean ± SD (n=3).
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Figure 6-8. Influence of storage time on the % drug retention in liquid dispersion
of CSLAHNPs at 2-8oC
The data were presented as mean ± SD (n=3).
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showed that the lyophilized form retained the physicochemical properties CSLAHNPs
compared to the liquid dispersion after 2-8oC storage condition for 60 days.
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CHAPTER 7.

SUMMARY AND CONCLUSION

Lung cancer is the leading cause of cancer related death worldwide. Among
various histological subtypes, NSCLC is the most prevalent type accounting for 85 to 90
% of all lung cancer cases. One of the main reasons for the poor survival rates among
patients with advanced stages of NSCLC is the limited efficacy of traditional
chemotherapy along with severe adverse effects of the high doses of cytotoxic anticancer
drugs. To over the limitations of conventional chemotherapy, molecularly targeted agents
were developed to target specific receptors or pathways of tumor cells with higher
specificity. For instance, erlotinib was approved for the treatment of locally advanced or
metastatic NSCLC after failure of at least one chemotherapy regimen. ETB is a highly
selective inhibitor of HER1/ EGFR-TK. However, limitations of oral administration of
ETB tablet include several adverse effects/toxicities in cancer patients and development
of drug resistance by P-glycoprotein mediated efflux pump or other pathways by NSCLC
tumors. Nanoparticulate carriers are attractive for cancer chemotherapy due to their
ability to enhance accumulation of anticancer agents at the tumor site, resulting in an
increased tumor cell kill efficacy, reduction in total dose and dose-related adverse effects
to healthy cells. In addition, NPs often overcome drug resistance to tumors by evading
the normal pathways of drug resistance. Recently, core–shell-type lipid–polymer hybrid
nanoparticles have emerged as a promising drug delivery platform. This unique platform
combines the mechanical advantages of biodegradable polymeric nanoparticles and
biomimetic advantages of liposomes. The system provides advantages such as
controllable particle size, surface functionality, high drug loading, potential for
entrapment of multiple therapeutic agents, tunable drug release profile, and good serum
stability. The overall goal of this project was to develop untargeted and anti-EGFR halfantibody conjugated core-shell type lipid-albumin hybrid nanoparticles (CSLAHNPs) for
the targeted delivery of ETB in NSCLC cells. The central hypothesis of the project was
that CSLAHNPs will improve therapeutic efficacy and thereby reduce toxicities of ETB
in NSCLC therapy.
The first aim was to design, prepare and optimize blank CSLAHNPs without drug
and targeting antibody as described in Chapter 2. Blank CSLAHNPs were designed and
prepared with albumin core and phospholipid bilayer shell by the two step method using
bovine serum albumin, DPPC, cholesterol, and DSPE-PEG2000 as the formulation
ingredients. All the ingredients used were biodegradable, biocompatible, nonimmunogenic or mildly immunogenic and approved by FDA for human use. The
formulation and process variables were identified and optimized for the preparation of
blank CSLAHNPs. Various factors influenced the physicochemical properties including
mean size, polydispersity index, and zeta potential of both ANPs (core) and CSLAHNPs.
For the preparation of ANPs (core) by the desolvation method, the optimized variables
include albumin concentration of 20 mg/mL, pH of the albumin solution at 8, ethanol
addition rate 1 mL/min, volume ratio of water to ethanol 1:2, and gluteraldehyde-toalbumin ratio 0.47% w/w. For the lipid shell, DPPC, cholesterol, and DSPE-PEG2000
were used at a molar ratio of 60:30:10. The critical parameter of the lipid-film hydration
method was identified as the weight ratio of lipid-to-ANPs (WLipid/WANPs) during the
128

optimization of CSLAHNPs. The experimental WLipid/WANPs was found around 15% w/w
(equivalent WDPPC/WANPs ~ 8% w/w) which was close to the calculated value (~10%
w/w) based on the theoretical assumptions. TEM images showed smooth and spherical
particles of both ANPs (core) and CSLAHNPs with some degree of polydispersity. A
distinct electron dense corona around periphery of the CSLAHNPs was visible which was
absent in ANPs.
Following the preparation of blank CSLAHNPs, the aim of Chapter 3 was to load
the drug erlotinib in the CSLAHNPs to prepare ETB loaded CSLAHNPs. The drug
binding capacity of albumin in solution was studied and optimized at various pH
conditions, durations of incubation, incubation temperatures, and drug-to-albumin molar
ratios. The maximum drug binding capacity of albumin was observed at 12h incubation
in pH 7.4 at room temperature with drug-to-albumin molar ratio 10:1. ETB-CSLAHNPs
were successfully designed, prepared and optimized by the two step method as described
in Chapter 2. Two strategies for drug loading in ANPs were studied; incorporation and
sorption method. Sorption method provided better drug loading and entrapment
efficiency in ETB-ANPs compared to incorporation method. Additional ETB was
incorporated in the lipid bilayer to maximize the drug loading and entrapment efficiency
of ETB-CSLAHNPs. ETB-CSLAHNPs were 194nm in size with PDI 0.16, zeta potential
-15.6mV, yield 83.5% w/w, DL 2.08% w/w, and DEE 32.75% w/w. SEM and TEM
images showed smooth and spherical particles of ETB-CSLAHNPs. Drug release from
ETB-CSLAHNPs occurred in a sustained manner up to 96h with a biphasic release
pattern in pH 7.4. Drug release was faster in acidic pH of 5.2. Drug release kinetics
analysis showed a first order release kinetics with non-fickian diffusion mechanism.
ETB-CSLAHNPs were stable in serum for up to 6h.
The specific aim of chapter 4 was to prepare and characterize targeted anti-EGFR
half-antibody conjugated ETB loaded CSLAHNPs (hAb-ETB-CSLAHNPs). Targeted
hAb-conjugated ETB-CSLAHNPs were prepared by maleimide-thiol conjugation
reaction after incorporating 1 mol % DSPE-PEG2000-maleimide in ETB-CSLAHNPs
during preparation. Anti-EGFR mouse monoclonal antibody (mAb) was reduced to halfantibodies (hAb) using TCEP at 50:1 molar ratio of TCEP: mAb and coupled to
maleimide-terminated ETB-CSLAHNPs. Targeted hAb-ETB-CSLAHNPs were ~ 200
nm in mean hydrodynamic size with PDI ~ 0.13, zeta potential ~ -13mV, DL ~ 2 % w/w,
and DEE ~ 31% w/w. TEM image showed smooth and spherical particles with moderate
degree of polydispersity. Drug release from hAb-ETB-CSLAHNPs occurred in a
sustained manner up to 96h with a biphasic release pattern in pH 7.4. A faster rate of drug
release was observed in acidic pH of 5.2. The hAb-ETB-CSLAHNPs were stable in 50%
serum for up to 12h.
The specific aim of Chapter 5 was to evaluate the cellular uptake, intracellular
trafficking, and cellular viability of ETH-CSLAHNPs and targeted hAb-ETBCSLAHNPs in two human lung adenocarcinoma cells, A549 and HCC827 cells. A549
cells express low levels of wild-type EGFR whereas HCC827 cells express higher levels
of EGFR due to the acquired mutation in the EGFR tyrosine kinase domains. For
intracellular imaging, 1 mol % of NBD-PC was incorporated into CSLAHNPs. The
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targeting ability of hAb-ETB-CSLAHNPs was confirmed by cell association study.
Confocal microscopy and flow cytometry results showed higher uptake of hAb-ETBCSLAHNPs and ETB-CSLAHNPs in HCC827 cells compared to A549 cells up to 4 h.
Endocytosis inhibitor assay showed major mechanism of particle uptake was via
caveolae-mediated endocytosis. Significantly higher reduction in cell viability was
observed for both targeted and untargeted ETB-CSLAHNPs compared to ETB-solution
form in HCC827 compared to A549 cells. Similar results were observed for colony
formation assay. Western blot results showed significant downregulation of
phosphorylated EGFR after ETB-CSLAHNPs treatment compared to control. The results
suggest the potential therapeutic advantages of targeted and untargeted ETB-CSLAHNPs
over ETB in solution in EGFR-overexpressing NSCLC.
The final aim of the project was to prepare lyophilized CSLAHNPs and also to
perform the storage stability for both liquid dispersion and lyophilized solid powder. The
present study also showed that CSLAHNPs can be stabilized both during the
lyophilization process as well as for long-term storage using adequate concentrations of
suitable lyoprotectants. Among two disaccharides (sucrose and trehalose) used as
lyoprotectants, sucrose was the best in preserving the cake properties and
physicochemical characteristics at 1:16 weight ratio of CSLAHNPs to sucrose.
Accelerated temperature storage at 25oC had a negative influence on both lyophilized
and liquid form stability. The study also showed that the lyophilized form retained the
physicochemical properties CSLAHNPs compared to the liquid dispersion form at 2-8oC
storage condition for 60 days of storage.
Overall, the results suggest successful design and development of targeted hAbETB-CSLAHNPs and untargeted ETB-CSLAHNPs. Various formulation and process
variables were optimized to obtain prototype formulation with acceptable
physicochemical properties including mean size, polydispersity index, zeta potential,
drug loading efficiency and drug release profiles. The study also showed the potential
therapeutic advantages of targeted and untargeted ETB-CSLAHNPs over ETB in solution
in EGFR-expressing NSCLC cells. Lyophilzed power of CSLAHNPs containing sucrose
exhibited refrigerated storage stability for 2 months retaining acceptable physicochemical
properties. Therefore, the overall experimental data supported the central hypothesis of
improved therapeutic efficacy of anti-EGFR half-antibody conjugated erlotinib loaded
CSLAHNPs as a potential targeted drug delivery system for the therapy of non-small cell
lung cancer.
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